FOXO3a and ID1 as targets of chemotherapy in breast cancer by McGovern, Ursula Brigid & McGovern, Ursula Brigid
 1 
 
     
          FOXO3a AND ID1 AS TARGETS OF 
 
CHEMOTHERAPY IN BREAST CANCER 
 
 
 
Thesis submitted by 
 
 
Ursula Brigid McGovern 
 
                                    
 
                                        To 
 
Imperial College London 
 
For the degree of Doctor of Philosophy 
 
 
 
 
 
 
 
 
 
Department of Oncology 
Division of Surgery, Oncology, Reproductive Biology and Anaesthetics 
8th Floor Cyclotron MRC Building 
Hammersmith Hospital 
Du Cane Road 
London W12 ONN 
 
2009 
 2 
 
DECLARATION OF ORIGINALITY 
 
 Unless otherwise stated in the text, this thesis is the result of my own work. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3 
ABSTRACT 
 
Cancer is one of the leading causes of death and more than 
40000 women are diagnosed every year in the UK with breast 
cancer.  Chemotherapy regimens containing the anthracycline 
epirubicin are often used in the medical management of breast 
cancer, but the cellular mechanisms of action and the molecular 
pathways underlying response to treatment are not fully 
understood. 
 
The FOXO family of transcription factors are downstream targets 
of   the phosphatidylinositol-3-kinase (PI3K)/Akt pathway and 
play a role in a variety of processes including cellular 
differentiation, metabolism, cell-cycle arrest, cell death and 
protection from stress.  This work identifies the transcription 
factor FOXO3a as a cellular target of epirubicin. Treatment of 
the MCF7 breast cancer cell line with epirubicin causes G2/M cell 
cycle arrest and leads to upregulation of FOXO3a at the 
transcriptional, translational and gene promoter level.  FOXO3a 
accumulates in the nucleus following treatment with epirubicin 
and silencing of FOXO3a by RNA interference confers protection 
against the cytotoxic effects of the drug.  FOXM1, another 
member of the Forkhead family, is repressed at the protein, 
RNA and gene promoter level by epirubicin. This repression is 
relieved when FOXO3a is silenced or prevented from binding the 
FOXM1 promoter in gene promoter assays, suggesting FOXO3a 
regulates the repression of FOXM1.    
 
This work also identifies Id1 as a target of epirubicin.  Id1 is 
highly expressed in chemoresistant cell lines and is rapidly 
downregulated following treatment of MCF7 cells with epirubicin 
in sensitive cell lines.  Overexpression of Id1 confers resistance 
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to epirubicin and knockdown of Id1 increases the sensitivity of 
MCF7 cells to a number of chemotherapeutic agents. Id1 activity 
is independent of FOXO3a regulation. 
 
Analysis of clinical samples confirms the changes seen in cell 
lines in FOXO3a, FOXM1 and Id1 following chemotherapy and 
treatment with the EGFR inhibitor gefitinib.  Thus, in the future, 
FOXO3a, FOXM1 and Id1 could be used as indicators and 
predictors of response in the treatment of breast cancer. 
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1.1 CANCER – an overview 
Cancer is the second largest cause of mortality in the Western 
world after cardiovascular disease and was responsible for 27% 
of all deaths in the UK in 2005 - 29% for males and 25% for 
females  (Mortality Statistics: Cause England & Wales, 2006.)  
More than 200 distinct varieties of cancer are recognised but the 
four most common causes of cancer - lung, bowel, breast and 
prostate cancer account for the majority of deaths seen.   
Cancers are heterogeneous diseases, where multiple genetic 
alterations within cells leads to transformation of normal cells 
into cancer cells.   At the core of this process are cancer causing 
or oncogenic mutations in critical genes, which cause sustained 
proliferation in cells and leads to escape from the normal cues 
that will inhibit cell growth or promote cell death (Luo and 
Elledge, 2008). Tumourigenesis and tumour progression in 
humans is a multistep process, requiring a number of genetic 
alterations that drive the progressive transformation of normal 
cells, via a series of premalignant states, into highly invasive 
derivatives. These steps include self sufficiency to growth 
signals, insensitivity to growth inhibitory signals, limitless 
replicative potential, evasion of programmed cell death 
(apoptosis), sustained angiogenesis, tissue invasion and 
metastasis - all of which can give rise to the cancer genotype 
that collectively dictates malignant growth (Hanahan and 
Weinberg, 2000).      
1.1.1 Oncogenes and tumour suppressors   
 Oncogenes are genes whose inappropriate activation can lead 
to cancerous or oncogenic transformation of cells.  Their protein 
products are often regulators of cell growth and proliferation 
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and are involved in signalling pathways controlled by feedback 
mechanisms  (Pollard and Earnshaw, 2008).  The first oncogene 
identified was RAS and the RAS gene is now known to be 
mutated in more than 30% of human cancers.   The small 
GTPase proteins of the RAS family are signalling molecules 
which are normally activated by growth factor receptors to 
promote cell proliferation – single nucleotide mutations in their 
coding sequences can lead to constitutive activation, resulting in 
deregulated cell growth and cell death and the ability to induce 
new blood vessel formation    (Downward, 2003).  Three 
members of the RAS family are found to be activated by 
mutation in human tumours – HRAS, KRAS and NRAS.  These 
proteins are normally highly expressed, with KRAS being found 
in virtually all cell types and it is in KRAS that point mutations 
are most frequently seen (85% of total RAS mutations). RAS 
signalling pathways are commonly activated in cancers, 
especially those which overexpress growth factor receptor 
tyrosine kinases, the most common examples being ERBB2 
(human epidermal growth factor receptor 2/HER2/neu) and 
EGFR (epidermal growth factor receptor 1). Downstream of RAS 
is the protein serine/threonine kinase RAF.  GTP-bound RAS 
binds to and activates RAF, causing its relocation to the plasma 
membrane where it can initiate the mitogen-activated protein 
kinase (MAPK) cascade, leading to ERK activation.  RAS can also 
activate the phosphatidylinositol-3-kinase (PI3K) pathway 
(Downward, 2003).    Therefore, aberrant RAS signalling can 
lead to continuous activation of pathways promoting cell cycle 
progression and survival, a key component of malignant 
transformation.         
Myc has been identified as another potent oncogene and 
deregulated expression of c-Myc has been identified in a broad 
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range of human cancers and is often associated with a poor 
prognosis (Pelengaris et al., 2002).  The transcription factor c-
Myc orchestrates the expression of up to of 15% of all genes 
and its targets are involved in the cell cycle, protein synthesis, 
metabolism and survival (Hoffman and Liebermann, 2008).  C-
Myc is widely expressed during embyrogenesis and is found in 
tissues with high proliferative rates such as the skin and gut, 
where its expression strongly correlates with cell proliferation  
(Pelengaris et al., 2002). With multiple extracellular and 
intracellular signalling cascades converging to regulate Myc, 
activation of these pathways, often seen in many cancers, can 
induce Myc overexpression and lead to the transcription of its 
target genes, promoting genomic instability, proliferation, 
angiogenesis and blocking differentiation (Ponzielli et al., 2005).     
Tumour suppressors are genes whose inactivation can lead to 
cancerous transformation as their protein products typically 
inhibit products of oncogenes or negatively regulate cell 
proliferation.  Two of the most well characterised tumour 
suppressors are the retinoblastoma protein (pRb) and p53. The 
Rb tumour suppressor has a central role in enforcing cell cycle 
checkpoints, which are activated in response to intra and 
extracellular stresses, including DNA damage, growth factor 
deprivation and nucleotide depletion (Macleod, 2008).  There 
are three mammalian Rb-related proteins – pRb, p107 and p130 
– and these proteins regulate a family of transcription factors 
known as E2F.   Rb regulates the ability of E2F to activate genes 
required for progression through the cell cycle as complexes 
between Rb family members and E2Fs actively repress gene 
transcription by associating with the promoter regions of target 
genes, blocking transcription (Sherr and McCormick, 2002).  Rb 
can also recruit histone deacetylases (HDACs), which cause 
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compaction of chromatin structure, thus repressing genes 
required for cell cycle progression.  However, phosphorylation of 
Rb by cyclin dependent kinases (Cdks) prevents the association 
of Rb with both HDACs and E2Fs, enabling E2F dependent gene 
transcription, particularly those required for DNA replication.  A 
cell that can phosphorylate Rb can pass through the cell cycle, 
whereas cells that cannot remain arrested   (Alberts et al., 
2008). 
Rb is one of the most characterised tumour suppressors – loss 
of Rb can lead to inappropriate cell cycle progression, rendering 
cells independent of growth factor stimulation and insensitive to 
antigrowth factors, such as TGFβ, that can block the cell cycle.   
Mutations occur frequently in the Rb pathway through mutation, 
deletion or epigenetic silencing.  Individuals who inherit one 
defective Rb gene in the germ line and then develop a somatic 
mutation in the remaining normal allele often develop 
retinoblastomas as children and osteosarcomas as adults, the 
classic example of a cancer caused by loss of a tumour 
suppressor gene.  Rb inactivation is seen in a variety of cancers, 
including breast, prostate, colon and lung cancer (Sherr and 
McCormick, 2002).   
p53 is a transcription factor that plays a central role in the 
cellular response to a variety of stress signals, including DNA 
damage, hypoxia and the presence of oncogenic activation, 
including mutant RAS and Myc.   p53 prevents cells from 
entering or progressing through the cell cycle in conditions that 
could perpetuate or generate DNA damage  and it is essential 
for effective tumour suppression in humans (Toledo and Wahl, 
2006). Mutations in TP53, the gene that encodes p53, are found 
in 50% of human cancers and in those tumours that do not 
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have mutated p53, a large proportion have inactivated p53 
function via other mechanisms, including disrupted p53 
signalling pathways.  A germline mutation in p53 can cause Li 
Fraumeni syndrome, characterised by an abnormally high and 
early incidence of cancer.  p53 null mice are viable but nearly all 
develop cancers before six months of age (Horn and Vousden, 
2007).  
In contrast to Rb, most cells have minimal levels of p53 protein 
under normal conditions, as it is rapidly degraded and is 
negatively regulated by MDM2 ubiquitin ligase which binds it 
and targets it for destruction by proteosomes.    However, under 
conditions of cellular stress or DNA damage, the protein kinase 
ATM stabilises and activates p53 by phosphorylation and the 
nuclear levels of p53 increase dramatically, where it becomes a 
potent transcriptional activator (Pollard and Earnshaw, 2008).  
Depending on the cell type, cell environment and oncogenic 
alteration, this activation of p53 leads to induction of 
senescence, inhibition of cell cycle progression, differentiation or 
apoptosis – thus allowing p53 to exert its tumour suppressor 
function  (Pietsch et al., 2008).  
Over time, cells lacking the p53 regulated damage response 
accumulate cancer causing mutations. The most common 
mutations observed in p53 in human tumours are in its DNA 
binding domain, preventing p53 from binding to its DNA target 
sequences.  p53 dependent stress responses are abolished and 
cells can escape apoptosis and continue to proliferate with a 
corrupted genome.  This can lead to loss of other tumour 
suppressor genes, such as p21Cip1 and p27Kip1, and to activation 
of oncogenes. Loss of p53 can also make cancer cells less 
sensitive to irradiation and cytotoxics.  Drugs and radiation used 
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commonly in the treatment of cancer can induce p53 in normal 
cells, contributing to their own destruction and hence treatment 
related toxicity.  However, p53-/- cells are resistant to drug 
induced apoptosis and mutations in p53 or in the p53 pathway 
can produce multidrug resistance in vitro and in vivo (Johnstone 
et al., 2002).   
1.1.2 Epigenetics in cancer 
Epigenetics is defined as heritable changes in gene expression 
that are not due to an alteration in the DNA sequence.  The 
abnormal epigenetic silencing of genes is equally as important 
as mutations in DNA sequences in the development of many 
cancers (Alberts et al., 2008). Genetic and epigenetic changes 
can cause oncogenes to be activated by chromosome gains, 
amplification of genes, chromosomal translocations and 
activating point mutations.  Similarly, tumour suppressor genes 
can become inactivated by loss of whole chromosomes, point 
mutations and deletions.   
Epigenetic changes can involve covalent modifications of the 
amino acid residues found in histones wrapped around DNA but 
the best known epigenetic marker is DNA methylation. During 
embryonic development, DNA methylation patterns are 
important in cellular growth and differentiation and occur in 
cytosine residues that precede guanines – dinucleotide CpGs, 
with the “p” referring to the phosphodiester bond between the 
cytosine and guanine nucleotides.   These CpG sites are not just 
randomly distributed but are found in CpG rich regions called 
CpG islands, spanning the 5’ regulatory end of many genes.  In 
normal cells, these islands are not usually methylated and can 
be found in up to 40% of the promoters of human genes 
(Esteller, 2008). 
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CpG methylation plays an important role in maintaining normal 
gene silencing, and methylated cytosines in gene promoters are 
associated with chromatin from which transcription is blocked – 
essential for monoallelic expression of genes and X-chromosome 
inactivation (Kirsten, 2007).  Modification of histone proteins 
also occurs with DNA methylation.   Core histones can normally 
be modified post-translationally in a variety of ways, including 
acetylation, phosphorylation, methylation and ubiquitination 
(Pollard and Earnshaw, 2008).  Their long amino terminal ends 
protrude outside the nucleosome and can interact with various 
nuclear factors which bind modified histones and dictate 
whether particular regions of chromatin and transcribed or held 
in an inactive state.  This is essential for the normal 
physiological activity of cells and tissues.  However, in cancers, 
methylated cytosine residues can alter the coding regions of 
genes by introducing point mutations and causing genomic 
instability.  Focal hypermethylation of gene promoters can 
inactivate gene transcription, thus silencing key genes involved 
in the cell cycle, DNA repair, angiogenesis, metabolism of 
carcinogens and apoptosis, allowing neoplastic transformation 
(Esteller, 2008). Changes in the DNA methylation pattern of the 
cell result in aberrant histone modification profiles.  
Hypoacetylation and hyperacetylation of histones and the 
appearance of repressive histone markers resulting from 
hypermethylated CpG islands, can lead to the silencing of genes 
with tumour suppressor like functions and promote the 
development of tumours  (Esteller, 2008; Esteller  and 
Almouzni, 2005). 
CpG hypermethylation at the promoters of tumour suppressor 
genes is likely to be the most common mechanism of tumour 
suppressor inactivation in cancer. There are many classical 
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tumour suppressor genes which are mutated in the germline of 
patients with hereditary cancers, giving rise to specific cancer 
syndromes and these genes can also be inactivated by 
methylation in sporadic tumours. Examples include RB1 and 
BRCA1, where hypermethylation gives rise to the sporadic 
variant of retinoblastoma and breast cancer (Kirsten, 2007).  
Promoter hypermethylation is seen in a wide variety of other 
cancers, including colon, pancreas, lung and ovarian cancers 
and may have potential use in the development of novel cancer 
therapies.  DNA methylation and histone modifications are 
reversible and demethylating agents have been used to re-
express DNA methylated genes in cancer cell lines: the drug 
decitabine, a DNA demethylator, has been approved in the 
treatment of leukaemia and myelodysplastic syndrome.  
Similarly, a HDAC inhibitor, SAHA, which can induce cell cycle 
arrest and promote apoptosis in vitro, has been approved for 
the treatment of cutaneous T-cell lymphoma (Mack, 2006)   
1.1.3 Chromosomal abnormalities and cancer 
Cytogenetic abnormalities are a characteristic often seen in 
cancer cells and clonal chromosome abberations are found in 
most major tumour types.  Chromosomal abnormalities in 
cancer can be broadly classified into two main types – 
chromosomal rearrangements and chromosomal imbalances 
(Frohling and Dohner, 2008). 
Chromosomal rearrangements seen in cancer include 
translocations, inversions and insertions.  These rearrangements 
often have functional consequences, leading to the formation of 
a chimeric fusion gene with altered or new activity or 
chromosomal changes that cause altered expression of a normal 
gene, by bringing genes closer to enhancer or promoter 
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elements (Nambiar et al., 2008). Initially seen most commonly 
in haematological cancers, rearrangements can also play a role 
in the pathogenesis of epithelial cancers.   
The most common chromosomal translocations result in the 
formation of a chimeric gene, via the fusion of parts of two 
genes.  The genes most commonly involved are those coding for 
tyrosine kinases and transcription factors.  The most well 
described chimeric fusion gene is the Philadelphia chromosome, 
found in most patients with chronic myeloid leukaemia (CML) 
where there is a reciprocal translocation between chromosome 9 
and 22, in which sequences of the Bcr gene are joined to 
portions of the gene encoding the Abl tyrosine kinase.  This 
results in the chimeric fusion protein Bcr-Abl, resulting in 
constitutive activation of tyrosine kinase activity. The discovery 
of the Philadelphia chromosome led to one of the biggest 
breakthroughs in cancer therapeutics over the last twenty 
years, namely the development of the selective tyrosine kinase 
inhibitor imatinib, a drug which has revolutionised the treatment 
of CML.  
Chromosomal imbalances, where there is gain or loss of genetic 
material, are also seen in cancers.  Changes in the number of 
whole chromosomes lead to genetic instability and gains 
(polysomy) and losses (aneusomy) are seen in a number of 
epithelial cancers, leading to activation of oncogenes and 
inactivation of tumour suppressors (Reinholz et al., 2009).  
Genomic gains can enhance the activity of genes in the affected 
chromosomal region.  One of the most well known gains is 
amplification of the gene on band 17q21.1 encoding the ERBB2 
receptor kinase – of interest in particular in breast cancer, as a 
specific target for the monoclonal antibody herceptin 
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(traztuzumab).  Other examples of gene amplifications include 
those encoding for EGFR and KRAS, which are seen in a variety 
of cancers (Frohling and Dohner, 2008).  Extensive genomic 
deletions, which can affect multiple genes, are also frequently 
seen in tumours, including deletions affecting PTEN, the PI3K 
pathway inhibitor, and the previously mentioned Rb and TP53. 
1.1.4 DNA damage and cancer 
Human cells experience a large amount of DNA damage events 
every day and cell division must not occur with damaged 
genomes or inaccurate replication as this can lead to cell death 
and mutations.  Cells have evolved a number of systems to 
repair damaged DNA and the activity of these pathways 
depends on the type of DNA damage inflicted on the cell (Pollard 
and Earnshaw, 2008).  In response to stress or DNA damage, 
cells possess a number of DNA damage checkpoints, which can 
arrest the cell cycle allowing cells the chance to repair their 
genome. Cancer is associated with a disrupted DNA damage 
response and impaired DNA repair pathways, making cells 
dependent on a reduced and more error prone set of DNA repair 
mechanisms (Helleday et al., 2008).      
There are a number of mechanisms by which cells can repair 
DNA damage.  When both strands of the double DNA helix are 
broken – double strand breaks – there is no intact template left 
to ensure accurate repair.  This can be caused by radiation, free 
radicals or chemicals. Two mechanisms exist to overcome this: 
non homologous end joining and homologous recombination.  In 
the former, there is connection and resealing of the two ends of 
a DNA double strand break by DNA ligation, often with the loss 
of one or more nucleotides at the site of joining (Alberts et al., 
2008).  Homologous recombination is a much more accurate 
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type of repair, which can copy the DNA sequence, using the 
sister chromatid as a template, thus repairing or bypassing 
replication lesions (Helleday et al., 2008). 
Mismatch repair is a process which occurs during DNA 
replication to correct base pairing errors, such as insertion or 
deletions, not detected by the proofreading activity of DNA 
polymerase.  When a mismatch is detected,    a complex of 
mismatch repair proteins can identify this mismatch, excise the 
DNA strand involved and resythesize the missing strand.  
Defects in mismatch repair, where defects go unrepaired, can 
lead to microsatellite instability.  Microsatellites are repeated 
sequences of DNA, varying in length and appearing normally 
throughout the genome. When DNA repair genes are mutated, 
these sequences can accumulate errors, become shorter, longer 
and unstable, hence the term microsatellite instability. 
Mutations cause replication errors to go unfixed, and the 
resulting frameshift mutation or epigenetic changes can switch 
off key tumour suppressor genes, promoting tumourigenesis (de 
la Chapelle, 2003).  
Damage to individual DNA bases can also be repaired by base 
excision repair, where the altered base is removed and replaced 
by a DNA glycosylase enzyme, or by nucleotide excision repair, 
where sections of the damaged DNA strand is removed as an 
oligonucleotide from the double helix and the opposite strand 
used as a template for repair (Alberts et al., 2008).       
DNA repair pathways are not only important in the development 
of cancer, but can also be targeted in the treatment of cancer.  
Several chemotherapeutic agents produce excessive DNA 
damage which can cause cell cycle arrest and death either 
directly or following S phase DNA replication, where lesions can 
 32 
obstruct replication fork progression leading to lethal double 
strand breaks (Helleday et al., 2008).   Drugs such as the 
platinum agent cisplatin and carboplatin can cause chemical 
modifications of DNA bases, known as adducts. By cross-linking 
DNA with proteins or cross-linking two DNA bases within the 
same strand of DNA, replication forks are blocked.  
Antimetabolites, such as 5-fluorouracil (5-FU), inhibit nucleotide 
metabolism pathways, by depleting cells of dNTPs by mimicking 
nucleotides, their precursors or co-factors which are required for 
normal nucleotide biosynthesis (Swann et al., 1996). 
DNA strand breaks can arise naturally during DNA synthesis and 
these can also be exploited and targeted by anticancer agents. 
The topoisomerase enzymes induce transient DNA breaks, 
relaxing supercoiled DNA which allows resolution of torsional 
strains imposed on the DNA double helix during replication. 
Topoisomerase inhibitors, such as the anthracyclines, can 
prevent resealing of these breaks by trapping the enzymes in 
complexes with the DNA (Wang, 2002). Thus, tumour 
development can be associated with disrupted DNA damage 
repair pathways and response, but these pathways can also be 
exploited by chemotherapeutic agents to produce excessive cell 
damage and subsequent death of tumour cells.  
In summary, there are multiple mechanisms and events that 
can lead to the transformation of normal cells into cancerous 
cells (Figure 1.1).  
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 Figure 1.1 Mechanisms of cancer development 
  
 
1.2 BREAST CANCER   
 
Breast cancer has now become the most prevalent cancer in the 
UK, despite its low incidence in men.  In 2005, over 45000 new 
cases were diagnosed and in women there is a one in nine 
lifetime risk of developing the disease (Cancer Research UK).  
Several risk factors for breast cancer development have been 
identified, many of which relate to reproductive events. These 
include early menarche, nulliparity, late age at first birth and 
late natural menopause. These risks may arise from the 
cumulative exposure of breast tissue to endogenous oestrogens.  
The use of exogenous hormones may also increase the risk of 
breast cancer, with an association seen between the use of 
hormone replacement therapy and the development of breast 
cancer. The risk of breast cancer for current or recent users of 
HRT increases per year of use. A strong family history of breast 
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cancer is another known risk factor, particularly when first 
degree relatives have been diagnosed, although in most cases 
there is no family history of the disease. Perhaps the most well 
defined genes where mutations have been found to substantially 
increase the risk of breast cancer are BRCA1 and BRCA2, both 
discovered in the mid 1990’s (Futreal et al., 1994; Wooster et 
al., 1995). These cancers tend to be associated with high 
histological grade, inactivation of p53 and BRCA1 tumours in 
particular are often ER negative (Tutt and Ashworth, 2008).  
These two genes however are very different in terms of their 
structure and function.  BRCA1 is involved in chromatin 
remodelling, regulation of transcription and also has a key role 
in the DNA damage response, whereas BRCA2 maintains 
genome stability through DNA repair by homologous 
recombination (Ashworth, 2005; Gudmundsdottir and Ashworth, 
2006). When the function of these genes is lost, and defective 
DNA repair and genomic instability results, mutation associated 
breast and ovarian cancers can develop. However, most breast 
cancers do not have a known genetic predisposition and by far 
the strongest risk factor for breast cancer (after gender) is age: 
the older the woman, the higher her risk and more than 80% of 
breast cancer cases are seen in women aged 50 and over.   
 
The incidence of breast cancer has continued to increase over 
the last twenty years, but survival rates are improving and now 
more than 80% of newly diagnosed patients can expect to 
survive beyond five years. The earlier the stage at diagnosis, 
the better the outcome - hence the importance of detecting 
cancers at an early stage, when treatment is more likely to be 
curative (Figure 1.2).  
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Figure 1.2 Age standardised incidence and mortality rates of 
female breast cancer 1975-2006.  (Cancer Research UK) 
 
 
1.2.1 Presentation and diagnosis 
 
The breast cancer screening programme was set up in 1988 and 
uses mammography to screen all women between 50 and 70 
who are registered with a GP in the UK.  The screening 
programme diagnoses around 10000 cases of breast cancer 
each year (Cancer Research UK).  However, the vast majority of 
breast cancers are self-detected.   
 
A diagnosis is usually made following triple assessment – clinical 
examination, imaging and core biopsy/fine needle aspiration 
(FNA).  This allows a decision to be made about the appropriate 
primary medical treatment, whether it be surgery in the form of 
wide local excision or mastectomy, or in the case or large or 
locally advanced cancers, neo-adjuvant treatment.  Breast 
cancers can be categorised into low, intermediate and high risk 
depending on a number of predictive and prognostic factors.  
Patients at low risk of recurrence include those with small, low 
grade tumours, lymph node negative, HER2 negative and age > 
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35 years.  Risk of relapse increases with higher histological 
grade, tumour size, nodal involvement, HER2 positivity and 
younger age (Smith and Chua, 2006).  Thus, the medical 
management a particular patient receives will depend on a 
number of factors, including the characteristics of the tumour 
itself and the risk of recurrence.   
 
1.3 MEDICAL MANAGEMENT OF BREAST CANCER  
 
The management of breast cancer involves a multimodality 
approach with many women receiving a combination of medical 
options including surgery, endocrine treatment, chemotherapy, 
radiotherapy and targeted agents.  Amongst these, it is 
undoubtedly the use of endocrine treatment and adjuvant 
chemotherapy that has contributed most to the improved 
survival rates seen in breast cancer over the last twenty years.   
 
1.3.1 The oestrogen receptor (ER)  
 
The ER belongs to a superfamily of nuclear hormone receptors, 
which classically function as transcription factors when bound to 
their ligands in the nucleus.  The two main forms of ER - ERα 
and ERβ - have similar structures but are the products of 
different genes (Osborne and Schiff, 2005).   ER plays a role in 
the proliferation, differentiation and survival of both normal and 
malignant breast epithelial cells (Madureira et al., 2006).  
Classical (genomic) activity of ER involves protein activation by 
phosphorylation when oestrogen binds to ERα.  This also causes 
a conformational change and dissociation of chaperone proteins 
such as heat-shock protein 90.  Hormone bound ER can then 
dimerize with another receptor, interact with coregulatory 
proteins and bind to oestrogen response elements (ERE) found 
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in the promoter area of target genes leading to the transcription 
of these oestrogen responsive genes (Osborne and Schiff, 
2005). Many ER regulated genes are involved in cell cycle 
progression, including cyclin D1 and in survival, such as the 
anti-apoptotic Bcl-2 (Madureira et al., 2006). 
 
ER can also have non-genomic activity and can mediate 
transcription through ligand independent effects.  Several 
kinases in the growth factor signaling pathways can 
phosphorylate ER, largely on serine residues in the AF1 region 
of ERα creating crosstalk between ER and other signalling 
pathways. This may be important in the development of 
endocrine resistance – increased growth factor signalling may 
lead to the loss of oestrogen dependence and an increase in 
ligand independent effects.  Endocrine resistance may also 
develop due to ER mutations or disrupted coregulator 
expression or recruitment (Pearce and Jordan, 2004). 
 
1.3.2 Endocrine treatment  
 
Oestrogens have been implicated in the development of breast 
cancer for many years and endocrine therapy has become an 
integral part in the treatment of cancers expressing the 
oestrogen receptor (ER).    These drugs block ER function, but 
have different mechanisms to achieve their effects. Tamoxifen, 
a selective ER modulator (SERM), binds ER and partially 
antagonizes its activity.  The third generation aromatase 
inhibitors, such as anastrazole and exemestane, block the 
peripheral synthesis of oestrogen and inhibit ligand-induced 
activation of ER and steroidal antioestrogens such as fulvestrant 
bind ER and can induce receptor degradation (Osborne and 
Schiff, 2005). 
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Historically, tamoxifen has been the most commonly used 
endocrine agent in the adjuvant setting and is suitable for both 
pre and post menopausal women.  The Oxford overview of 2005 
confirmed that in ER positive breast cancers, five years of 
adjuvant tamoxifen reduces the annual breast cancer death rate 
by 31%, largely irrespective of the use of chemotherapy and of 
age (EBCTCG, 2005).  Additional benefits were seen in patients 
receiving both chemotherapy and 5 years of tamoxifen, as 
discussed later in this chapter.  
 
The emerging role of aromatase inhibitors has been addressed 
by a number of influential trials. In postmenopausal women, the 
Arimidex, Tamoxifen Alone or in Combination (ATAC) trial 
compared 5 years of anastrazole with five years of tamoxifen – 
initially this showed a small disease free survival benefit, but 
the 100 month follow-up analysis failed to show a survival 
advantage in favour of anastrazole (Forbes et al., 2008).  
However, a recent update of the Breast International Group 
(BIG) 1-98 trial has shown a trend towards better overall 
survival in patients receiving letrozole as compared with 
tamoxifen (Coates et al., 2007).  The Intergroup Exemestane 
Study (IES) compared exemestane versus 2-3 years of 
tamoxifen followed by exemestane.  The results suggested early 
improvements in disease free survival in the patients who 
switched over to an aromatase inhibitor, translating into a 
modest reduction in risk of death (Coombes et al., 2007).  
Further studies are ongoing to elucidate the optimum endocrine 
treatment strategy.    
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1.3.3 The anthracyclines  
 
The first anthracyclines, including doxorubicin, were extracted 
from the pigment producing Streptomyces peucetius in the 
1960’s.  They have a characteristic four ring structure (rings A-
D), linked to an amino sugar via a glycoside bond (Moro et al., 
2004). Epirubicin, a semi-synthetic derivative of doxorubicin, is 
structurally modified, with an axial to equatorial epimerization of 
the hydroxyl group at C-4’ (Minotti et al., 2004) (Figure 1.3).   
 
               
                            
 
Figure 1.3 Structure of the anthracyclines doxorubicin and 
epirubicin   (Minotti et al, 2004).  
 
Although this positional change does not have much of an effect 
of the mode of action of epirubicin when compared to 
doxorubicin, it does introduce metabolic and pharmacodynamic 
changes such as increased volume of distribution and shorter 
terminal half-life (Danesi et al., 2002; Robert and Gianni, 
Doxorubicin   
Epirubicin 
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1993). These differences may contribute in part to the fact that 
greater cumulative doses of epirubicin can be tolerated by 
patients than those of doxorubicin and that epirubicin is less 
cardiotoxic.     
 
The anthracyclines are some of the most widely prescribed 
chemotherapy agents and are used in the treatment of a variety 
of cancers.  Their primary cellular target is the topoisomerase 
enzymes.  These are ubiquitous enzymes with a key role in DNA 
replication and transcription as well as chromosome structure 
and segregation (Froelich-Ammon and Osheroff, 1995).  
Topoisomerases can modify DNA topology without any 
alterations in sequence or deoxynucleotide structure.  There are 
two main classes – topoisomerase I and topoisomerase II, with 
the former causing transient single strand DNA breaks and the 
latter leading to double strand breaks, both of which can be 
resealed.  DNA double helix supercoiling is modulated 
throughout the different phases of the cell cycle and depends on 
transcriptional activity, hence the important role of 
topoisomerases in DNA replication (Binaschi et al., 2001).   
 
Topoisomerase II in particular appears to be the main target for 
the anthracyclines.  As a multi-subunit protein, it requires ATP 
for its catalytic activity and creates breaks in the DNA backbone, 
by passing an intact DNA helix through a transient double 
strand break, thereby regulating winding of the double helix and 
resolving nucleic acid tangles and knots (Froelich-Ammon and 
Osheroff, 1995).   The anthracyclines are topoisomerase II 
poisons, stabilising a reaction where DNA strands are cut and 
linked covalently to topoisomerase II by tyrosine residues.  
Thus, an anthracycline-DNA –topoisomerase complex is formed, 
preventing DNA resealing – in effect, a transient double strand 
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break becomes permanent.   The resulting unrepaired breaks 
lead to a wide range of toxic effects on the cell and damage to 
the genome, including mutations, insertions, deletions and 
chromosomal aberrations (Minotti et al., 2004).  
 
Following topoisomerase II inhibition, the subsequent 
mechanisms of anthracycline induced cytotoxicity remain 
unclear, but it is likely a number of mechanisms are involved.  
The proteasome plays a crucial role in the normal turnover of 
cytosolic and nuclear proteins, including those involved in cell 
growth and metabolism. The proteasome has a role in 
modulating anthracycline activity, by transporting the drug from 
the cytoplasm into the nucleus, where it can then bind DNA and 
exert its cytotoxic effect (Adams, 2003; Kiyomiya et al., 2002).  
Once in the nucleus the anthracyclines can activate p53-DNA 
binding, thus leading to cell cycle arrest and p53 mediated 
apoptosis (Ruiz-Ruiz et al., 2003).  Reactive oxygen species 
(ROS) are generated early on following anthracycline 
administration and these can also modulate the activity of 
several kinases and transcription factors associated with cell 
cycle progression and apoptosis (Laurent and Jaffrezou, 2001).  
Anthracyclines can directly release cytochrome c from 
mitochondria inducing apoptosis and they can also activate 
downstream cell death effector-mediated pathways and 
downregulate activity of the PI3K/Akt pathway. Thus,  
anthracycline induced apoptosis brings into play a wide, 
complex network of cellular events, many of which are not yet 
fully understood (Laurent and Jaffrezou, 2001; Martin et al., 
2002).   
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1.3.4 The anthracyclines and early breast cancer 
 
For nearly thirty years, the anthracyclines have been pivotal in 
the management of early stage, operable breast cancer.  
Improvements have been seen in adjuvant chemotherapy as a 
result of their incorporation into non-cross resistant regimens 
such as cyclophosphamide, methotrexate and fluorouracil 
(CMF), their combination with the taxanes, dose-dense 
administration and new scheduling approaches (Gianni and 
Valagussa, 2009).    
 
Evidence for the benefit of adjuvant chemotherapy in breast 
cancer first emerged in the 1970’s, where Bonnadonna and 
colleagues first published data on the benefits of CMF as 
adjuvant treatment for node positive breast cancer. Their data 
showed that twelve months of postoperative chemotherapy with 
CMF decreased the risk of recurrence in patients with positive 
axillary lymph nodes (Bonnadonna et al., 1976). Long term 
follow up (median observation period 28.5 years) from this 
initial pivotal trial has confirmed that both relapse free survival 
and overall survival remained significantly superior in women 
receiving adjuvant CMF (29% and 25%) than in those treated 
with surgery alone (22% and 16%).  CMF contributed to 
reducing the relative risk of disease relapse by 34% and of 
death from all causes by 22% (Bonadonna et al., 2005).  The 
main therapeutic effect of adjuvant CMF was to reduce the 
incidence of distant metastases (absolute difference of 11% in 
long term analysis). Thus developed the theory that 
micrometastases, which are not clinically detectable, may be 
present at the time of surgery on the primary tumour and are 
unaffected by local treatment.  Operable breast cancer could 
therefore be considered a systemic disease at presentation and 
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therapy directed at the primary tumour fails to affect 
micrometastases which may disseminate, ultimately leading to 
metastatic disease.  It is these micrometastases that are 
targeted by adjuvant chemotherapy. 
 
Once a clear benefit for the use of adjuvant chemotherapy had 
been established, the additional benefits of including an 
anthracycline were addressed.   The use of doxorubicin, which 
had good activity in advanced breast cancer, was investigated in 
combination with cyclophosphamide and proved to have 
equivalent efficacy and greater tolerability than CMF.  The 
National Surgical Adjuvant Breast and Bowel project (NSABP) 
studies B-15 and B-23 found equivalence between four cycles of 
doxorubicin and cyclophosphamide (AC) and six cycles of CMF in 
terms of event free survival, relapse free survival (RFS) and 
overall survival (OS), regardless of nodal status, age or ER 
status.  However, AC offered the advantages of fewer side 
effects and a shorter treatment course (Fisher et al., 2001).  
Subsequent trials looked at the combination of 5-fluorouracil, 
epirubicin and cyclophosphamide (FEC), replacing doxorubicin 
with the less cardiotoxic epirubicin.   In the MA5 trial, pre- or 
post-menopausal women received either FEC or CMF and there 
was a statistically significant improvement in RFS and OS in the 
FEC arm, which has subsequently been maintained throughout a 
ten year follow up period (Levine et al., 2005).  The meta-
analysis reported by the Early Breast Cancer Trialists’ 
Collaborative Group in 1998 confirmed that anthracycline 
containing regimens were associated with significant reductions 
in the rates of recurrence and death when compared to CMF  
(EBCTCG, 1998).   
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Up until this point, many trials had looked at the incorporation 
of an anthracycline, whether doxorubicin or epirubicin, into a 
CMF regimen.  The National Epirubicin Adjuvant Trial (NEAT) 
and the BR9601 trial were designed to determine the value of 
anthracyclines in the adjuvant setting, paying particular 
importance to their scheduling.  The NEAT trial compared four 
cycles of epirubicin followed by four cycles of CMF with six 
cycles of CMF alone.  BR9601 compared four cycles of epirubicin 
followed by four cycles of CMF with eight cycles of CMF alone.  
The primary end points were RFS and OS.   Both trials, involving 
2391 women in total, confirmed a superiority of epirubicin plus 
CMF over CMF alone.  5 year RFS was 76% vs. 69% and overall 
survival was 82% vs. 75% (p<0.001). The incidence of adverse 
effects was higher with epirubicin plus CMF than with CMF 
alone, but this did not affect the dose delivered intensity or 
quality of life (Poole et al., 2006).   
 
Numerous other trials have looked at the benefits of adjuvant 
therapy, whether involving CMF, FEC or FAC.  The Oxford 
overview from 2005, performed by the EBCTCG, perhaps gives 
the most up-to-date analysis of all the trial data available.  
Collaborative meta-analyses were undertaken of 194 
unconfounded randomised trials of adjuvant chemotherapy that 
began by 1995.  The results combined three chemotherapy 
meta-analyses: anthracycline-based versus no chemotherapy 
(8000 women); CMF-based versus no chemotherapy (14000 
women) and anthracycline-based versus CMF-based 
chemotherapy (14000 women).  The findings of the overview 
confirmed that six months of adjuvant anthracycline based 
chemotherapy (FAC or FEC) reduces the annual breast cancer 
death rate by 38 % for women <50 years of age and by 20% 
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for those of age 50-69.  Such regimens were significantly more 
effective than CMF chemotherapy (EBCTCG, 2005).    
    
1.3.5 Neo-adjuvant chemotherapy 
 
The use of chemotherapy before definitive surgery (neo-
adjuvant chemotherapy) began in the late 1970’s and has now 
become a well established treatment option in the management 
of large and potentially operable locally advanced breast 
cancers.  The rationale behind this treatment is to allow more 
women to have breast conserving surgery - if large tumours can 
be downsized with pre-operative chemotherapy, the need for 
mastectomy may be avoided. Most patients respond to 
treatment (60-90%). Also, the tumour itself can be used as a 
measure of response to treatment in vivo and achievement of a 
complete pathological response (pCR), which is seen in 3-16% 
of patients, is a good predictor of long term survival (Jones and 
Smith, 2006). Randomised clinical trial data has shown that 
women who have large, operable tumours and who receive neo-
adjuvant chemotherapy have similar survival to patients treated 
with adjuvant chemotherapy.  One of the largest of these trials, 
the National Surgical Adjuvant Breast and Bowel Project 
(NSABP) trial B-18, randomised 1523 women to either pre-
operative or post-operative doxorubicin and cyclophosphamide 
(Fisher et al., 1998) and at a follow up point of nine years, no 
significant difference was seen between the two groups in terms 
of either disease free survival or overall survival. A 2005 
overview has confirmed that neo-adjuvant and adjuvant 
treatment are equivalent in terms of survival and overall disease 
progression. (Mauri et al., 2005) 
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With the development of the taxanes, trials have been designed 
to look at the addition of paclitaxel and docetaxel in the neo-
adjuvant setting.  In the NSABP B-27 trial, 2411 women were 
randomised to either four cycles of pre-operative doxorubicin 
and cyclophosphamide, followed by four cycles of docetaxel 
either pre or post-operatively (Bear et al., 2006).   Outcome 
was best in the group receiving both the anthracycline and 
taxane containing regimen pre-operatively, with a higher clinical 
complete response (63.6%) and pCR (26.1%) when compared 
to the other two groups (40.1% and 13.7% respectively). 
 
Detection of response to neo-adjuvant chemotherapy is useful 
for a number of reasons.  Early signs of response can be used 
as a predictor of pCR, a predictor of long-term outcome and in a 
decision aid to identify patients who may require a switch in 
systemic treatment (Untch and von Minckwitz, 2009) 
   
1.3.6  Predictors of response to chemotherapy 
 
Decision making regarding the use and benefit of both adjuvant 
and neo-adjuvant chemotherapy depends on a set of clinical 
criteria including axillary lymph node status, tumour size, 
lymphovascular invasion, grade and hormone receptor status. 
However, with the advent of new biological and targeted 
treatments and the development of new molecular techniques it 
still remains difficult to clearly identify those patients who will 
benefit from chemotherapy whilst on the other hand heavily 
over treating individuals who may derive little benefit from 
systemic therapy (McGovern and Stebbing, 2009).    
 
The presence of the oestrogen receptor (ER) predicts to some 
extent the response of breast cancer to endocrine treatment. 
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Patients with tumours which are also strongly positive for the 
progesterone receptor (PgR) have the highest likelihood of 
response (Ravdin et al., 1992).  ER and/or PgR expression is an 
independent prognostic factor in breast cancer (Burcombe et al., 
2004). However, in terms of benefit from chemotherapy, it 
appears that ER negative tumours tend to respond better to 
chemotherapy, rather than ER positive tumours. Studies have 
also shown that the likelihood of achieving a pathological 
complete response (pCR) with primary chemotherapy, a good 
surrogate for long-term survival in the neo-adjuvant setting, is 
also significantly higher in ER negative tumours (Tewari et al., 
2008). Thus, patients who have ER negative cancers likely 
derive the most benefit from adjuvant chemotherapy. 
  
HER2 expression can be used as a predictor of response to 
chemotherapy. Some studies have shown that patients who 
have HER2 positive tumours will benefit particularly from an 
anthracycline containing chemotherapy regimen although the 
exact mechanism for this remains unclear. There is close 
proximity of the HER2 gene to the TOP2A gene located on 
chromosome 17q and topoisomerase II is the main target of the 
anthracyclines, amongst other proteins (Pritchard et al., 2008). 
A number of studies have suggested that deletion or 
overamplification of TOP2A, perhaps closely associated with 
coamplification of HER2, leads to a worse prognosis but greater 
response to anthracycline containing regimens.   Using samples 
from the MA.5 trial, which compared CEF chemotherapy to CMF, 
patients who showed TOP2A alterations (either amplifications or 
deletions) had an increased responsiveness to the anthracycline 
containing regimen, similar to that seen with HER2 amplification 
(O'Malley et al., 2009).  
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The absence of the expression of certain receptors can also be a 
predictor of chemotherapy response. A number of different 
pathological subclasses of breast cancer have been identified, 
based on gene expression profiles, including triple negative 
breast cancers i.e. breast cancers which do not express ER, PgR 
or HER2. This subtype comprises approximately 15-20% of 
breast cancers and the majority of triple negative cancers have 
basal like expression profiles, expressing cytokeratins 5, 14 and 
17, normally found in the cell layer lying closest to the epithelial 
basement membrane (Irvin Jr and Carey, 2008). Similar 
markers are also expressed in BRCA1-associated cancers. 
Tissue microarray studies have shown a high rate of EGFR 
overexpression in these triple negative cancers (Colleoni et al., 
2008) and c-kit expression is also higher. Interestingly, these 
tumours are sensitive to chemotherapy, and the pCR rate may 
be higher in these cancers than some of the other subtypes. 
However, they have a high risk of relapse in contrast to other 
cases with pCRs. The association of these triple negative 
tumours with BRCA1 mutation carriers may have implications 
for choice of therapeutic agent. Tumours with BRCA1 
dysfunction have deficient double-stranded DNA repair 
mechanisms and evidence is now emerging that these cancers 
may be more sensitive to DNA damaging agents such as the 
platinums (Taniguchi et al., 2003). 
 
Ki67 is a proliferation marker that has become a useful means 
of monitoring cell proliferation.  Ki67 is expressed and can be 
detected in cells in the G1 phase of the cell cycle, but not in 
quiescent G0 cells (Jones et al., 2008).  MIB-1, a monoclonal 
antibody, has been used to assess the expression of Ki67 in 
formalin fixed, paraffin embedded tissue sections and correlates 
well with Ki67 measurement (Cleator et al., 2002; 
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Urruticoechea et al., 2005).  Studies have shown that a 
significant fall in Ki67 occurs as a result of neo-adjuvant 
chemotherapy and that higher pre-treatment proliferation is 
associated with a better response to treatment (Archer et al., 
2003; Ellis et al., 1998).  Also, tumours that show a >75% 
reduction in Ki67 post-chemotherapy were more likely to 
achieve a pathological response (Burcombe et al., 2004).    
 
Therefore, the type of chemotherapy offered to patients may in 
the future not just depend on their risk or recurrence but also 
the particular characteristics of their tumour.  ER negative 
cancers and cancers that overexpress HER2 and have TOP2A 
alterations may particularly benefit from the use of 
anthracyclines in the adjuvant setting and patients still 
displaying elevated proliferation markers, such as Ki67, post 
chemotherapy may benefit from other non cross-resistant 
regimens.   
 
1.3.7 Chemotherapy resistance 
 
Resistance to chemotherapy remains one of the biggest limiting 
factors in the treatment of all cancers.  Chemotherapy 
resistance can be intrinsic, where no response to initial 
treatment is seen, or acquired, where failure to respond to 
treatment develops over time, perhaps after multiple lines of 
therapy (Perez, 2009).  There are multiple mechanisms by 
which cells can develop drug resistance including apoptosis 
evasion, membrane transporters, defects in DNA repair and 
intracellular drug inactivation (Raguz and Yague, 2008).  
 
The exact mechanism by which many chemotherapeutic agents 
are taken up by cells remains unclear.  However, more is known 
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about drug efflux, which is mediated by the ATP-binding 
cassette (ABC) transporters.  These membrane proteins function 
as drug efflux pumps, reducing intracellular concentrations of 
drug in an energy dependent manner, thereby leading to drug 
resistance (Chien and Moasser, 2008). This family includes the 
P-glycoprotein (P-gp) membrane protein encoded by MDR1 (or 
ABCB1) and the multidrug-resistance-associated protein MRP1 
and the breast cancer resistance protein (BCRP).  In vivo, these 
proteins function physiologically by clearing excessive 
intracellular concentrations of toxins and they are thought to 
play a vital role in cellular protection from endogenous 
substrates. For example, P-gp is found on the luminal surface of 
endothelial cells involved in the formation of the blood brain 
barrier, thus protecting the central nervous system from 
cytotoxins.   Other “sanctuary” sites include testicular tissue and 
the developing foetus (Gottesman et al., 2002).  ABC 
transporter genes are often overexpressed in cancer and the 
anthracyclines are known to be substrates for both P-gp and 
MRP1.  These proteins can actively transport the drug out of the 
cell, and seem particularly effective at targeting hydrophobic 
drugs such as the anthracyclines (Longley and Johnston, 2005).    
 
Other mechanisms of resistance can include inactivation of 
cytotoxics.  For example, up to 80% of the anti-metabolite 5-FU 
is metabolised in the liver, by dihdropyridimine dehydrogenase 
(DPD).  Studies have shown that high levels of DPD mRNA in 
colorectal tumours correlate with 5-FU resistance, likely to be 
due to drug degradation of 5-FU by DPD (Salonga et al., 2000).  
Other drugs, such as the platinum agents, can form conjugates 
with the thiol glutathione (GSH) and the resulting complex 
inactivates the drug, which then becomes a substrate for the 
ABC transporter proteins and ultimately leads to efflux from the 
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cell (Longley and Johnston, 2005).  Cytochrome P450 enzymes, 
an inducible oxidative enzyme from the liver, can be 
overexpressed in solid tumours, and can inactivate drugs such 
as irinotecan and altered activity of enzymes such as 
topoisomerase II can prevent anthracycline binding to the 
topoisomerase-DNA complex, thus allowing broken DNA strands 
to be repaired and bypassing the toxic effects of the drug 
(Raguz and Yague, 2008).           
 
Other factors that lie downstream of the initial cytotoxic insult 
also contribute to drug resistance.  Following chemotherapy, 
there is a critical balance between cell cycle arrest, which allows 
for DNA repair and survival, and cell death.  Mutations in these 
downstream events can lead to drug resistance.  Loss of normal 
cell cycle checkpoints, mutated DNA repair pathways and an 
ability to evade apoptotic death are all mechanisms by which 
tumour cells can develop resistance to chemotherapy 
(Johnstone et al., 2002) and are discussed later in this chapter.        
   
1.4  THE CELL CYCLE 
 
A cell reproduces by performing an orderly sequence of events, 
producing two daughter cells that are accurate copies of the 
parent. This cycle of division and duplication is known as the cell 
cycle and consists of a series of steps allowing replication of 
DNA and the segregation of the duplicated chromosomal DNA 
equally to the two daughter cells. A key aspect of cancer is 
dysregulated cell cycle control. 
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Figure 1.4 Mammalian cell cycle  (Dehay and Kennedy, 2007) 
 
There are four main phases of the cell cycle: G1, S, G2 and M 
phase (Figure 1.4).  Chromosomal duplication occurs during S 
phase (DNA synthesis), occupying almost half the cell cycle time 
in mammalian cells.  Chromosomal segregation and cell division 
occurs in M phase, including nuclear division (mitosis) and 
cytoplasmic division (cytokinesis). More time is required for 
growth and protein synthesis and the gap phases of G1 and G2 
allow for this: G1 between M phase and S phase and G2 between 
S phase and mitosis.  In a typical cell in culture, G1, S, G2 (also 
known as interphase) may last for 23 hours of a 24 hour cycle, 
with 1 hour for M phase (Alberts et al., 2008). 
 
G1 is the phase during which cells respond to extracellular 
stimuli that ultimately determine whether cells make the 
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decision to divide and replicate DNA or, alternatively, to exit the 
cell cycle and enter a quiescent state known as G0.  However, 
once cells have made the commitment to begin DNA replication, 
a time late in G1  known as the restriction point, they are 
irreversibly committed to complete the cycle, even if the 
extracellular signals that stimulate cell growth and division are 
removed (Sherr, 2000).  The restriction point is the first of three 
checkpoints in the cell cycle.  The second is the G2/M 
checkpoint, where the early mitotic events that lead to 
chromosome alignment on the spindle in metaphase is triggered 
and the third at the metaphase to anaphase transition, where 
sister chromatid separation takes place, leading to the 
completion of mitosis and cytokinesis (Schafer, 1998).  These 
checkpoints can block cell-cycle progression and also trigger cell 
death by apoptosis.  
 
The key components of the cell cycle control system are 
members of a protein kinase family known as the cyclin 
dependent kinases (Cdks) and their activity fluctuates as the 
cell progresses through the cell cycle, resulting in cyclical 
changes in the phosphorylation of intracellular proteins which 
initiate and regulate the major cell cycle events.  These 
serine/threonine kinases are dependent on a discrete protein 
partner, a cyclin, for activity.  The catalytic activity of Cdks is 
determined by the binding of this regulatory cyclin subunit.  
Cyclin binding and phosphorylation can stimulate activity, whilst 
phosphorylation of residues adjacent to the Cdk ATP-binding 
site and binding of inhibitory proteins can inhibit Cdk activity 
(Pollard and Earnshaw, 2008). 
 
The cyclins are defined by the stage of the cell cycle at which 
they bind Cdks and by their function.  The G1/S cyclins (cyclins 
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D and E) activate Cdk2, Cdk4 and Cdk6 late in G1 and help 
trigger progression through the restriction point, leading to 
commitment to entry to the cell cycle.  The S-cyclins (cyclin A) 
bind Cdk1 and Cdk2 to promote chromosome duplication and 
some early mitotic events.  The M-cyclins (cyclin B) activate 
Cdk1 to stimulate entry into mitosis at the G2/M checkpoint 
(Alberts et al., 2008).   
 
The cyclin D kinases, in combination with their catalytic partners 
Cdk4 and Cdk6, are the critical integrators of mitogenic signals 
for the cell cycle and cyclin D1 expression is seen early following 
cell cycle entry. Its assembly with Cdk4 is key to allowing cells 
to progress through the restriction point following mitogenic 
stimulation. Cyclin D dependent kinases catalyse the 
phosphorylation dependent inactivation of Rb, releasing E2F 
complexes which in turn transcriptionally activate genes whose 
products are critical for cell cycle progression, such as cyclin E 
(Diehl, 2002).    
 
A number of mechanisms can inactivate Cdks.  Phosphorylation 
of threonine and tyrosine in the roof of the kinase active site 
can inhibit the activity of cyclin-Cdk complexes.  A protein 
kinase known as Wee1 can phosphorylate these sites – 
dephosphorylation by the Cdc25 phosphatases can reverse this.  
Another strategy for inactivating Cdks involves the binding of 
cyclin-dependent kinase inhibitors (CKIs) and inhibitors of Cdk4 
(INK4).     
 
1.4.1 Cdk inhibitors 
 
Binding of CKIs regulates cyclin-Cdk complexes, by stimulating 
a rearrangement in the structure of the Cdk active site, thus 
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rendering it inactive.  There are two main families of inhibitors – 
INK4 proteins, named after their ability to inhibit Cdk4 (INK4A, 
INK4B, INK4C AND INK4D) and the Cip/Kip family, composed of 
p21Cip1, p27Kip1 and p57kip2 (Malumbres and Barbacid, 2009).    
INK4 proteins target the cyclin D dependent kinases and 
sequester Cdk4/6 proteins, which in turn liberates Cip/Kip 
proteins, thereby inhibiting cyclin E-Cdk2 to ensure cell cycle 
arrest in G1 (Sherr, 2000).    
 
p27Kip1 is an important Cdk inhibitor that regulates cell 
proliferation, motility and apoptosis. A variety of signal 
transduction networks can regulate p27Kip1 and its activity is 
controlled by its concentration, subcellular localisation and 
phosphorylation status (Chu et al., 2008).  In quiescent cells, 
p27kip1 is nuclear, its levels are high and it is mobilised to inhibit 
cyclin E-Cdk2, arresting cell cycle progression.  However, when 
cells enter the cell cycle after mitogenic stimulation and 
accumulate cyclin D dependent kinases, the Cip/Kip proteins are 
sequestered in complexes with these cyclin D –dependent Cdks, 
eventually targeting them for destruction in proteosomes 
(Sherr, 2000).     
 
1.4.2 The cell cycle and cancer 
 
A variety of genetic and epigenetic events can cause 
overactivity of the cell cycle in human cancers – cells are no 
longer subject to normal proliferative and inhibitory effects, with 
signal transduction pathways overactive and their normal 
inhibitory mechanisms switched off.   Transformed cells often 
exhibit reduce growth factor requirements and a number of cell 
cycle regulators are known to be mutated, deleted or 
overexpressed in human cancers  (Schafer, 1998).  p53, 
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responsible for promoting G1 arrest after DNA damage and with 
a key role in the DNA damage checkpoint, is mutated in up to 
50% of malignancies.  After DNA damage, p53 is stabilised and 
initiates the transcription of p21Cip1, leading to G1 arrest.   
However, when p53 is mutated or in p53 null cells, the DNA 
damage checkpoint is abrogated, allowing cells to continue 
through the cell cycle, ensuring that after mitosis the damage is 
fixed in the genome (Schafer, 1998). Deletions and missense 
mutations, resulting in a truncated, non-functioning pRb are 
also seen in human cancers.  Phosphorylation of pRb, leading to 
its inactivation, releases E2F and the cell cycle is initiated.  
Abrogation of pRb function in cancers can again lead to loss of 
restriction point control and  cell cycle inhibitory mechanisms 
(Schafer, 1998).  
 
 Cyclin D1 is frequently overexpressed in tumours, particularly 
breast cancer.  This can result from chromosomal translocations 
and gene amplification.  Its role in malignancy is multifactorial – 
it can drive the cell cycle through interaction with its catalytic 
partners Cdk4 and 6, prevent the inhibitory functions of the 
Cip/Kip family by sequestration, promote phosphorylation of 
pRb and may even have a role as a transcriptional co-factor for 
steroid receptors such as the androgen receptor (AR) and the 
oestrogen receptor (ER), deregulating hormone dependent gene 
expression (Diehl, 2002).  
 
p27Kip1 is rarely mutated or deleted in tumours, but protein 
levels are often reduced or mislocalised in many human cancers 
- this is associated with a poor prognosis.  Oncogenic activation 
of the receptor tyrosine kinase pathways, such as PI3K and Ras-
MAPK can also enhance inactivation of p27Kip1 and accelerates its 
proteolysis in human cancers. (Chu et al., 2008).  
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1.5 APOPTOSIS 
 
An organism has two main mechanisms for the elimination of 
cells – necrosis and apoptosis.  Cell death is an essential part of 
embryonic development, tissue homeostasis, immunity and 
regulation of cell viability by growth factors and hormones. It is 
disruption of these pathways that allow cancer cells to survive. 
Necrosis results from irreversible injury to the cell and a 
collapse of normal cell physiology – the plasma membrane is 
damaged and ruptures, spilling cytoplasmic contents into the 
surrounding tissues.  This produces a local, inflammatory 
reaction, activating phagocytic cells which ingest the debris 
(Pollard and Earnshaw, 2008).    
 
Apoptosis is a form of programmed cell death that allows 
organisms to remove damaged, senescent or unwanted cells 
and is the best-defined mechanism for counteracting tumour 
growth (Russo et al., 2006).   It is characterised by 
morphological changes, such as shrinkage of the cell, 
cytoskeletal collapse, condensation of nuclear chromatin and the 
formation of small membrane enclosed fragments, called 
apoptotic bodies,  that can be engulfed without initiating 
inflammation (Jaattela, 2004).  Cells can recognise damage and 
can kill themselves by undergoing apoptosis. In the case of DNA 
damage, where cancer promoting mutations may occur if not 
repaired, cells can detect this damage and undergo apoptosis.  
These cells display characteristic biochemical changes which 
allow the identification of apoptotic cells, for example cleavage 
of chromosomal DNA by endonucleases produce DNA fragments 
of distinctive sizes, generating multiple new DNA ends which 
can be identified by the addition of labelled deoxynucleotide 
(dUTP) to the 3’-OH ends of DNA fragments – the TUNEL 
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technique. These cells also express negatively charged 
phospholipids on their outer leaflet, which can be visualised with 
a labelled form of the Annexin V protein, which specifically binds 
to this phospholipid.(Alberts et al., 2008; Pietsch et al., 2008).  
 
Apoptosis is carefully regulated and the caspases, specialized 
proteases with a cysteine in their active site, have a key role in 
inactivating cellular survival pathways and activating factors 
promoting cell death. Caspases are selective enzymes, 
responsible for cleaving a limited subset of cellular proteins. 
They can cleave protein kinases, producing constitutively active 
enzymes that can promote cell death.  They can also cleave and 
inactivate proteins that normally function in the detection and 
repair of DNA damage (Pollard and Earnshaw, 2008).   Once 
activated, caspases cleave and activate other procaspases, 
resulting in an amplifying proteolytic cascade, which eventually 
leads to activation of a nuclease, ultimately destroying the 
chromosomal DNA of the cell.   
 
 Two principle pathways lead to cell death by apoptosis – the 
extrinsic and intrinsic pathways.  Extracellular signal proteins 
which bind to cell surface death receptors activate the extrinsic 
pathway.  These death receptors are transmembrane proteins, 
consisting of an extracellular ligand-binding domain and an 
intracellular ‘death domain’, essential for the receptors to 
activate apoptosis (Alberts et al., 2008).  The receptors belong 
to the tumour necrosis factor (TNF) receptor family, including a 
receptor for TNF itself and the Fas death receptor.  Activation of 
these receptors by means of specific ligands, such as TNFα and 
TRAIL, bring about the recruitment of other family members, 
resulting in the chain activation of caspases 8, 3 and 7 
(Dempsey et al., 2003). Death receptor activation can also 
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trigger intracellular signalling pathways which do not result in 
apoptosis. For example, TNF receptors can also activate the 
NFκB pathway, responsible for cell survival and the activation of 
genes involved in the inflammatory response (Shen and 
Tergaonkar, 2009). 
 
In the intrinsic pathway, there is release of mitochondrial 
proteins that can activate a proteolytic caspase cascade in the 
cytoplasm, leading to apoptosis.  These mitochondrial events 
are regulated by the Bcl-2 family of proteins.  A crucial protein 
released from the mitochondria is cytochrome C, which 
associates with the scaffolding protein Apaf-1, forming an 
apoptosome, which in turn can bind caspase 9 and recruit and 
activate caspase 3, a key effector of both the intrinsic and 
extrinsic pathways (Li et al., 1997).  Further downstream 
executioner procaspases are then activated to induce apoptosis.   
 
1.5.1 Bcl-2 proteins 
 
The human Bcl-2 homologues make up the major apoptosis 
regulatory gene family and like the caspases family have been 
conserved in evolution from worms to humans.  The apoptosis 
suppressing Bcl-2 gene was initially discovered in low grade B-
cell non Hodgkin’s lymphoma (NHL), at the breakpoints of 
t(14;18) chromosomal translocation, moving the Bcl-2 gene into 
the immunoglobulin heavy-chain gene cluster, a site of active 
gene transcription. (Tamm et al., 2001).  Overexpression of Bcl-
2 and other antiapoptotic proteins inhibits cell death induced by 
growth factor deprivation, oxidative stress and hypoxia (Yip and 
Reed, 2008).   The Bcl-2 family consists of more than 30 anti- 
and proapoptotic molecules which can bind to each other, 
forming homo- and heterodimers.  They are characterised by 
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the presence of one to four conserved Bcl-2 homology (BH) 
domains, termed BH1 to BH4.  The antiapoptotic members, 
including Bcl-2 and Bcl-XL are primarily localised to the outer 
mitochondrial membrane, the endoplasmic reticulum and the 
nuclear membrane, where they prevent the release of 
cytochrome C and other proapoptotic proteins into the 
cytoplasm and nucleus.  The pro-apoptotic members can be 
divided into two sub groups – the multidomain groups, such as 
BAX, and the BH3 only proteins, including BIM and BAD. These 
act as sensors of cellular damage and can initiate cell death  
(Pommier et al., 2004).  In response to cellular insults, BH3-
only family members are activated, through increased 
transcription, proteins stabilisation and post-translational 
modifications.  This induces mitochondrial permeabilisation, 
leading  to release of  cytochrome C and other proapoptotic 
proteins from the mitochondrion (Letai, 2008).  BH3-only 
proteins are the crucial link between apoptotic stimuli and the 
intrinsic pathway of apoptosis. When cells are deprived of 
extracellular survival signals, the transcription of the gene 
encoding the BH3-only protein Bim can then activate the 
intrinsic pathway. Similarly, when DNA damage occurs, the 
tumour suppressor p53 accumulates, promoting the intrinsic 
pathway and thus eliminating a potential cancerous cell (Alberts 
et al., 2008). 
 
1.5.2 Apoptosis and chemoresistance 
 
Apoptosis is key to cell signalling pathways, the cell cycle, cell 
structure but also to the development of human diseases, in 
particular – cancer.  A block in apoptosis is essential for cancer 
maintenance. The regulation of genes encoding Bcl-2 family 
proteins is altered in a variety of cancers. As well as the 
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chromosomal translocations observed in NHL, Bcl-2 gene 
amplification is seen in other lymphomas and small cell lung 
cancer (SCLC).  Other mechanisms of elevated gene expression 
include loss of endogenous microRNAs which normally repress 
Bcl-2 gene expression and gene hypomethylation (Cimmino et 
al., 2005; Hanada et al., 1993). Overexpression of Bcl-2 and 
other antiapoptotic proteins has been implicated in resistance to 
chemotherapy.  Most cytotoxic agents and radiation kill cancer 
cells by inducing apoptosis and there is emerging evidence that 
Bcl-2 is a multidrug resistant protein, preventing induction of 
apoptosis, regardless of the mechanism of action of the drug 
(Yip and Reed, 2008). This is distinct from other forms of drug 
resistance, namely mechanisms involving drug metabolism, 
drug efflux and drug inactivation.  Whether it be through DNA 
breaks (platinum), microtubule depolymerisation (taxanes), 
topoisomerase inhibition (anthracyclines) or receptor inhibition 
(anti-androgens and oestrogens), most drugs appear to depend 
on Bcl-2 dependent mechanisms to exert their cytotoxic effect.  
Cancer cells may escape apoptosis through a number of Bcl-2 
mediated mechanisms. This includes eliminating the activation 
of pro-death BH3-only proteins such as Bim or increased 
expression of Bcl-2 itself, leading to bound and sequestered 
anti-apoptotic proteins.  Defective expression of pro-apoptotic 
Bcl-2 family members can also occur when p53 function is lost, 
as Bcl-2 genes are regulated by p53.   
 
Bcl-2 has been therapeutically targeted, with the most advanced 
approach utilizing an antisense oligonucleotide to down regulate 
Bcl-2 expression (Genasense or G3139).  In preclinical studies, 
antisense inhibition of Bcl-2 could induce death in cancer cell 
lines, although clinical studies have failed to reach their 
designated endpoints.  In a recent study however in chronic 
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lymphocytic leukaemia (CLL), an improvement in response rate 
was seen in relapsed patients when treated with G3139 in 
combination with fludarabine and cyclophosphamide (O'Brien et 
al., 2007).These drugs may have use in the future, synergising 
with more traditional cytotoxic agents.    
      
1.6 THE PHOSPHATIDYLINOSITOL-3-KINASE PATHWAY 
 
The phosphatidylinositol 3-kinase (PI3K) family is a large family 
of lipid and serine/threonine kinases, a highly conserved group 
of intracellular lipid kinases which phosphorylate the 3’-hydroxyl 
group of phosphatidlyinositol and phosphoinositides (Engelman 
et al., 2006).  This pathway is activated downstream of a 
number of extracellular signals and PI3Ks generate second 
messengers that have a key role in cell growth, proliferation and 
cell survival –activation or inactivation of components in this 
pathway can disrupt normal cellular signalling pathways leading 
to malignant transformation and this pathway is frequently 
dysregulated in human cancers and targeted by genomic 
abberations such as mutations, amplifications and 
rearrangements (Dillon et al., 2007; Hennessy et al., 2005).  
 
The PI3K pathway is important in internalising the effects of 
extracellular growth factors and of membrane tyrosine kinases.  
Ligand binding activates receptor tyrosine kinases by bringing 
together a pair of kinase domains on the cytoplasmic surface of 
the membrane.  This dimerisation allows kinase domains to 
activate each other by phosphorylation on tyrosine residues, 
creating phosphotyrosine binding sites for downstream effectors 
and adaptor proteins (Pollard and Earnshaw, 2008) (Figure 1.5).   
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Once activated, PI3K catalyses phosphorylation at the 3’- 
position of the inositol ring of phosphatidylinositol (PI), 
generating several phosphoinositides second messengers such 
as PI 3,4 bisphosphate (PIP2) and then PI 3,4,5 –trisphosphate 
(PIP3), which can then recruit and serve as docking sites for 
signaling proteins with PIP3-binding pleckstrin-homology (PH) 
domains, including one of the main effectors - AKT (protein 
kinase B) (Alberts et al., 2008).  PIP3 is also a substrate for the 
phosphatase PTEN (phosphatase and tensin homolog deleted on 
chromosome 10) which dephosphorylates PIP3 to generate PIP2, 
thus negatively regulating PI3K signalling, switching off the 
pathway and acting as a tumour suppressor.  Many human 
cancers also show inactivation of PTEN, which results in 
constitutive activation of the PI3K pathway (Bader et al., 2005).   
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 Signalling through the PI3K/AKT pathway   
(Adapted from Hennessy et al., 2005) 
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1.6.1 Class 1 PI3K proteins 
 
There are multiple isoforms of the PI3K superfamily and these 
are divided into three main classes, based on their lipid 
substrate specificity and sequence homology.  Class I PI3Ks are 
comprised of a p110 catalytic subunit and a p85 regulatory 
adaptor subunit, Class II PI3Ks are monomeric, consisting of 
only a catalytic subunit and lack adaptor subunits and 
preferentially phosphorylate PtdIns and PtdIns(4)P and class III 
phosphorylate only PtdIns and are implicated in autophagy 
(Cantrell, 2001).   
 
The activity of class I PI3Ks is tightly controlled, with 
extracellular signals recruiting them to the plasma membrane. 
They are activated by extracellular stimuli via receptor tyrosine 
kinases or G-protein-coupled-receptors - only Class I PI3Ks 
have been implicated in cancer, with no known link between 
class II and III PI3Ks and malignancy  (Zhao and Vogt, 2008). 
The production of the second messenger PIP3 is a unique feature 
of Class I PI3Ks, which has a key role in cell growth and 
replication and it is this that is likely to contribute to their 
oncogenic potential.  Class I PI3Ks have both protein and lipid 
kinase activity but it is the latter which appears critical for their 
role in cancer development (Zhao and Vogt, 2008). Class I 
PI3Ks are heterodimeric proteins.  There are four isoforms of 
the catalytic subunit: p110α, p110β, p100δ and p110γ.  These 
isoforms share similar domain compositions, including an 
adaptor binding domain, a Ras binding domain, and a C2 
(protein-kinase-C- homology-2) domain with affinity for lipid 
membranes (Walker et al., 1999).   
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Class I PI3Ks can be further subdivided into Class IA and Class 
IB, according to their regulatory subunits and connection to 
upstream signalling.  Class IA, which encompasses p110α, 
p110β and p110δ are activated by receptor tyrosine kinases and 
associate with the p85 regulatory subunits of which there are 
five species; p85α, p85β, p55α, p55γ and p50α. p85 has two 
Src homology 2 (SH2) domains, responsible for linking the p85-
p110 PI3K enzyme complex to upstream signals from receptor 
tyrosine kinases (Kok et al., 2009). Class IB, which consists of 
p110γ, bind the non p85 regulatory subunit p101 as well as p84 
and p87PIKAP and can be activated by small G-proteins (Denley 
et al., 2007).  When upstream signals are absent, the 
regulatory subunits stabilize p110 and suppresses its catalytic 
activity (Luo et al., 2005; Yu et al., 1998). 
 
Specific roles have been identified for the multiple isoforms of 
PI3Ks. Mouse knockout models have shown that p110α and 
p110β knockouts are embryonically lethal, whereas p110δ and 
p110γ knockouts are viable, but have defects in immune 
response components (Bi, 2002; Bi et al., 1999; Sasaki et al., 
2000).    
 
1.6.2 Akt/Protein kinase B (PKB) 
 
One of the most important downstream effectors of PI3K is the 
serine/threonine kinase Akt (also known as protein kinase B or 
PKB). Akt is the primary downstream mediator of PI3K, 
regulating a variety of cellular processes through the 
phosphorylation of a diverse set of substrates. Akt has a role in 
cell cycle regulation by phosphorylating the cell cycle inhibitors 
p21Cip1 and p27Kip1, leading to their cytoplasmic retention and 
can also cause increased translation and stabilisation of cyclin 
 66 
D1 (Diehl et al., 1998; Viglietto et al., 2002; Zhou et al., 2001).  
Akt plays a role in cell survival, by inhibiting the proapoptotic 
Bcl2 family member Bad and by inhibition of the Forkhead 
family of transcription factors, which activate proapoptotic 
related genes (Datta et al., 1997).  Akt also leads to NFκB 
mediated expression of prosurvival genes and can activate 
mTOR (Kane et al., 1999; Li et al., 2004). 
 
All Akt isoforms share similar structures, containing an N-
terminal regulatory domain including a pleckstrin homology (PH) 
domain, a hinge region where the PH domain is connected to a 
serine/threonine kinase domain and a C-terminal region 
responsible for its kinase activity (Franke, 2008).  Three 
isoforms of Akt have been identified in mammalian cells – Akt1, 
Akt2 and Akt3, all of which are encoded for by different genes 
but share a high degree of amino acid homology (West et al., 
2002).  Akt1 is the most ubiquitously expressed, Akt2 is found 
at high levels in insulin-sensitive tissues such as the liver and 
adipose tissue and Akt3 is expressed at highest levels in the 
brain and testes (Hill et al., 1999; Nakatani et al., 1999; Paul J. 
Coffer, 1991). 
 
Akt is activated by a dual regulatory mechanism.  PIP3 is 
generated on the inner leaflet of the plasma membrane 
following PI3K activation and this recruits Akt by direct 
interaction with its PH domain. Once at the plasma membrane, 
another PH-domain containing serine/threonine kinase, called 3-
phosphoinositide-dependent protein kinase-1 (PDK1) 
phosphorylates Akt on Thr308 (Vanhaesebroeck and Alessi, 
2000). Maximal activation of Akt however requires further 
phosphorylation at Ser473, although the exact mechanism of 
this second phosphorylation event is not fully understood, but is 
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likely to occur via the kinase PDK2 (Vivanco and Sawyers, 
2002). Once phosphorylated at Ser473 and Thr308, Akt is 
highly active and can translocate to the cytoplasm and nucleus 
to phosphorylate a diverse set of substrates (Thompson and 
Thompson, 2004). 
 
Mechanisms of inactivation of Akt remain poorly understood, 
with no specific Akt phosphatase having been identified.  
However, treatment of phsophorylated Akt with a serine-
threonine phosphatase PP2A, has been shown to 
dephosphorylate Akt and abolish its activity (Andjelkovic et al., 
1996). 
 
1.6.3 The PI3K pathway and cancer 
 
The PI3K pathway has been implicated in cancer and it is one of 
the most frequently targeted pathways in human tumours, with 
up to 30% of all cancers estimated to have mutations in PI3K 
pathway components (Luo et al., 2003).   Chromosomal 
amplification of PI3K or Akt, constitutive activation of Akt and 
PTEN deletions are seen in a wide variety of cancers and play a 
role in the tumorigenic process (Thompson and Thompson, 
2004).  Other transforming events that do not directly modify 
PI3K, Akt or PTEN can still cause constitutive activation of the 
PI3K pathway, including EGFR and HER2 overamplification, as 
these receptors signal through the PI3K pathway.   
 
The gene encoding for the p110α catalytic subunit of PI3K, 
PIK3CA, is mutated in a wide variety of human cancers, often 
arising from single nucleotide substitutions.  These mutations 
are seen in around 30% of common epithelial tumours, 
including breast, colon and prostate cancer (Zhao and Vogt, 
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2008).  Point mutations in p110α often cluster around two 
hotspots – E545 in the helical phosphatidylinositol kinase 
homology domain and H1047 near the end of the catalytic 
domain (Engelman et al., 2006). In cell lines, the expression of 
these p110α mutants leads to Akt activation in the absence of 
growth factor stimulation and a gain in function in p110α with 
significant upregulation of the lipid kinase activity of the mutant 
protein (Kang et al., 2005; Samuels et al., 2004).  
Overamplification of p110α (or PIK3CA) is seen in bowel, 
ovarian, head and neck and other cancers, where the 
subsequent overexpression of a structurally normal protein is 
likely to contribute to malignant transformation, analogous to 
HER2 overexpression in breast cancer (Vivanco and Sawyers, 
2002).  Studies have shown also that amplification of the 
PIK3CA locus during lung cancer progression occurs in high 
grade, but not low grade pre-invasive lesions, further evidence 
that gain in PI3K function represents commitment to tumour 
progression (Massion et al., 2004).  Interestingly, mutations in 
p110α and other mechanisms of activating PI3K signalling seem 
to be mutually exclusive.  Cancers that frequently harbour 
p110α mutations, such as breast and bowel cancer, rarely show 
PIK3CA amplification and in tumours where PIK3CA 
amplification is common, such as gastric cancer, mutations are 
much less frequently observed (Campbell et al., 2004).  Thus, 
only one mutation may be sufficient for tumour development 
and double mutations may in fact have a negative effect (Yuan 
and Cantley, 2008).   
 
p85 mutations and translocations are rare but have been 
identified in transformed cell lines and in human tumour 
samples.  Mutated p85 leads to constitutive activation of PI3K 
signalling and expression of mutant p85 in mouse models leads 
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to the development of solid tumours (Bader et al., 2005; R.-
Borlado et al., 2000). 
 
Akt itself is another target of genomic and epigenetic changes in 
cancer and amplification in multiple Akt isoforms have been 
seen in ovarian, breast and gastric cancers (Engelman et al., 
2006).  Some of these changes may be isoform specific. 
Mutations in the PH domain of Akt1 result in prolonged 
constitutive activation of Akt and prolonged association with the 
plasma membrane sufficient to transform cells in culture 
(Carpten et al., 2007).   The expression of Akt2 and Akt3 is 
pathologically increased in human cancers and elevated Akt2 
activity can increase cell motility and metastatic potential, a 
phenotype not exhibited in cells expressing activated Akt1 
(Arboleda et al., 2003; Hutchinson et al., 2004).   
 
Finally, the tumour suppressor PTEN has been shown to be 
mutated or deleted in many human tumours. The normal 
function of PTEN is critical for cells to maintain homoestasis and 
the absence of functional PTEN in cancer cells results in elevated 
levels of PIP2 and PIP3, causing constitutive activation of the 
PI3K signalling pathway through downstream components such 
as Akt and mTOR (Cantrell, 2001; Sansal and Sellers, 2004).  
There is growing evidence that inactivation of PTEN may be as 
frequent as p53 mutations in many adult epithelial cancers. 
Germline mutations in the PTEN gene result in Cowdens disease, 
a familial disease characterised by a high risk of harmatomas 
and cancers (Sansal and Sellers, 2004).  Knockout mice 
rendered heterozygous for PTEN develop cancers, particularly 
endometrial cancers and up to 50% of human endometrial 
cancers have been shown to harbour PTEN mutations.  
Interestingly, PTEN mutations are also seen in early preinvasive 
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endometrial conditions such as endometrial hyperplasia, 
suggesting loss of PTEN may be an early event in cancer 
development (Maxwell et al., 1998; Mutter et al., 2000; 
Podsypanina et al., 1999; Stambolic et al., 2000).   Somatic 
mutations, gene deletion or gene inactivation of PTEN occur in 
glioblastomas, prostate and breast cancer and malignant 
melanoma (Engelman et al., 2006).  Loss of PTEN protein is 
seen in about one fifth of prostate cancers and this correlates 
with Gleeson score and advanced stage, suggesting 
accumulation of mutations and progressive loss of PTEN is 
associated with advanced disease (McMenamin et al., 1999).  
 
1.6.4 Therapeutic approaches targeting the PI3K 
pathway 
 
Many cancers depend on a persistently activated PI3K signalling 
pathway to promote proliferation, survival and migration thus 
making this pathway an attractive target for therapeutic 
intervention by disrupting PI3K signalling.  For example, the Rak 
tyrosine kinase interacts with PTEN, leading to its 
phosphorylation on Tyr336.  Ectopic expression of Rak can 
suppress breast cancer cell proliferation and invasion, whilst  
knockdown of Rak promotes PTEN protein degradation, thus 
suggesting Rak may be an interesting target to modulate 
activity of the PI3K pathway (Yim et al., 2009).  Similarly, 
overexpression of Inositol Polyphosphate 4-Phosphatase Type II 
(INPP4B), which can target PIP2 hydrolysis, reduces tumour 
growth and promotes cellular senescence, whilst knockdown of 
INPP4B results in enhanced Akt activation in breast cancer cells, 
again identifying a potential therapeutic target to disrupt PI3K 
signalling (Gewinner et al., 2009). Modulation of the PI3K 
pathway is seen after chemotherapy administration in vitro.  
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Inhibition of Akt is seen in chemotherapy induced cytotoxicity – 
treatment of MCF7 cells by paclitaxel is accompanied by Akt 
inactivation (Sunters et al., 2006).  However the effects of 
chemotherapy are often non-specific and the development of 
more specific agents is likely to lead to greater efficacy and less 
toxicity. Wortmannin and LY294002 are both PI3K inhibitors 
that have been used in cell lines with good effect, by inhibiting 
the catalytic activity of the p110 subunit of PI3K, but these have 
not been developed for clinical applications, in part due to 
unfavourable pharmacokinetic properties and a narrow 
therapeutic index (Vivanco and Sawyers, 2002). 
 
Receptor tyrosine kinase inhibitors have had clinical success, at 
least in part by shutting off upstream signalling to the PI3K 
pathway.  Drugs such as traztuzumab (herceptin) which targets 
the Erb2/HER2 receptor and imatinib (Gleevec) which inhibits 
the Bcr-Abl, c-KIT and PDGF-R tyrosine kinases are licensed for 
use in breast cancer and CML respectively, but resistance does 
develop.  This could be due to gene amplifications or activating 
mutations of downstream components, such as Akt, p110 and 
p85 or the inactivation of PTEN as a negative regulator, 
suggesting targeting one single component of the PI3K pathway 
is insufficient to achieve long term clinical success (Luo et al., 
2003).  Mutated kinases may be more specific targets – in 
NSCLC, tumours that have mutated forms of the tyrosine kinase 
EGFR are more responsive to EGFR inhibitors such as erlotinib 
and gefitinib when compared to tumours expressing wild-type 
EGFR (Lynch et al., 2004).           
 
Isoform specific inhibitors of p110 or Akt would appear to be an 
attractive therapeutic option and may be less toxic and have a 
higher therapeutic index than “pan-PI3K” inhibitors – p110α 
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inhibitors in particular may be useful in treating cancers that 
have PIK3CA mutations.  However, specific isoform inhibition 
may have unwanted effects on other cellular pathways. For 
example, p110α has a key role to play in insulin signalling and 
any anti-cancer effect may be outweighed by interference with 
glucose metabolism and a diabetic effect (Engelman et al., 
2006).   
 
mTOR is another attractive target in cancer treatment.  The 
serine/threonine kinase mTOR is involved in cell growth control, 
functioning as a molecular sensor regulating protein synthesis 
and both the Ras and PI3K pathways converge to activate it 
(Shaw and Cantley, 2006).  mTOR is a direct target of Akt.  
Rapamycin, the prototype inhibitor of mTOR, induces G1 cell 
cycle arrest, prevents CDK activation and accelerates cyclin D1 
turnover (West et al., 2002).  Results have been promising in 
clinical trials, with rapamycin and its analogues showing anti-
tumour activity, including tumour regression and prolonged 
stable disease in patients with non-small cell lung cancer 
(Gridelli et al., 2008). 
 
It is likely that activation of the PI3K pathway, due in part to its 
many downstream effectors, has a role to play in resistance to 
chemotherapy. Therefore, the development of new compounds 
to target particular proteins in this pathway which can be used 
alone or in combination with existing therapies, may enhance 
the efficacy of current cytotoxic treatment.       
 
1.7 FOXO TRANSCRIPTION FACTORS 
 
Transcription factors are modular proteins and have a distinct 
function in the expression of protein-encoding genes by binding 
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to their regulatory elements.  Once bound, additional factors are 
recruited to the initiation complex, resulting in either the 
initiation or repression of transcription.  The DNA-binding 
domains of transcription factors tend to be highly conserved, 
thus they can be grouped and classified on the basis of their 
shared structural domains that bind DNA in a sequence specific 
manner (Arden and Biggs, 2002; Carlsson and Mahlapuu, 
2002). 
 
FOXO transcription factors belong to the large Forkhead protein 
family of proteins, transcriptional regulators found in all 
eukaryotes and characterized by a conserved DNA-binding 
domain, known as the ‘forkhead box’, named after the founding 
gene member in Drosophila (Kaestner et al., 2000).  There are 
at least 39 distinct members of the Forkhead family in humans 
and these have been further divided into 19 subgroups (FOX for 
‘Forkhead Box’ A to S) (Greer and Brunet, 2005).   The 
‘forkhead box’ is a conserved 100 amino acid DNA binding 
domain, forming a butterfly shaped structure, comprising three 
tightly packed α helical domains at the N-terminal region, three 
β-sheets and two loop regions located at the C-terminal end, 
giving it a three dimensional “wing-like structure” – hence the 
Forkhead box is sometimes referred to as the winged-helix 
motif.  It is the third helix (H3) that interacts with DNA bases 
within the major groove of double stranded DNA, allowing 
Forkhead proteins to bind to DNA (Burgering and Medema, 
2003).   
 
Within the larger Forkhead family are a subfamily of 
transcription factor named FOXO (Forkhead box, class O), 
consisting of the members FOXO1, FOXO3a, FOXO4 and FOXO6.  
These are homologous to the transcription factor DAF-16, found 
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in the nematode worm C. elegans and known to have a critical 
role in metabolism and longevity  (Birkenkamp and Coffer, 
2003).  These transcription factors bind as monomers to a 
consensus DNA-binding sequence, determined as TTGTTTAC 
(Furuyama et al., 2000).   
 
1.7.1 The structure and function of FOXO proteins 
 
FOXO proteins are expressed in a wide variety of tissues.  
FOXO1 mRNA is abundant in adipose tissue, FOXO3a is highly 
expressed in the brain and FOXO4 in the heart.  The most 
recently identified, FOXO6, is mainly expressed in the 
developing brain, suggesting it may have a role in the central 
nervous system (Fu and Tindall, 2008; Jacobs et al., 2003).  
Initially FOXO proteins were identified in fusion genes occurring 
as a result of chromosomal translocations in human cancers and 
leukaemias – in particular alveolar rhabdomyosarcomas (Maiese 
et al., 2008). These chromosomal translocations resulted in a 
chimeric protein in which the FOXO transactivation domains 
were fused to the DNA-binding domains of other transcriptional 
regulators resulting in constitutive activation and nuclear 
retention – the first insight into the potential role of FOXO 
factors in cancer  (Fu and Tindall, 2008). 
 
FOXO transcription factors play a critical role in a number of 
physiological processes.  From the early stages of development, 
FOXO proteins are crucial components in the development of the 
immune, reproductive and haematopoeitic systems.  Foxo3a-/- 
null mice are infertile, with ovarian follicle depletion.  
Lymphoproliferation, organ inflammation and enhanced T-helper 
cell activity is seen in these mice (Maiese and Chong, 2003; 
Maiese et al., 2008).  FOXO proteins also play a role in cell 
 75 
metabolism and are linked to the prevention of diabetic 
complications by preserving cellular energy and mitochondrial 
integrity (Maiese and Chong, 2003).  The release of reactive 
oxygen species (ROS) during oxidative stress can contribute to 
a wide variety of pathological states such as ischaemia, 
Alzhiemer’s disease and cerebrovascular disease  (Chong et al., 
2005)  and as discussed later, FOXO has a key role to play in 
repairing the damage caused by ROS. 
 
FOXO proteins consist of four domains – the highly conserved 
Forkhead DNA-binding domain (DBD), a nuclear localization 
signal (NLS) located downstream of the DBD, a nuclear export 
sequence (NES) and a C-terminal transactivation domain.  
FOXO1, FOXO3a and FOXO6 are all of similar length – 
approximately 650 amino acid residues, whereas FOXO4 is 
shorter, with approximately 500 amino acid residues. Highly 
conserved regions between FOXO proteins include not only the 
Forkhead DBD but also the N-terminal region containing an 
Akt/PKB phosphorylation site, the NLS and part of the C-
terminal transactivation domain (Obsil and Obsilova, 2008). It is 
FOXO3a that is the main focus of work in this thesis (Figure 
1.6). 
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Figure 1.6 Structure and phosphorylation sites of 
FOXO3a. Phosphorylation sites of FOXO3a, as indicated by the 
specific amino acid positions.  The position of the nuclear 
localization site (NLS), nuclear export sequence (NES) and 
transactivation domains are indicated.  (Adapted from Arden, 
2006).  
 
FOXO proteins function predominantly as transcription factors in 
the nucleus, binding their DNA-targeting sequences.  They can 
exert their cellular function via different mechanisms and can 
bind directly to the promoter of target genes, recruiting other 
co-activators or transcription factors to initiate transcription.  
FOXO proteins can repress transcription by competing with 
other transcription factors at promoter binding sites or recruit 
other co-activators which can initiate or repress transcription via 
promoters lacking FOXO binding sites (Fu and Tindall, 2008). 
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1.7.2 FOXO activity and signaling pathways 
 
The FOXO family is one of the best characterized substrates of 
the protein kinase Akt in response to extracellular stimulation by 
growth factors or insulin.  When growth factors or insulin bind to 
their tyrosine kinase receptors, PI3K is recruited and activated, 
which in turn activates Akt and also the related SGK (serum and 
glucocorticoid inducible kinase) family of proteins (Greer and 
Brunet, 2005).  Evidence that the PI3K pathway was important 
in FOXO activity came initially from studies in the nematode 
worm C.elegans.  As mentioned previously, the transcription 
factor DAF-16 was identified as a Forkhead transcription factor 
in this organism and was found to have a critical role in 
metabolism and longevity – analysis of the amino acid sequence 
of DAF-16 identified three sites corresponding to the consensus 
Akt/PKB phosphorylation sites, suggesting that PI3K activity 
suppresses the function of DAF-16 and that this and other 
Forkhead transcription factors may be direct targets of Akt 
(Birkenkamp and Coffer, 2003).  It has subsequently been 
shown that Akt can directly phosphorylate FOXO transcription 
factors on multiple threonine and serine residues, triggering the 
rapid relocalisation of FOXO proteins from the nucleus into the 
cytoplasm.  Akt can phosphorylate FOXO1, FOXO3a and FOXO4. 
On FOXO3a there are three key sites – Thr 32, Ser 253 and Ser 
315 – sites which are conserved between species (Alessi et al., 
1997). SGK can also phosphorylates FOXO factors, but 
preferentially at Ser 315, whereas Akt preferentially 
phosphorylates Ser 253 – Thr 32 is phosphorylated by both 
kinases (Greer and Brunet, 2005).  A number of growth factors 
can trigger phosphorylation via Akt and SGK, including insulin 
and EGF, suggesting FOXO transcription factors can integrate a 
wide variety of external stimuli and selectively respond to these 
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stimuli depending on which site is phosphorylated (Furukawa-
Hibi et al., 2005).       
 
The main consequence of these phosphorylation events is a 
change in the subcellular localization of FOXO transcription 
factors.  Shuttling of proteins between the cytoplasm and the 
nucleus is a highly regulated process, requiring accessory 
proteins that recognize and bind to specific sequences on their 
targets, including the nuclear localisation signal (NLS) and the 
nuclear export signal (NES).  A 14-3-3 protein, which harbours 
a NES,  has been shown to bind FOXO proteins in a 
phosphorylation dependent manner (Burgering and Kops, 
2002).  14-3-3 proteins belong to a highly conserved family of 
molecules involved in regulating intracellular signal transduction 
events within cells and form homo- and heterodimeric U-shaped 
structures that are able to bind to phosphorylated signalling 
molecules through a large central channel located in the centre 
of the U.  14-3-3 protein localizes to the nucleus in the absence 
of ligand binding and associates with nuclear phosphorylated 
FOXO3a, with the NES functioning as a binding interface 
between the 14-3-3- protein and FOXO3a  (Brunet et al., 2002).  
Under conditions of low Akt activity, FOXO is located in the 
nucleus, anchored to DNA but AKt activation, following growth 
factor stimulation for example, leads to phosphorylation of 
FOXO - probably at multiple sites Thr32, Ser253 and Ser315 – 
inducing the binding of 14-3-3 to FOXO and thus releasing it 
from the DNA.  Once shuttled back into the cytosol, 14-3-3 can 
prevent nuclear re-entry by masking the NLS and preventing 
binding of accessory transport proteins (Burgering and Kops, 
2002) (Figure 1.7).  
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Figure 1.7 FOXO subcellular localisation. In the absence of 
growth factors, FOXO transcription factors are localized in the 
nucleus, upregulating key target genes.  In the presence of 
growth factors, the PI3K/SGK pathways is activated, FOXO 
factors are phosphorylated and sequestered in the cytoplasm  
(Greer and Brunet, 2005). 
 
Akt mediated phosphorylation of FOXO may regulate its 
transcriptional activity via other mechanisms.  Phosphorylation 
may prevent FOXO interacting with other co-factors essential for 
transcription – for example, phosphorylation of FOXO1 prevents 
binding of the histone acetylase p300, essential to activate 
transcription (Mahmud et al., 2002 ). 
 
Phosphorylation is key to FOXO localization, but there are other 
post-translational modifications that occur which play an 
important role in FOXO function.  Binding of co-activator or co-
repressor complexes can alter FOXO acetylation levels. 
Acetylation of FOXO factors can have an inhibitory effect on 
their transactivation activity and may reduce their DNA-binding 
activity. Many FOXO acetylation sites are located in the DNA 
binding domain and acetylation of FOXO may interfere with 
 80 
FOXO-DNA binding and prevent transcription.  SIRT1, a 
deacteylase which requires NAD+ as a co-factor, can deacteylate 
FOXO, promoting FOXO dependent transcription of genes 
involved in stress resistance whilst repressing transcription of 
genes involved in apoptosis  (Greer and Brunet, 2005; Motta et 
al., 2004).     
 
The degradation of FOXO involves an irreversible post 
translational modification – ubiquitination mediated by the 
ubiquitin-proteosome pathway.  Akt is involved in degradation 
of FOXO3a and FOXO1 – in particular phosphorylation of Ser256 
is the primary site for FOXO1 ubiquitination.  Subcellular 
localization of FOXO is also important in terms of degradation – 
when all three Akt phosphorylation sites are mutated to alanines 
and the NLS is mutated, FOXO1 is forced to localize to the 
cytoplasm and ubiquitination is reduced.  Similarly, when 
phosphorylated FOXO1 is maintained in the cytoplasm due to 
NES mutation, ubiquitination is also decreased.  Thus, for 
successful degradation, FOXO1 needs to be located in the 
cytoplasm.  The F-box protein Skp2 has been identified as the 
key E3 ubiquitin ligase responsible for this polyubiquitination of 
FOXO1, although neither FOXO3a or FOXO4 interact with Skp2, 
suggesting different ubiquitin ligases may be involved (Arden, 
2006; Huang et al., 2005).  I KappaB kinase β (IKKβ) can also 
contribute to proteosomes dependent degradation of FOXO.  
The    IKKβ   signaling pathway has antiapoptotic activity and 
IKKβ can phosphorylate FOXO3a at Ser644, found at the C-
terminal end of the molecule.  This inhibits FOXO3a activity, 
promoting proteolysis of FOXO3a by the ubiquitin dependent 
proteosome pathway (Hu et al., 2004).     
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1.7.3 Transcriptional targets of FOXO proteins 
 
 FOXO proteins have a wide range of cellular roles and can 
induce the transcription of target genes involved in 
differentiation, glucose metabolism, protection from oxidative 
stress, cell death, DNA repair and cell cycle arrest (Greer and 
Brunet, 2005). 
         .     
FOXO plays a role in the cellular resistance to oxidative stress.  
ROS are required for normal cell proliferation but also have the 
ability to induce apoptosis. In quiescent cells, which lack the 
protective mechanism of Akt mediated signalling, FOXO3a can 
protect the cell from oxidative stress by inducing the expression 
of manganese superoxide dismutase (MnSOD), a free radical 
scavenging antioxidant enzyme leading to a reduction in ROS, 
and protection from apoptosis (Kops et al., 2002a).  FOXO3a is 
phosphorylated on a number of serine or threonine residues, 
excluding those targeted by Akt, in response to oxidative stress 
by as yet unidentified kinases.  It has been postulated that 
some of these phosphorylation events may interfere with 14-3-3 
binding of FOXO, thus allowing nuclear accumulation of FOXO.  
Alternatively, the stress activated protein kinase (MAPK) c-Jun 
NH2-terminal kinase (JNK) may phosphorylate 14-3-3 and allow 
translocation of FOXO to the nucleus (Furukawa-Hibi et al., 
2005).   Growth factor-activated Akt and stress-activated JNK 
appear to be in a tight balance regulating the subcellular 
localization of FOXO.  Akt can inhibit FOXO dependent 
transcription by phosphorylation of FOXO and cytoplasmic 
sequestration.  However, in response to stress stimuli, JNK can 
phosphorylate FOXO, leading to nuclear sequestration of FOXO 
and cause FOXO mediated transcription of target genes involved 
in the stress response, promoting longevity (Greer and Brunet, 
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2005).   JNK phosphorylated nuclear FOXO can also recruit 
SIRT1 and SIRT1 deacetylation of FOXO3a can lead to the 
transcription of stress resistant genes, such as GADD45 and 
p27kip1, whilst preventing the transcription of the pro-apoptotic 
genes Bim and Fas ligand.  The transcriptional co-activator p300 
can also interact with FOXO and acetylates it on several lysine 
resisudes, leading to inhibition of FOXO transactivation activity. 
However, SIRT1 can bind to and deacetylate FOXO, reversing 
the inhibitory effects of p300 (Furukawa-Hibi et al., 2005). 
Therefore, deacetylation protects against apoptosis and 
promotes survival under stress through FOXO-mediated 
transcription (Reagan-Shaw and Ahmad, 2007).   
 
FOXO family members are involved in cell cycle control and 
have roles at both the G1/S and G2/M checkpoints. Ectopic 
expression of FOXO1, FOXO3a or FOXO4 can block cell cycle 
progression through G1, predominantly by inducing the 
transcription of the cell cycle inhibitor p27Kip1 (Weidinger et al., 
2008).  FOXO can directly activate the transcription of the 
p27Kip1 gene, the promoter of which contains multiple consensus 
FOXO binding motifs.  FOXO can also increase the expression of 
a reporter gene controlled by the p27Kip1 gene promoter and can 
stabilize  p27Kip1 protein (Nakamura et al., 2000).  Upregulation 
of p27Kip1 and subsequent binding to the cyclin E/cdk2 complex 
can prevent entry of cells into S phase (Weidinger et al., 2008).   
 
FOXO can also inhibit cell cycle progression in a p27Kip1 
independent mechanism.  Progression from G1 to S phase of the 
cell cycle is regulated by the cyclin/cdk complexes cyclin 
D/Cdk4/6 and cyclin E/Cdk2. Activation of FOXO reduces protein 
expression of cyclin D1 and D2, resulting in impaired ability of 
Cdk4 to inactivate the S-phase suppressor pRb.  Conversely, 
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ectopic expression of cyclin D1 is able to overcome FOXO 
induced cell cycle arrest (Schmidt et al., 2002).   
 
FOXO proteins play a role at other cell cycle checkpoints.  
FOXO3a functions at the G2M checkpoint, triggering the repair of 
damaged DNA.  Microarray analysis has shown that FOXO3a 
modulates the expression of genes involved in regulating the 
cellular responses to stress at G2/M, including the cyclin G2 and 
growth arrest and DNA damage inducible protein 45 (GADD45).  
In response to stress stimuli, FOXO3a induces a delay in G2/M, 
contributing to the repair of damaged DNA in a GADD45 
dependent manner (Tran et al., 2002).  FOXO can also 
contribute to exit from the cell cycle and quiescence of cells 
(G0).  FOXO3a can directly control transcription of the 
retinoblastoma-like p130 protein, binding directly to consensus 
binding motifs in the p130 promoter and upregulating its protein 
expression. In quiescent cells, p130 is hypophosphorylated and 
bound to the transcription factor E2F-4, which results in 
repression of the expression of genes required for re-entry into 
the cell cycle and maintainance of cells in G0 (Kops et al., 
2002b).   Therefore, the ability of FOXO3a to induce cell cycle 
arrest at multiple checkpoints and to control cell cycle re-entry 
makes it a likely candidate as a tumour suppressor.   
 
In addition to a role in cell cycle arrest, FOXO has a role in 
programmed cell death.  Under low stress conditions, FOXO may 
be able to regulate the resistance of cells to stress by promoting 
DNA repair, but with higher levels of cellular insult, cell death 
may be inevitable and FOXO is integral to commitment to the 
induction of apoptosis.  Target genes of FOXO that mediate 
apoptosis include Bim, a member of the pro-apoptotic Bcl-2 
family member and the death cytokines, including Fas ligand 
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(FasL) and TRAIL (Greer and Brunet, 2005).  Bim functions at 
the mitochondria, disrupting mitochondrial integrity and 
promoting the release of cytochrome c, triggering the cascade 
of proteolytic events which are hallmarks of apoptosis (Tran et 
al., 2003).  Apoptosis induced by PI3K inactivation is reduced in 
lymphocytes from Bim deficient mice (Greer and Brunet, 2005) 
and FOXO3a activation causes induction of Bim expression in 
Ba/F3 cells, a mouse pro-B cell line – with an active mutant of 
FOXO3a inducing Bim expression at both mRNA and protein 
level (Dijkers et al., 2000).  FOXO3a can also induce the 
expression of Bcl-6, a potent transcriptional repressor, which in 
turn negatively regulates the expression of the antiapoptotic 
protein BCL-XL, suggesting that FOXO may induce apoptosis by 
Bcl-2 mediated repression of BCL-XL (Tang et al., 2002). Thus, 
FOXO may trigger apoptosis by modulating the ratio of 
prosurvival and prodeath Bcl-2 family members.     
 
As well as regulating transcription by direct FOXO/DNA 
interactions, FOXO proteins can have a DNA-binding 
independent effect on transcription through interaction with 
nuclear receptors – leading to changes in the activity of both 
proteins (Van Der Heide et al., 2004). FOXO can interact in a 
ligand dependent manner with the AR, ER, the thyroid hormone 
receptor and the glucocorticoid steroid receptors amongst 
others.  These receptors are normally localised in the 
cytoplasm, but when ligand binding occurs, they are released 
from their chaperones and dimerise, entering the nucleus and 
binding to the specific response elements of their target genes,  
which initiates transcription (Rochette-Egly, 2003). Non-steroid 
receptors are primarily located in the nucleus and are associated 
with HDAC-containing complexes in the absence of ligand 
binding, resulting in chromatin compaction and silencing of the 
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promoter region of target genes.  When ligand binding occurs, 
this complex dissociates and the nuclear receptor can bind to 
their responsive elements and initiate transcription.  All FOXO 
factors contain an LxxLL domain located at the C-terminus end 
of the Forkhead DNA binding domain and it is thought that 
FOXO may interact with nuclear hormone receptors through this 
motif – regions flanking the LxxLL motif differ between FOXO 
family members and may play a role in receptor selectivity (Van 
Der Heide et al., 2004).     
  
The physiological roles of FOXO proteins in stress, cell cycle 
progression and apoptosis are perhaps the most well 
characterised, but FOXO proteins have other important cellular 
roles. They are linked to the prevention of diabetic 
complications through their role in preserving mitochondrial 
integrity and cellular energy reserves (Maiese and Chong, 
2003).  They are protective during ageing and promote 
longevity – in cultured fibroblasts, silencing of FOXO3a leads to 
senescence, slows proliferation and the generation of ROS 
(Kyoung Kim et al., 2005).  In summary, FOXO transcription 
factors are important signalling integrators and by regulating 
their stability, cellular localization and transcriptional activity, 
they play a wide role in growth, cell cycle regulation, 
metabolism, differentiation and survival of normal cells.    
 
1.7.4 FOXO proteins and cancer 
 
The ability of FOXO proteins to control cell survival and cell 
death suggests that FOXOs may function as tumour 
suppressors.  Their role in cell cycle arrest, DNA repair and 
apoptosis suggests that loss of FOXO function may lead to a 
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decreased ability to arrest the cell cycle and promote genomic 
instability, resulting in tumour development.    
 
A number of studies have pointed to a role for FOXO 
transcription factors in cancer regulation.  As mentioned 
previously, FOXO1, FOXO3a and FOXO4 are present at 
chromosomal breakpoints in human cancers – 
rhabdomyosarcoma for FOXO1 and acute myeloid leukaemia for 
FOXO3a and FOXO4, resulting in fusion proteins no longer 
controlled by Akt and constitutively present in the nucleus   
(Greer and Brunet, 2005).  The signalling pathways modulating 
FOXO activity have all been implicated in cancer – Ras, PI3K 
and Akt all have oncogenic activity whilst PTEN acts to suppress 
tumour formation (Tran et al., 2003).  In prostate cancer, early 
studies observed that PTEN is mutated in up to 80% of tumours 
and this was associated with loss of FOXO1 and FOXO3a 
activity.  Suppression of FOXO3a activity promotes prostate 
cancer cell growth and the progression of prostate cancer from 
androgen sensitive to androgen resistant involves decreased 
FOXO3a expression and reduced p27Kip1 promoter activity  
(Lynch et al., 2005).   
 
Ras is a powerful negative regulator of FOXO and can promote 
oncogenesis by two independent pathways.  Ras can activate 
the PI3K pathway, leading to phosphorylation of FOXO and 
nuclear export.  Ras can also activate the ERK-MAPK pathway, 
which targets FOXO and leads to ERK phosphorylated FOXO 
being targeted for polyubiquitination by the MDM2 E3 ligase and 
subsequent proteosomal degradation (Yang et al., 2008). 
 
More recent studies have provided further evidence for a role of 
FOXO proteins as tumour suppressors – conditional deletion of 
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FOXO1, FOXO3a and FOXO4 simultaneously induces 
spontaneous tumour formation in mice and thymocytes from 
FOXO triple-knockout mice show increased proliferation and 
decreased apoptosis (Dansen and Burgering, 2008).  FOXO3a 
has been shown to interact in the nucleus with the tumour 
suppressor p53 in response to stress or nutrient deprivation.  
Combined with the findings that FOXO and p53 share some 
target genes, such as p21Cip1 and GADD45, this would suggest 
that these two proteins may coordinate tumour suppression.  In 
fact, activation of FOXO3a in p53 mutated cancer cells is 
sufficient to induce tumour suppression (Hu et al., 2004; Yang 
et al., 2008).   p53 and FOXO are both phosphorylated and 
acetylated in response to UV radiation and oxidative stress and 
both can bind to SIRT1 deacetylase (Luo et al., 2001).  FOXO 
proteins are also known to interact in glioblastoma cells with the 
tumour suppressor SMAD, which promotes transforming growth 
factor-β (TGFβ) dependent activation of p21Cip1 and subsequent 
G1 cell cycle arrest (Seoane et al., 2004).   
 
FOXO factors also affect oncogenic activity.  When active, FOXO 
can inhibit induction of a number of genes targeted by the 
oncogene Myc as well as Myc-induced proliferation and 
transformation and loss of FOXO function allows myc to activate 
target genes that induce transformation (Bouchard et al., 
2004).  The oncogene β-catenin has also been shown to bind to 
FOXO factors and this can enhance the ability of FOXO to inhibit 
cell cycle progression.  In colorectal cancer β-catenin, in 
combination with T-cell factor, has been implicated in cancer 
progression suggesting that FOXO may sequester β-catenin 
away from T-cell factor and inhibit cell cycle progression and 
subsequent tumour progression (Essers et al., 2005).  
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With respect to breast cancer in particular, the presence of 
cytoplasmic FOXO3a in breast cancer tissue sections has been 
shown to correlate with poor overall survival in breast cancer 
patients. Cytoplasmic FOXO3a correlates also with expression of 
IKKβ and Phosphorylated Akt, again a poor prognostic factor.  
In breast cancer cell lines, constitutive expression of IKKβ 
promotes cell proliferation and tumourigenesis which can be 
overridden by FOXO3a, suggesting negative regulation of FOXO 
promotes tumour development (Hu et al., 2004).   
 
In summary, inactivation of FOXO appears to be an important 
step in malignant transformation.  The signaling pathways 
regulating FOXO activity are known to be implicated in cancer 
development and loss of the tumour suppressor role of FOXO 
activity may play a crucial role in many common cancers, 
making the restoration of FOXO activity an attractive 
therapeutic strategy.   
 
1.8 FOXM1 
 
FOXM1 is another member of the Forkhead box superfamily of 
transcription factors.  The human FOXM1 gene is a 10 exon 
structure spanning 25kb on chromosome 12. There are three 
splice variants of the human FOXM1 protein: A, B and C.  Both 
FOXM1B and FOXM1C are the transcriptionally active variants 
(Laoukili et al., 2007). FOXM1 is found in all embryonic tissues, 
especially in proliferating cells of epithelial and mesenchymal 
origin, but in adult tissue is only found in high levels in the 
thymus and testes and at moderate levels in the gut and lung – 
tissues which all have a high proliferative index. Loss of FOXM1 
is embryonically lethal in mice, due to failure to enter mitosis, 
and overexpression of the FOXM1B isoform potentiates the 
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development and growth of tumours in mouse models of 
prostate cancer (Kalin et al., 2006).   FOXM1 expression is also 
seen in cancer derived cell lines and it is a proliferation specific 
protein.  Protein and mRNA levels are low in quiescent cells but 
FOXM1 expression is induced when cells re-enter the cell cycle 
following serum starvation (Korver et al., 1997).  FOXM1 is 
critical for G1/S and G2/M cell cycle phase progression and also 
for mitotic spindle integrity (Myatt and Lam, 2007).  It can 
regulate the G1/S transition by diminishing levels of nuclear 
p21Cip1 and p27Kip1, the inhibitory cell cycle regulators, and can 
activate Cdc25A transcription. An increase in FOXM1 expression 
is seen at the onset of S phase and continues throughout G2 and 
mitosis, where it can activate transcription of Cdc25B, which in 
turn activates the Cdk-cyclin B complex (Costa, 2005) 
(Figure1.8).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.8 FOXM1 regulation of the cell cycle.  (adapted 
from (Costa, 2005).  
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FOXM1 is activated by phosphorylation and this requires the 
presence of appropriate mitogenic signals – MAPK mediated 
phosphorylation of FOXM1 can regulate subcellular localisation 
and transcriptional activity and Raf/MEK/MAPK signalling and 
cyclin E-Cdk2 promotes nuclear translocation of FOXM1 through 
phosphorylation before entry into the G2/M phase of the cell 
cycle, suggesting that multiple kinases may be required to 
phosphorylate FOXM1 at different stages of the cell cycle 
(Laoukili, 2007; Ma et al., 2005).  pRb phosphorylation by cyclin 
D1-Cdk4 may also be necessary to relieve FOXM1 repression by 
disrupting their direct interaction and increased expression of 
cyclin D1, often observed in breast cancer, may further drive 
the phosphorylation of FOXM1 (Wierstra and Alves, 2006).      
 
An increase in expression and activity of FOXM1 is associated 
with the development and progression of human cancers, 
including breast, prostate, pancreatic and lung cancer (Kwok et 
al., 2008). Overamplification of the FOXM1 gene locus on 
chromosomal band 12q13 is also seen in breast cancer 
suggesting FOXM1 may be an oncogene (Spirin et al., 1996). 
Increased FOXM1 activity may promote tumourigenesis by 
driving the cell cycle and proliferation by regulating down 
stream targets such as cyclin B1, CDC25b and Polo-like kinase-1 
(Plk1), promoting undifferentiated cells towards malignant 
transformation (Costa, 2005).  FOXM1 can also activate genes 
involved in angiogenesis and metastasis.    
 
In Foxm1 knock-out (KO) mouse models, mice die in-utero, 
shortly before birth.  Pathologically, these mice show abnormal 
liver development, with reduced hepatocyte proliferation, 
reduced liver perfusion and loss of intrahepatic bile ducts. 
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Pulmonary defects are also seen in foxm1-/- mice, with 
hypertrophic smooth muscle cells and defective pulmonary 
capillaries, suggesting FOXM1 is required during organogenesis 
(Laoukili et al., 2007).   This is accompanied by highly polypoid 
(>4n) cells in the heart and liver.  FOXM1 also has a role in co-
ordinating genes that are important in spindle assembly and 
chromosome segregation.  Pleiotropic cell cycle defects are seen 
with loss of FOXM1, including a delay in G2, mis-segregation of 
chromosomes and frequent failure of cytokinesis  (Laoukili et 
al., 2005). Thus, FOXM1 is crucial for the proper execution of 
mitosis.  
 
In pancreatic cell lines, downregulation of FOXM1 inhibits cell 
growth and inhibits the expression of vascular endothelial 
growth factor (VEGF) and the matrix metalloproteinase-2 (MMP-
2) and MMP-9, resulting in the inhibition of migration, invasion 
and angiogenesis (Wang et al., 2007).  Knock-out of FOXM1 in 
prostate cell lines slows cell proliferation and progression into S 
phase.  This is accompanied by an increase in nuclear p27kip1 
and reduced expression of cyclin A2, required for S phase 
promotion and reduced cyclin B1, required for M-phase entry 
(Kalin et al., 2006).  FOXM1 expression has also been shown to 
be up-regulated in gastric cancer – constitutive expression of 
FOXM1 is required for the proliferation of gastric cancer cells 
and knock down of FOXM1 leads to cellular senescence and 
impaired clonogenesis (Zeng et al., 2009). 
 
1.8.1 FOXM1 as a therapeutic target 
 
FOXM1 has been identified as a potential target for anticancer 
agents.  FOXM1 has been shown to be a physiological regulator 
of oestrogen receptor α (ERα) in breast cancer cells. FOXM1 and 
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FOXO3a co-operate to regulate ERα gene transcription and 
ectopic expression of FOXM1 can upregulate the expression of 
ERα at the protein and transcript level (Madureira et al., 2006).  
This may have a role in the response of cancers to anti-
oestrogens such as tamoxifen and also to the development of 
endocrine resistance in tumours.   
 
 The thiopeptide antibiotic thiostrepton has been shown to have 
anticancer properties and can cause cell cycle arrest and cell 
death in the MCF-7 breast cancer cell line, accompanied with a 
reduction in the invasiveness and transforming ability of these 
cells. Thiostrepton can induce a rapid and sustained loss of 
FOXM1 protein and mRNA expression, leading to cell cycle 
arrest at G1 and S phase and overexpression of a constitutively 
active FOXM1 mutant, ΔN-FOXM1, can abrogate the 
antiproliferative effect of the drug (Kwok et al., 2008).  No such 
effect is seen in the untransformed MCF-10A breast epithelial 
cells.   
 
1.9 ID PROTEINS 
 
Inhibitor of DNA binding (Id) family members are key regulatory 
proteins involved in a wide range of developmental and cellular 
processes.  They belong to the helix-loop-helix (HLH) family of 
transcription factors, which comprises over 200 family members 
and have been identified in organisms from yeast to man 
(Norton, 2000).   
 
HLH proteins coordinate cell type specific gene expression and 
play a role in cell lineage determination, cell proliferation, cell 
death and differentiation in most tissues.  They are grouped into 
seven classes (I-VII) based on their tissue distribution, their 
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ability to dimerise and their DNA binding specificities (Coppé et 
al., 2003). One of the most characteristic features of HLH 
proteins, which is essential to their normal function, is their 
ability to form homo- and heterodimers with each other through 
their highly conserved HLH domain. Most of these proteins 
belong to a further subclass – the basic HLH (bHLH) family, 
which share a common sequence motif of a stretch of basic 
amino acids.  bHLH proteins act as transcriptional enhancers or 
inhibitors of various genes.  The basic region within the protein 
is required for binding to DNA, commonly to a region that 
includes a specific sequence motif (CANNTG) known as the E-
box in the promoter region of target genes (Sikder et al., 2003).   
 
The Id proteins belong to Class V HLH proteins, and are 
characterized by the fact that they do not possess a basic DNA 
binding domain.  Thus, whilst Id proteins are capable of 
dimerizing with ubiquitous and tissue specific bHLH factors, the 
heterodimers formed are unable to bind DNA, ensuring Id 
proteins function as dominant negative regulators of bHLH 
transcription factors (Desprez et al., 2003) (Figure 1.9).  
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                    Basic DNA binding domain 
 
Figure 1.9 Id proteins as dominant negative regulators of 
bHLH transcription factors. (adapted from Sikder et al, 
2003).    
  
As well as their interaction with the bHLH E-protein family, Id 
proteins can also bind to other important cell cycle regulatory 
proteins, such as pRb and the Ets family of transcription factors, 
suggesting they may have a key role in cell cycle regulation and 
transformation (Zebedee and Hara, 2001). 
 
In mammals, four members of the Id protein family have been 
identified to date, Id1 through to Id4.  They derived their name 
from their ability to inhibit both DNA binding and act as 
inhibitors of differentiation.  The genes encoding for the four Id 
proteins are located on different chromosomes and although the 
proteins share the highly conserved HLH region and have similar 
sizes of between 13-20KDa, they display extensive sequence 
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differences and show distinct expression patterns (Wong et al., 
2004).  Id proteins have been shown to have a role in 
development.  During mouse development, there is widespread 
expression of Id1, Id2 and Id3 from early gestation through to 
birth, with considerable overlap between the expression of Id1, 
Id2 and Id3, whilst Id4 appears limited to the nervous system.  
In knock-out animal models, deletion of the Id1 gene alone 
does not lead to any phenotypic abnormalities, whereas mice 
that are null for Id2 and Id3 possess defects in immunity 
(Yakota, 2001).  However, mice null for both Id1 and Id3 
possess embryonic lethality, with aberrant neuronal 
differentiation and angiogenesis (Lyden et al., 1999).  
Increasing evidence has pointed to a role for Id proteins in 
differentiation and development.  Differentiation of a number of 
cell lineages is accompanied by downregulation of Id expression 
whilst overexpression of Id in keratinocytes, myeloid precursor 
cells and mammary epithelial cells inhibits their ability to 
differentiate (Lasorella et al., 2001).       
 
Id proteins are thought to have a critical role in the cell cycle, 
promoting G1-S cell cycle transition.  Id proteins are mitogen 
responsive – quiescent cells express low or undetectable levels 
of Id proteins. However, when fibroblasts are stimulated by 
mitogens, Id expression is rapidly induced, within 1-2h, as part 
of a cascade of early response genes, and levels are sustained 
through G1 until the onset of S phase (Norton, 2000).  Only 
some of the cell cycle targets of Id proteins have been 
characterized.  Id2 and Id4 (but not Id1 or Id3) are known to 
directly interact with pRb.  Id2 can bind to pRb and abolish its 
growth suppressing activity – binding is dependent on the HLH 
domain of Id2 and the pocket domain of pRB as growth arrest 
by pRb is not antagonized in-vitro using Id2 lacking the HLH 
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domain  (Lasorella et al., 1996).  In addition to binding to pRb, 
Id proteins may promote cell cycle progression by 
downregulation of other key cell cycle inhibitors.  The bHLH 
protein E2A can block G1 to S phase transition through the 
transcriptional activation of p21Cip1.  Id proteins can 
heterodimerise with E2A, repressing the transcription of p21Cip1, 
ensuring cell cycle progression (Prabhu et al., 1997).   
 
Id proteins may also play a role in promoting normal cell 
survival by overcoming replicative senescence - id1-/- primary 
mouse embryonic fibroblast undergo premature senescence and 
conversely overexpression of Id1 in normal primary cells 
overcomes replicative senescence in several cell types (Alani et 
al., 1999).  Transfection of human primary keratinocytes with 
ectopically expressed Id1 results in prolonged survival of normal 
cells and cotransfection of Id1 with the antiapoptotic factor Bcl-
2 leads to immortalization of primary rodent fibroblasts  (Norton 
and Atherton, 1998).   
 
Id proteins are regulated at multiple levels with transcriptional 
regulation, proteins stability and post translational modifications 
all contributing to their function.  However, very little is known 
about the upstream signaling pathways that couple Id protein 
expression to extracellular signals.  Like many cell cycle 
regulators, Id proteins are immediate early genes, and generally 
have a very short half-life, although they are stabilized by the 
formation of dimers with bHLH factors (Bounpheng et al., 
1999).  Id proteins lack a nuclear localization sequence, but as 
small proteins with molecular weights less than 40kDa can 
freely pass through the nuclear pore, it has been suggested that 
their subcellular distribution may be determined in part by 
passive diffusion (Makita et al., 2006).  Alternatively, the E 
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proteins they bind may act as nuclear chaperones (Ruzinova 
and Benezra, 2003).       
 
Id proteins can undergo phosphorylation and Id2, Id3 and Id4 
(but not Id1) are substrates for Cdk2-dependent 
phosphorylation during late G1 and early S phase.  
Phosphorylation alters the bHLH dimerisation specificity of Id2 
and Id3 and appears essential for cell cycle progression – Id2 
and Id3 mutants lacking Cdk2 phosphorylation sites elicit arrest 
in S phase and cell death (Hara et al., 1997).    
 
The rapid turnover and degradation of Id proteins is thought to 
be due to proteolysis through the ubiquitin-proteasome 
pathway.  Id1, Id2 and Id3 are ubiquitinated and degraded by 
the 26S proteasome, a large protein complex which cellular 
proteins are targeted to for degradation by the covalent addition 
of multiple molecules of ubiquitin (Bounpheng et al., 1999).  
The rapid degradation of Id proteins is necessary to ensure 
stringent control of their signalling activity and their role in the 
cell cycle.  
 
1.9.1 Id1 
 
Id1 was the first Id protein to be identified and is the most well 
characterized of all the Id proteins and is the focus of the work 
in Chapter 4 of this thesis.  Early evidence supporting Id1 as an 
inhibitor of differentiation came from studies in haematopoietic 
cell lineages, where high Id1 expression was detected in 
precursor cells but decreased during progression through 
differentiation (Kreider et al., 1992).  Id1 blocks erythrocyte 
differentiation in cultured K562 cells and upregulation of Id1 in 
CD34+ primary cells correlates with inhibition of erythrocyte 
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differentiation and induction of granulocyte differentiation 
(Cammenga et al., 2003) and Id1 also has a role in cell fate 
determination choice, with overexpression of Id1 in embryonic 
and postnatal cerebral cortex resulting in inhibition of neuronal 
development in favour of glial cell fate (Cai et al., 2000). 
 
Although Id1-/- mice do not produce an obvious phenotype, 
double knockouts of Id1 and Id3 are lethal, suggesting Id1 
expression alone is not essential for embryonic development 
(Lyden et al., 1999).  However, forced expression of Id1 in adult 
mouse small intestine results in the formation of adenomas, 
suggesting that although the function of Id1 may overlap with 
other Id proteins in development, the role it plays in promoting 
cell survival and malignant transformation could be unique 
(Wice and Gordon, 1998).  
 
Id1 expression is seen in normal mouse mammary gland 
development and during early pregnancy, when epithelial ductal 
cells proliferate and invade the stroma, high expression is seen.  
During mid pregnancy and the lactating period, Id1 is 
downregulated and undetectable, corresponding to a highly 
differentiated state  (Parrinello et al., 2001),  The SCp2 cell line, 
a mouse mammary epithelial cell line, which was developed 
from a midpregnant mouse mammary gland,  gave the first 
insight into a potential role for Id1 in tumour development – 
transfection of SCp2 cells with a constitutively expressed Id1 
gene lead to failure of the cells to differentiate and lead to cell 
proliferation and invasion, suggesting Id1 can induce an 
invasive phenotype (Fong et al., 2003).    
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1.9.2 Id1 and cancer  
 
Id1 overexpression results in three key events that can 
contribute to the phenotype of a malignant cell – inhibition of 
differentiation, enhanced proliferation and invasiveness (Perk et 
al., 2005).  There is now much evidence to suggest an 
oncogenic role for Id1 in human cancers.  In a number of 
epithelial cancers, correlation has been seen between levels of 
Id1 and malignant potential.  In ovarian tumours, strong 
expression of Id1 correlates with poorly differentiated and more 
aggressive tumours, resulting in a worse clinical outcome for 
patients (Schindl et al., 2003).  A similar pattern is seen in early 
stage cervical cancer, where strong or moderate expression of 
Id1 in tumours is found in patients with shorter disease free 
survival and overall survival (Schindl et al., 2001).  In colorectal 
adenocarcinomas, Id1 expression is elevated in tumours when 
compared to normal bowel mucosa, and correlates with mitotic 
index and p53 immunoreactivity – a marker of mutational 
inactivation of p53 function (Wilson et al., 2001).   
 
Further evidence for the oncogenic role of Id1 comes from the 
observation that upregulation of Id1 protein is mediated by well 
established oncogenes such as Myc and Ras – induction of Id1 
by Myc is required for breast cancer cells to enter S phase in 
culture and overexpression of Myc in breast epithelial cell results 
in increased expression of Id1 mRNA (Swarbrick et al., 2005).  
Mitogenic signals driven by oestrogens and insulin growth factor 
can induce expression of Id1 and some of the extracellular 
signlas that elevate Id1 levels may be mediated by the 
Ras/Erk/MAPK cascade and the PI3K pathway (Lasorella et al., 
2001). 
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With respect to breast cancer in particular, Id1 is highly 
expressed in aggressive breast cancer cell lines with loss of 
serum dependent regulation.  When a constitutively expressed 
Id1 cDNA is introduced into a non aggressive cell line (T47D), 
this conferred a more aggressive phenotype as measured by 
growth and invasiveness.  In breast cancer biopsies a similar 
pattern was seen, with higher expression of Id1 in invasive 
carcinomas when compared to ductal carcinoma in situ (Lin et 
al., 2000).   In lymph node negative breast cancer, patients 
with strong or moderate Id1 expression have a significant 
shorter disease free and overall survival compared to those 
patients with low/absent Id1 expression (Schoppmann et al., 
2003).  Id1 may also have an impact on the development of 
metastases, with an increase prevalence of Id1 positivity among 
lung metastases when compared to primary breast tumours – 
consistent with its role in invasiveness and sustained 
proliferation (Gupta et al., 2007). 
 
In summary, Id1 is overexpressed in a variety of cancers and 
may act as a marker of progression, metastases and outcome. 
Id1 therefore could be an attractive therapeutic target as it is 
expressed at low levels in normal tissues but reactivated in 
many cancers and plays a key role in proliferation, 
differentiation and invasiveness – events that promote 
malignant transformation.    
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THESIS AIMS AND OBJECTIVES 
 
 
The aim of this thesis was to explore the hypothesis that 
FOXO3a and its putative downstream targets FOXM1 and Id1 
have a role in breast cancer development and progression and 
are therefore targets for anticancer therapeutics.  
 
Experiments were conducted to demonstrate if:  
 
1) FOXO3a was a target of the commonly used 
chemotherapeutic agent epirubicin  
2) FOXO3a was involved in the regulation of FOXM1 in 
breast cancer cells 
3) Id1 was a target of epirubicin and was regulated by 
FOXO3a 
 
Finally, results obtained in cell line work were then explored to 
demonstrate if changes observed were reproducible in clinical 
samples.   
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CHAPTER 2                                     
MATERIALS AND METHODS 
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2.1 CELL CULTURE 
 
The human breast carcinoma cell lines MCF-7 and MDA-MB-231 
were cultured in Dulbecco’s modified eagle medium (DMEM) 
(Life Technologies Gibco/BRL, Paisley, UK). The medium was 
supplemented with 10% foetal calf serum (FCS) (First Link Ltd, 
Birmingham, UK), 2mmol/L glutamine and 100 U/mL 
penicillin/streptomycin (Sigma-Aldrich, Poole, UK).  Cells were 
maintained at 37°C in a humidified incubator with an 
atmosphere of 10% CO2. Other breast cell lines used for cell 
panel work were cultured by a similar technique and are listed 
below (table 2.1). Cell lines were originally all obtained from the 
American Type Culture Collection (ATCC).   
 
Doxorubicin resistant MCF-7 cells, generated previously in the 
laboratory, were cultured in a similar way and maintained with 
the addition of 0.01mg/ml doxorubicin to the culture media 
(Pfizer, UK).  
 
MCF-10A cells were cultured in DMEM/Ham’s F-12 (1:1 mix; 
Sigma) supplemented with 5% (v/v) horse serum, 10ng/mL 
insulin, 5mg/mL hydrocortisol, 100ng/mL cholera toxin, 
20ng/mL epidermal growth factor, 100U/mL penicillin and 
100μg/mL streptomycin (all supplements from Sigma, UK). 
 
ΔN-MCF-7 cells were generated in the laboratory by Mr Jimmy 
Kwok (Kwok et al., 2008) by transfecting the selection plasmid 
pBABApuro (Addgene) containing a puromycin selection marker 
and a ΔN-FOXM1 plasmid.  The cell line was maintained in 
0.75μg/ml of puromycin.   
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    CELL LINE                  SOURCE 
      MCF-10A ATCC - fibrocystic mammary gland 
        MCF-7 ATCC - pleural effusion 
        ZR751 ATCC - ascites 
        BT474 ATCC - invasive ductal carcinoma 
         T47D ATCC - pleural effusion 
    MDA-MB-231 ATCC - pleural effusion 
    MDA-MB-453 ATCC - pericardial effusion  
    MDA-MB-468 ATCC - pleural effusion 
 
Table 2.1  List of breast cancer cell lines used  
 
2.1.1  Sub-culturing of adherent cells 
 
Cells were grown and split at 80% confluency. Media was 
aspirated and the cell monolayer was washed in warm PBS and 
then detached by the addition of 1x trypsin-EDTA.  After 5 min 
at 37°C, the trypsin was inactivated by the addition of complete 
media.  The cells were then resuspended in a flask at a defined 
ration (1:5) or counted by use of a haemocytometer and seeded 
in the appropriate plates.  
 
2.1.2  Preservation of cells 
 
Cells were trypsinized, washed in complete media and spun 
down at 500x g for 5 min. The cell pellet was then resuspended 
in FCS with 10% DMSO (dimethyl sulphoxide).  1ml aliquots 
were transferred to cryotubes and frozen at -80°C overnight 
before transfer to storage in liquid nitrogen.    
 
When defrosting cells, the cryotube solution was added to 
complete media, then spun at 1200rpm for 3 min to remove any 
DMSO-containing media and the pellet was resuspended in  
12ml of media in a 25cm2 flask. 
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2.2 CHEMICALS 
 
Epirubicin (2mg/ml in 0.9% sodium chloride) and doxorubicin 
(2mg/ml in 0.9% sodium chloride) were obtained from Pfizer, 
UK and stored in solution at 4°C.   
 
2.3 PROTEIN ANALYSIS 
 
2.3.1 Preparation of total protein extracts 
 
Whole cell protein extracts were prepared by initially harvesting 
cells, washing the cell pellet in PBS before centrifuging at 250 x 
g for 5 min.  The supernatant was discarded and pellets were 
frozen at -80°C until lysis was performed.  Frozen pellets were 
lysed in 2 volumes of NP40 lysis buffer (1% (v/v) Nonidet P-40, 
150mM NaCl2, 50mM Tris-HCl (pH 7.8), 5mM EDTA, 1mM DTT, 
1mM NaF, 1mM PMSF, 1mM Na3VO4 and protease inhibitors 
(complete protease inhibitor mixture, as instructed by the 
manufacturer (Roche Applied Sciences, UK) on ice for 15 min. 
Insoluble material was removed by microcentrifugation at 
13000rpm at 4°C for 10 min. The supernatant was transferred 
to a clean eppendorf tube and its protein concentration was 
assayed. 
 
2.3.2 Determination of protein concentration 
 
Protein concentration was determined using the Bio-Rad Dc 
protein assay (Bio-Rad Laboratories, CA, USA). 20μl of reagent 
S was added to 1ml of reagent A.  A standard curve was 
established by assaying 5 dilutions of a protein standard within 
the range of 0.2mg/ml to 1.5mg/ml protein.  100μl of reagent A 
was added to 2μl of each dilution and mixed with 800μl of 
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reagent B.  After 15 min, absorbance was read at 750nm and a 
standard curve was established.   The absorbance of the 
experimental samples were read at 750nm and their protein 
concentration determined by multiplying the absorbance of the 
sample by the standard curve’s regression co-efficient.  
 
2.3.3 (Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis) SDS-PAGE 
 
Gels for resolution of proteins were made using a 37.5% (w/v) 
acrylamide/bis stock solution.  Ammonium persulphate (APS) 
and TEMED were used as polymerisation catalysts.  The 
percentage of gel used depends on the size of the protein being 
isolated - 7 and 14% gels predominantly.  Gels consisted of a 
lower resolving gel and a 5 % upper stacking gel, according to 
the following table:  
 
Resolving  
gel 
7% 14% Stacking gel 5% 
dH2O 5.02ml 2.68ml dH2O 3.67ml 
1M Tris-HCl  
(pH 8.8) 
 
2.5ml 
 
2.5ml 
1M Tris-HCl 
(pH 6.8) 
 
 0.42ml 
Acrylamide: 
Bisacrylamide 
(37.5:1) 
 
2.33ml 
 
4.67ml 
Acrylamide: 
Bisacrylamide 
(37.5:1) 
 
 0.83ml 
10% SDS 100μl 100μl 10% SDS  50μl 
25% APS 40μl 40μl 25% APS  20μl 
TEMED 10μl 10μl TEMED  10μl 
TOTAL 10mls 10 ml TOTAL  5 ml 
 
Table 2.2 Proportions of the constituents of SDS-PAGE 
resolving and stacking gels 
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To separate the proteins, 25μg of lysate was added to 1 volume 
of 2x SDS loading buffer (4% (w/v) SDS, 62.5mM Tris-HCL (pH 
6.8), 1% (v/v) glycerol, 0.01% (w/v) bromophenol blue, 10% 
(v/v) β-mercaptoethanol) and boiled at 100°C for 3 min. 
Samples were then loaded into the stacking gel wells and 
fractionated by electrophoresis on the SDS-PAGE gels and run 
at a constant voltage of 100V in running buffer (25mM Tris-
base, 250mM glycine, 0.1% (w/v) SDS).  Proteins were 
separated alongside an Amersham rainbow marker (GE 
Healthcare Ltd, UK) to monitor progress of protein 
electrophoresis and the molecular weight of the separated 
proteins. 
 
2.3.4  Western blotting of SDS-PAGE 
 
Once separated by SDS-PAGE, proteins were then transferred to 
a nitrocellulose membrane (Whatman, Germany) by 
electrophoretic transfer in a wet tank blotting system (Bio-Rad 
Laboratories Trans-Blot cell) in transfer buffer (25mM Tris, 
190mM glycine and 20% (v/v) methanol) for 90 min at 90V.  
The nitrocellulose membrane was then blocked at RT for 1 h in 
5% (w/v) skimmed milk powder (Marvel, Premier Brands, UK) 
dissolved in Tris Buffered Saline/Tween (TBS-T) (20mM Tris (pH 
7.6), 136mM NaCl, 0.05% (v/v) Tween) with shaking.  The 
membrane was then incubated overnight with the primary 
antibody of choice (Table 2.3) in 25ml 5% BSA TBS-T at 
dilutions recommended by the supplier.  The next day, the 
membrane was washed five times in TBS-T for 10 min each at 
RT, prior to incubation with the secondary anti-mouse, anti-
rabbit or anti-goat horseradish peroxidase (HRP) conjugated 
secondary antibody (Dako (UK) ltd, Ely, UK).  The membrane 
was then exposed to an auto-radiographic film for varying 
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lengths of time and bands visualized using the ECL detection 
system (GE Healthcare, UK). 
 
 
             Antibody 
 
                      
               Supplier 
         Actin (L-19) 
         Goat polyclonal 
Santa Cruz Biotechnology, CA 
         Akt (5G3) 
         Mouse monoclonal 
 Cell Signalling Technologies 
         Bim (Y36) 
         Rabbit polyclonal 
         Abcam Ltd, UK 
         CDC25b (C-20) 
         Rabbit polyclonal 
Santa Cruz Biotechnology,CA 
         Cyclin B1(H-433) 
         Rabbit polyclonal 
Santa Cruz Biotechnology,CA 
         Cyclin D1 (HD11)  
         Mouse monoclonal 
Santa Cruz Biotechnology,CA 
 
         FOXO3a (H-144) 
         Rabbit polyclonal 
Santa Cruz Biotechnology,CA 
         FOXM1(C-20) 
         Rabbit polyclonal      
Santa Cruz Biotechnology,CA 
         Id1 (C-20) 
         Rabbit polyclonal 
Santa Cruz Biotechnology,CA 
  Phospho-Akt(Thr308) 92755 
         Rabbit polyclonal 
 Cell Signalling Technologies 
  Phospho-Akt(Ser473) 9271L 
         Rabbit polyclonal 
 Cell Signalling Technologies 
Phospho-FOXO3a(Thr32) 9464C 
         Rabbit polyclonal 
 Cell Signalling Technologies 
         p21 (F-5) 
         Mouse monoclonal 
Santa Cruz Biotechnology,CA 
         p27 (C-19) 
         Rabbit polyclonal 
Santa Cruz Biotechnology,CA 
         Plk  (3F8) 
         Mouse monoclonal 
Santa Cruz Biotechnology,CA 
         Sp1 (IC6) 
         Mouse monoclonal 
Santa Cruz Biotechnology,CA 
         Tubulin  (H-235) 
         Rabbit polyclonal 
Santa Cruz Biotechnology,CA 
 
Table 2.3 Antibodies used for Western blotting 
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2.4 RNA MANIPULATION 
 
2.4.1 Total RNA extraction 
 
Total RNA was isolated from cells using buffers from the RNeasy 
kit (Qiagen, Crawley, UK).  The kit allows samples to be lysed 
and homogenized by a guanidine-thiocyanate-containing buffer 
which is highly denaturing. This inactivates RNases to ensure 
purification of intact RNA.  Ethanol provides appropriate binding 
conditions and the samples are then applied to an RNeasy mini 
spin column, where high quality total RNA binds to the 
membrane and contaminants are washed away.   
 
Frozen cell pellets were disrupted by adding 350μl buffer RLT 
with 10% β-mercaptoethanol.  Samples were homogenized by 
pipetting, then 350μl 70% ethanol was added and 700μl of total 
sample was added to a spin column placed in a 2ml collection 
tube and microcentrifuged for 15s at 10000rpm.  Flow through 
was discarded and 700μl of buffer RW1 was added to the 
RNeasy spin column.  This was microcentrifuged for 15s at 
10000rpm and the flow through again discarded.   Next, 500μl 
of buffer RPE was added to the spin column and 
microcentrifuged at 10000rpm for 15s. The flow through was 
discarded and this step was repeated, followed by 2 min of 
centrifugation at 10000rpm.  The RNeasy column was then 
transferred to a new collection tube. 30μl of RNase-free water 
was added directly to the spin column membrane and the 
column was microcentrifuged for 1 min at 10000rpm to elute 
RNA.  The purity and concentration of RNA was determined by 
measuring the spectrophotometric absorption at 260nm and 
280nm. 
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2.4.2  Real-time quantitative PCR (RT-qPCR) 
 
2μg of total RNA was reversed transcribed to first strand cDNA 
using the Superscript III first strand synthesis system 
(Invitrogen, Paisley, UK).  1μl of random primers and 1μl 10mM 
dNTP mix was added to 2μl of total RNA and made up to a total 
volume of 13μl with sterile RNase free water.  The sample was 
heated at 65°C for 5 min to denature then placed on ice for at 
least 1 min.  The samples were then mixed with 4μl 5x first 
strand buffer, 1μl 0.1M DTT, 1 μl RNaseOUT and 1 μl 
Superscript III RT, to a final volume of 20 μl per sample.  The 
mixture was incubated at 25°C for 5 min then heated at 50°C 
for 50 min.  The reaction was terminated by heating at 70°C for 
15 min.    
 
The resulting cDNA samples were used as a template for RT-
qPCR, which was performed using the TAQMAN 7700 machine 
and 2x SYBRGreen Mastermix (Applied Biosystems) according to 
manufacturers instructions.  Gene specific primer pairs were 
designed using the ABI Primer Express Software (Applied 
Biosystems) or obtained from the literature.  Analysis was 
performed using the relative standard curve method, where    
1-2μg cDNA from each sample was mixed, diluted 1:2 and then 
1:4 for four serial dilutions. As an internal control, the L19 
ribosomal housekeeping gene was used to normalize input RNA.  
The reaction mix contained 2μl of sample and 23 μl of SYBR 
Master Mix and primers to a final volume of 25μl.  All 
measurements were performed in triplicate.  The TAQMAN 7700 
Real-time PCR machine was used.   Efficiency of PCR was 
obtained from the slope of the standard curve. 
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2.4.3  Primer optimization 
 
Each primer set was optimized with 10ng cDNA standard to 
determine the minimum concentration required for maximum 
yield and minimum non-specific amplification.  Dilutions of 50-
900nM of forward and reverse primers in different combinations 
were tested. The concentration that gave the lowest Ct value 
(10-35) with standard DNA and highest Ct value (40) with water 
was selected for use in further experiments.  The concentrations 
of primers used to amplify FOXM1 and L19 were optimized by 
Dr Demetra Constantinidou and Dr Rosaline Hui (E.lam’s 
laboratory, Imperial College, London.) 
 
Primers used for RT-qPCR were as follows: 
 
              Primer           Sequence 5’-3’ 
Human FOXO3a-sense TCTACGAGTGGATGGTGCGTT 
Human FOXO3a-anti-sense CGACTATGCAGTGACAGGTTGTG 
Human FOXM1-sense TGCAGCTAGGGATGTGAATCTTC 
Human FOXM1-anti-sense GGAGCCCAGTCCATCAGAACT 
Human Id1-sense CTGGACGAGCAGCAGGTAAA 
Human Id1-anti-sense AGCTCCTTGAGGCGTGAGTAA 
Human L19-sense GCGGAAGGGTACAGCCAAT 
Human L19-anti-sense GCAGCCGGCGCAAA 
 
Table 2.4 Primers used for RT-qPCR 
 
 
2.5  DNA TRANSFECTIONS OF MAMMALIAN CELLS 
 
2.5.1  Plasmid constructs 
 
The full length (-1480/-25) human FOXO3a promoter was 
cloned previously by Dr Karen Pomeranz and used in this study,  
having been introduced into a pGL3 basic vector (Promega, UK). 
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The human FOXM1 promoter construct was a gift from Professor 
Rene H. Medema (University Medical Center Utrecht, the 
Netherlands).  The FOXM1 promoter/ApaI fragment with 
mutations of forkhead binding sites were generated by Dr Maja 
Petkovic by  performing two rounds of PCR using the 
QuikChange® Site-Directed Mutagenesis Kit (Stratagene) 
following the manufacturers instructions. The PCR primers used 
were as follows:  
 
   First    
  round 
primer1F:cgccggcgccaatttcaccacgcggaacaaactgaaagc 
primer1R: cgtttcagtttgttccgcgtggtgaaattggcgccggcg 
 Second   
  round 
primer2F: ccaatttcaccacgcggccacaactgaaagctccggtg 
primer2R: caccggagctttcagttgtggccgcgtggtgaaattgg. 
 
Table 2.5 Primers used for FOXM1 promoter mutation.  
 
 
The wild-type and mutant Id1 promoters were a gift from 
Professor Paul Coffer (Department of Molecular Medicine, 
University of Utrecht, The Netherlands).  The promoter spanned 
the region upstream of the transcription start site (+1 to -
1692). Using site directed mutagenesis, Dr Kim Birkenkamp 
generated the FHRE (at position -131) mutated Id1 promoter 
which was cloned into pGL3-Basic vector (Promega, 
Southampton, UK) resulting in pGL3Id1FHREMUT. The pLZRS-Id1 
vector was also a gift from Professor Paul Coffer.   
 
2.5.2  Promoter assays 
 
24h prior to transfection, MCF-7 cells were cultured in a 96 well 
plate at a density of 3000 cells/well in 100µl of complete media 
and left overnight.  Cells were then transfected using Fugene 6 
transfection reagent (Roche, UK) according to the 
manufacturers instructions.  The transfections were performed 
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in triplicate.  20ng of pGL3 firefly-luciferase reporter plasmid, 
containing the appropriate cloned promoter sequence, and 5ng 
of pRLTK renilla plasmid (Promega, Southampton UK) was 
added to 0.075µl of Fugene diluted in 5µl of serum free DMEM 
and incubated at RT before addition to the cells.   
 
Cells were then left overnight, and drug added at the 
appropriate time points.  On completion of the time course, 
wells were then washed three times in PBS and stored at -80°C 
until ready for analysis.   
 
2.5.3  Transfection of plasmid DNA 
 
24h prior to transfection, MCF-7 cells were plated in a six well 
plate at a density of 200,000 cells per well.  Transfections were 
performed using a ratio of Fugene 6 (μl) to DNA (μg) of 3:1. 
After 15min incubation, the fugene/DNA mixture was added 
directly to each well and the cells were incubated for 5h at 37°C 
after which time the cells were washed in warmed PBS and 
fresh media added.  
  
2.5.4  Luciferase reporter assay 
 
Luciferase assay was performed with the LucLite Luminescence 
Reporter Gene Assay System (Perkin ElmerTM Life Sciences, 
Milan, Italy) coupled with coelenterazine (Lux Biotechnology, 
Edinburgh, UK) according to manufacturers instructions.   
 
Cells were lysed in 1xLucLite Reagent for 15min at RT.  100µl of 
lysate was transferred to a 96 well microplate and firefly 
luciferase activity was read with TopCount Luminometer (Perkin 
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ElmerTM Life Sciences) – two wells are read simultaneously for 
1s and counts per second are determined.   
 
To measure renilla activity, 25µl of RenLite reagent - 
coelenterazine (50µg/ml) in renilla buffer (0.5M HEPES, pH7.8, 
40mM EDTA) – was added to each well and incubated in the 
dark for 20min at RT, before measurement of renilla activity 
with the TopCount Luminometer.   
 
The relative luciferase activity was determined by dividing firefly 
luciferase activity by renilla luminescence values.   
 
2.6 FLUORESCENCE ACTIVATED CELL SORTING (FACS) 
ANALYSIS  
 
Cells were treated as indicated and then collected by 
centrifugation and washed in PBS.  Cells were fixed by 
resuspension in 90% ethanol with 10% PBS and stored at -20°C 
until analysis.  
 
For analysis, samples were microcentrifuged at 10000rpm to 
remove the ethanol and then resuspended in PBS and stained 
with propidium iodide (50μg/ml) and RNase A (5μg/ml) for 
30min at 4°C.  The cell suspension was then aspirated through 
a fine bore needle to generate a single cell suspension.   
 
Samples were analysed on a FACSCalibur flow cytometer 
(Becton Dickinson, Oxford, UK) using the FACSDivaTM (BD 
Biosciences) acquisition software.  Graphical results represent 
the % of cells (Y-axis) in each phase of the cell cycle 
determined by their DNA content (X-axis).   
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2.7 SULPHORHODAMINE B  (SRB assay) 
 
 The SRB assay is used for examination of cell 
proliferation/viability as the colorimetric measurement of the 
bound dye allows a measurement of cellular protein content.  
SRB is a water-soluble dye that can bind to the basic amino 
acids of cellular proteins. Cells were initially seeded in a 96 well 
plate at a density of 3000 cells/well and incubated overnight.   
On the day of harvesting, cells were fixed with 100µl cold 40% 
(w/v) trichloroacetic acid (TCA) and incubated for 1 h at 4º C.  
Plates were washed five times with slow running tap water then 
100µl of SRB solution (0.4% SRB in 0.1 % acetic acid) was 
added. Plates were left at room temperature for 1 h, then 
washed with 1% acetic acid to remove unbound dye and 
allowed to dry overnight.  
 
To read the plates, 100 µl of 10mM TRIS base solution was 
added to each well, solubilising the protein bound dye. The 
plates were then left on a shaker for 30 min.  Optical density 
(OD) at 492nm was measured on an Anthos 2001 microplate 
reader.  
 
2.8 RNA INTERFERENCE (RNAi) 
 
 
RNA interference is used to suppress gene expression in 
mammalian cells.  RNAi is triggered by an externally introduced 
double strand RNA (dsRNA).  The dsRNA is cleaved by the 
RNase-III enzyme, Dicer, into small interfering RNAs (siRNA) 
that are approximately 21-23 nucleotide fragments.  The siRNA 
then loads into an RNA-Induced Silencing Complex (RISC) which 
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facilitates the separation of the two siRNA strands and cleavage 
of the target mRNA.    
 
For the work in this thesis, genes were silenced using the 
SMARTpool TM product Insert – Version 2.0 (DHARMACON, RNA 
technologies).  The SMARTpool siRNAs used were siFOXO3a (L-
003007-00) and siId1 (L-005051-00).  The transfection reagent 
used was Oligofectamine (Invitrogen Ltd, UK).   
 
MCF-7 cells were plated at a density of 200,000 cells per well in 
a six-well plate 24h prior to transfection.  For each well, 70μl of 
optiMEM (Life Technologies Gibco/BRL, Paisley, UK) was mixed 
with 5μl of oligofectamine and incubated at room temperature 
for 10min.  This solution was then mixed with 250μl optiMEM 
and 7.5μl of the specific siRNA oligonucleotide for each gene, 
with a resulting final concentration of 50nM.  After a further 
25min incubation, 160μl optiMEM was added to each mix and 
500μl was then added to the wells, which had been washed 
immediately beforehand with warmed PBS.  After 4h of 
incubation at 37°C, 2ml of normal media, with 10% FCS, was 
added back to each well.   
 
Two types of controls were used for the siRNA experiments.  As 
a negative control, cells were transfected with a non-
specific/non-targeting siRNA (NSC D-001210-01-05, 
Dharmacon). This served to distinguish sequence specific 
silencing from non-specific effects.  These siRNAs have an 
impaired ability to be processed by the RISC and share little or 
no homology with known mRNA targets in the cell. Another 
control used was the untreated or mock control, where cells 
were cultured without any siRNA treatment.  This allows 
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detection of any cellular effects caused by the transfection event 
or delivery process and determines target gene level. 
 
48-72h post-transfection, cells were harvested and protein and 
mRNA levels were analysed by Western blotting or RTqPCR as 
described previously.      
 
2.9 SUBCELLULAR FRACTIONATION 
 
The NE-PER nuclear-cytoplasmic kit (Perbio, Belgium) was used 
to separate and prepare cytoplasmic and nuclear extracts from 
MCF-7 cells, according to the manufacturers instructions.  Two 
kit reagents, named CERI and CERII were added to the cell 
pellet, causing disruption of the cell membrane and release of 
cytoplasmic contents.  The intact nuclei were then recovered 
from the cytoplasmic extract by centrifugation and lysed with 
the NER kit reagent to yield the nuclear extract.   
 
Extracts were then used for Western blot analysis. Efficient 
fractionation was confirmed by analyzing the purity of the 
cytoplasmic fraction by blotting for tubulin and for the nuclear 
fraction with Sp1.     
 
2.10 IMMUNOHISTOCHEMICAL (IHC) STAINING 
 
Patients receiving neo-adjuvant chemotherapy at Charing Cross 
Hospital, London were identified from a clinical data-base.  A 
formal application to the Trust’s Tissue Management Committee 
(authorised by the Wales MREC to release tissue to researchers) 
was made and ethical approval granted to access the surgical 
blocks from the identified patients. 
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Tissue blocks from pre-chemotherapy core biopsies and post -
chemotherapy surgical specimens were matched for individual 
patients and collected from the tissue bank at Charing Cross 
Hospital. 5μm slides were cut from the blocks by Ms Mahrokh 
Nohadani, Research Laboratory Manager in the histopathology 
department at Hammersmith Hospital and immunohistochemical 
staining was performed on these formalin-fixed, paraffin 
embedded sections.  
 
Additional slides from a 2005 neo-adjuvant study of gefitinib 
were also stored in the laboratory and immunohistochemical 
staining was performed on these formalin-fixed, paraffin 
embedded sections. Ethical approval was obtained at the time of 
the study (Polychronis et al., 2005). 
 
Slides were loaded into a rack and placed in an oven at 70°C for 
1 h to melt the paraffin around the tissue sample. To remove 
the embedding material, the samples were deparaffinised and 
rehydrated.  This was done by sequentially placing the slides 
and rack in xylene twice for 10 min, 100% ethanol for 10 min, 
70% ethanol for 10 min then finally tap water.  The slides were 
then placed in 1l of pre-warmed citrate buffer (0.01M sodium 
citrate, pH 6) and then heated at full power for 15 min in a 
microwave for antigen retrieval. This allowed recovery of the 
antigenicity of the tissue which had been masked by formalin 
fixation. After 20 min of cooling at RT, the slides were 
transferred rapidly to a cuvette containing warmed PBS and 
washed a further two times in PBS.  To block endogenous 
peroxidase activity, which may result in high, non-specific 
background staining, slides were then immersed in 3% H2O2 in 
methanol for 10 min. This resulted in the irreversible 
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inactivation of endogenous peroxidase. Slides were then washed 
again twice in PBS for 5 min.  
 
Next, the slides were placed on a PBS moistened incubation tray 
and the tissue samples were outlined with a hydrophobic pen. 
Five drops of V block (Thermo Fisher Scientific, CA, USA) was 
added to each sample. This further reduced nonspecific 
background staining. After 5 min the primary antibody was 
added.    
 
The dilution of antibody used was determined by first 
performing a titration of antibody dilutions, to optimize tissue 
staining whilst eliminating excessive background or non specific 
staining.  For example, for optimization of FOXO3a staining with 
the upstate FOXO3a rabbit polyclonal antibody, the following 
dilutions were used: 1:100, 1:200, 1:400, 1:800 and 1:1600. 
Omission of primary antibody was used as a negative control.  
Sensitivity and staining quality was then imaged on light 
microscopy and the most appropriate dilution selected for 
subsequent staining. In the case of FOXO3a, 1: 400 was used 
as the optimal dilution for staining of the breast cancer samples 
(Figure 2.1).  Optimization of FOXM1 and Id1 staining was 
performed by the same method.   
 
The primary antibody was diluted in Lab vision UltraAntibody 
dilutent (Lab Vision Corporation, CA, USA) at the optimized 
dilutions (table 2.6) and 200μl was added to each sample and 
the slides were incubated overnight with the primary antibody 
at 4°C.  
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Figure 2.1 Optimisation of the FOXO3a antibody for tissue 
staining. For optimization of FOXO3a staining with the upstate 
FOXO3a rabbit polyclonal antibody, the following dilutions were 
used: 1:100, 1:200, 1:400, 1:800 and 1:1600. Omission of 
primary antibody was used as a negative control. The dilution 
giving optimum staining with minimal background was used for 
subsequent experiments.   
 
 
 
 
 
 
1 : 400 1 : 800
1: 100 1 : 200
1 in 1600 Negative
control
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Antibody 
 
 
Dilution 
FOXM1(C-20) 
Rabbit polyclonal         
Santa Cruz Biotechnology,CA 
 
1:400 
FOXO3a (07-1719) 
         Rabbit polyclonal 
                Upstate 
 
1:400 
Id1 (C-20) 
Rabbit polyclonal Santa Cruz 
Biotechnology,CA 
 
1:100 
 
Table 2.6 Antibodies and dilutions used for IHC staining 
 
The following day, the slides were washed three times in PBS 
for 5 min and incubated with biotinylated goat antipolyvalent 
secondary antibody (Lab Vision Corporation, CA, USA) for 15 
minutes. The slides were then washed twice in PBS for 5 min, 
dried off by gentle shaking and then streptavidin peroxidase 
(Lab Vision Corporation, CA, USA) was added for 15 min. Slides 
were then wash twice in PBS. 
 
Chromagen DAB/ substrate reagent solution was prepared from 
a DAKO kit (DAKO REAL EnVision Detection System, DAKO, 
Denmark) adding 20ul DAB chromagen to 1ml DAB buffer. (In 
the presence of a peroxidase enzyme, DAB will produce a brown 
precipitate that is insoluble in alcohol, thus allowing the slides to 
be dehydrated through alcohols to xylene in the final steps). 
The chromagen/DAB substrate was applied to the slides and the 
tissue was monitored for staining development and intensity.  
Staining was terminated by washing the slides in tap water for 5 
min.  4-5 drops of Mayer’s haematoxylin counterstain (DAKO, 
Denmark) was added to each sample, and removed after 30 s 
by washing in tap water.  
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The final steps involve dehydrating the slides by sequential 
washing in tap water for 10 min, 70% ethanol for 10 min, 100% 
ethanol for 10 min and xylene for 10 min.  Slides were mounted 
by adding one drop of mounting media (Histolab Products, 
Gothenburg, Sweden) to each sample, then covering the sample 
with a coverslip.  Slides were allowed to dry before examining 
under the microscope.  
 
For the tissue slides analysed from the gefitinib neo-adjuvant 
study, intensity of FOXM1, Ki67 and FOXO3a staining was 
evaluated using a 0 to 3 score system. A score of zero indicated 
no staining relative to background, 1+ = weak staining, 2+ = 
moderate staining, 3+ = strong staining. For comparison of 
staining, the results were quantified by calculation of H-scores 
that consider both staining intensity and the percentage of cells 
stained at a specific range of intensities. A complete H-score 
was calculated by multiplying the percentage cells stained at a 
given staining intensity (0–100) and the staining intensity itself 
(0–3). 
 
2.11 IMMUNOFLUORESCENT STAINING 
 
MCF-7 cells were plated in six well plates containing 2cm 
coverslips. 24 h after plating, media was removed, the cells 
were washed in warmed PBS and media containing a final 
concentration of 1μM epirubicin was added back to the wells.  
Cells were incubated with epirubicin containing media for the 
required time then the coverslips were removed with forceps 
and fixed with 4% formaldehyde in PBS for 10 min at room 
temperature (RT).  The fixative was removed and the cells were 
washed four times with PBS for 5 min.  The cells were then 
permeabilized with 0.2% triton in PBS for 5 min, washed again 
 123 
with PBS for 10 min, followed by blocking with 5% goat serum 
in 10% BSA for 30 min.   The primary antibody (FOXO3a, H144, 
Santa Cruz Biotechnology) was then added at a dilution of 
1:100 dissolved in 10% BSA blocking solution and the cells were 
incubated for 1 h, before further washing with PBS three times 
for 5 min.  The secondary antibody (Alexa-Fluor 555 anti –
rabbit, Invitrogen) was then added (1:500 dilution in 10% BSA) 
and the cells were incubated in the dark for 1h.  The cells were 
washed again three times in PBS for 5 min each.  Cells were 
then incubated in DAPI for nuclear staining (1:1000 dilution in 
10% BSA) for 1h in the dark.  The coverslips were placed on 
microscope slides, sealed with clear nail varnish and the slides 
analyzed on a Zeiss confocal microscope with LSM meta 510 
software.    
 
2.12 STATISTICAL ANALYSIS 
 
T-test was used to determine statistical significance of the 
differences between the mean of two groups using the excel 
programme. A p value of less that 0.05 was considered 
significant (*). 
 
In chapter 5, to test for differences between Ki67, nuclear 
FOXO3a and FOXM1 expression pre- and post-gefitinib 
treatment and FOXM1 expression in treated and control groups 
before and after treatment, Dunnett’s two-tailed t-test was 
performed and the mean difference considered significant at the 
p<0.05 level. The relationship between fold changes in H-score 
in FOXM1 and Ki67 or nuclear FOXO3a was statistically analysed 
using Pearson’s correlation test based upon their H-scores and 
was considered significant at p<0.05. All statistical analysis was 
performed with SPSS v.15 (SPSS inc, Chicago, IL, USA).    
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FOXO3a AS A TARGET OF EPIRUBICIN 
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3.1 INTRODUCTION AND OBJECTIVES 
 
Improvements have been seen in the last twenty years in the 
outcome of patients who develop breast cancer.  The use of 
adjuvant chemotherapy has undoubtedly contributed to this and 
central to many of the chemotherapy regimens that patients 
receive is the anthracycline epirubicin.  Given usually in 
combination with 5-flurouracil and cyclophosphamide, epirubicin 
remains one of the most widely prescribed drugs for breast 
cancer in the UK.  The anthracyclines inhibit the topoisomerase 
enzymes, interfering with the ability of the enzyme to repair 
transient double strand breaks in the DNA helix.  However, 
following topoisomerase inhibition, the subsequent mechanisms 
of anthracycline induced cytotoxicity are not fully understood. 
 
The FOXO family of transcription factors function downstream of 
the PI3K pathway and have a key role in a range of cellular 
processes.  A number of studies have also pointed to a role for 
FOXO in cancer regulation – their ability to control cell survival 
and cell death suggests they may function as tumour 
suppressors.  FOXO factors also appear to be cellular targets for 
anti-cancer drugs.  In leukaemic cells, treatment with imatinib 
and cell death is accompanied by activation of FOXO3a 
(Birkenkamp et al., 2007) and in breast cancer cells, FOXO3a 
has been shown to be a crucial target for the EGFR inhibitor 
gefitinib (Krol et al., 2007).  With respect to chemotherapy, 
paclitaxel mediated cell death is accompanied by increased 
FOXO3a activity and increased expression of its pro-apoptotic 
target Bim (Sunters et al., 2003; Sunters et al., 2006).  The 
effects of epirubicin on FOXO3a function and regulation have not 
previously been characterized and the work in this chapter 
aimed to determine whether the cellular effects of epirubicin are 
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via FOXO3a and to clarify the role of FOXO3a and its targets in 
epirubicin mediated cytotoxicity.     
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3.2 RESULTS       
           
3.2.1 FOXO3a expression in a breast cancer cell line 
panel   
 
To establish the expression of FOXO3a amongst breast cancer 
cells, Western blotting of 10 different breast cancer cell lines 
was performed (Figure 3.1).  FOXO3a was expressed in all the 
cell lines investigated, although there was a large amount of 
heterogeneity amongst the cell lines.  Interestingly, the non-
transformed MCF-10a also expressed significant amounts of 
FOXO3a, consistent with a role for FOXO3a not just in malignant 
cells but also in untransformed cells growing in culture.      
 
3.2.2 FOXO3a is highly expressed in growth arrested 
cells  
 
The breast cancer cell line panel confirmed the expression of 
FOXO3a in all cell lines investigated. To further characterize the 
expression pattern of FOXO3a, MCF-7 cells were serum starved 
for 24h, then serum containing media was reintroduced and the 
cells analysed at various timepoints.  The highest expression of 
FOXO3a protein and mRNA was found in growth arrested cells, 
consistent with a role for FOXO3a in cell cycle progression and 
arrest (Figure 3.2a and 3.2b).  As cells re-enter the cell cycle, 
FOXO3a levels fall.  A similar effect was observed at the gene 
promoter level, with FOXo3a promoter activity being highest in 
serum starved cells and gradually reducing as the cells are 
stimulated with full serum (Figure 3.2c).  
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Figure 3.1 The expression of FOXO3a in a breast cancer 
cell line panel.  Whole cell lysates were prepared from the 
panel of breast cancer cell lines as indicated. The expression of 
total FOXO3a was analysed by Western blotting.  Tubulin was 
used as a loading control.    
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Figure 3.2  FOXO3a expression is highest in growth 
arrested cells. A) MCF-7 cells were grown for 24 h in the 
absence of serum before readdition of complete media with 
10% FCS for the indicated timepoints.  The expression of 
FOXO3a was analysed by Western blotting. B)  Total RNA was 
isolated in parallel and the expression of FOXO3amRNA was 
measured by RTq-PCR and normalised to the level of L19. C)   
Cells were transfected with the WT FOXO3a promoter,then 
incubated in serum free medium for 24h.  Following starvation, 
complete media was added at the indicated timepoints.  
Promoter activity was measured and normalised to renilla.The 
results represent the average ±SD of three independent 
experiments.     
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3.2.3 The sensitivity of a panel of breast cancer cell 
lines to epirubicin 
 
To establish the sensitivity of the MCF-7 breast cancer cell line 
to epirubicin, SRB assays were initially performed to assess cell 
survival following treatment with a dose titration of epirubicin 
(Figure 3.3a).   Cells were treated with a dose titration of 
epirubicin ranging from 100nM to 10μM for 48h. Cells continued 
to proliferate at doses of 100nM and 500nM and a dose of 1μM 
and above was required to show an effect on cell survival and 
promote cell death.   1μM epirubicin was therefore chosen as a 
treatment dose for subsequent experiments.  A panel of cell 
lines was then treated with 1μM epirubicin, confirming 
sensitivity of the breast cancer cell lines MCF-7, ZR75-1, SKBR3 
and BT474 to the cytotoxic effects of epirubicin.  MDA-MB-231 
cells were resistant to the effects of 1μM epirubicin and 
continued to proliferate after 48 h of treatment (Figure 3.3b).   
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Figure 3.3 The sensitivity of breast cancer cells to 
epirubicin. A) MCF-7 cells were treated with a dose titration of 
epirubicin and cell survival measured by SRB assay. B) The 
breast cancer cell lines MCF-7, MDA-MB-231, ZR751, SKBR3 
and BT474 were plated in 96 well plates and 24 h later treated 
with 1μM epirubicin for 48 h and cell survival measured by SRB 
assay. Results are the mean ±SD of three independent 
experiments that included 6 replicates each.  
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3.2.4 Epirubicin causes G2/M arrest in MCF-7 cells 
 
The anthracyclines are topoisomerase poisons but the exact 
mechanisms by which they induce cell death are not fully 
understood.  To characterize the effects of epirubicin on the cell 
cycle, MCF-7 cells were treated with 1μM epirubicin and their 
cell cycle profile was anaylsed by FACS at certain timepoints 
after treatment.  This confirmed that epirubicin induces G2/M 
cell cycle arrest (Figure 3.4).  Changes in the cell cycle profile 
appeared after 16h of treatment and by 24h more than 50% of 
the cell population had arrested – by 48h a significant amount 
of cell death was observed.  The effects of epirubicin on the cell 
cycle appeared to be dose dependent. At low doses, little effect 
was seen on the cell cycle profile, with higher doses causing 
G2/M arrest and significant cell death, even after 24h of 
treatment (Figure 3.5a).  
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Figure 3.4  Epirubicin causes G2M arrest in MCF-7 cells. 
MCF-7 cells were treated with 1μM epirubicin and harvested 
after 24h. Cells were fixed with 90% ethanol and stained with 
propidium iodide.  DNA content was then analysed by flow 
cytometry. The percentage of cells in each phase of the cell 
cycle is indicated ( sub-2N, G1, S and G2/M).  
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Figure 3.5 Dose dependent effects of epirubicin. A) MCF-7 
cells were treated with a dose titration of epirubicin and 
harvested at 24h. Cells were fixed with 90% ethanol and 
stained with propidium iodide.  DNA content was then analysed 
by flow cytometry. The percentage of cells in each phase of the 
cell cycle is indicated (sub 2N, G1, S and G2/M). B) Cells were 
treated in parallel with a dose titration of epirubicin for 24h and 
whole cell lysates prepared and analysed by Western blotting 
with the indicated antibodies.   
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3.2.5 Epirubicin induces FOXO3a protein and mRNA 
expression   
 
The effects of epirubicin on targets both upstream and 
downstream of FOXO3a were next investigated.  The PI3K 
pathway is known to regulate FOXO3a and when MCF-7 cells 
were treated with epirubicin, phospho-Akt initially increased up 
to 4h after treatment, but then decreased significantly by 48h 
(Figure 3.6).  Total Akt remained essentially unchanged.  Total 
FOXO3a protein did not change significantly following epirubicin 
treatment, but there was a marked reduction in phospho-
FOXO3a protein levels, almost undetectable by 48h.  This would 
suggest that epirubicin may be activating FOXO3a. Phospho-
FOXO3a is the inactive, cytosolic form of the transcription factor 
and levels were decreasing whilst total levels of FOXO3a remain 
unchanged, implying that FOXO3a activity is rising following 
epirubicin treatment. This is supported by changes in the 
downstream targets of FOXO3a, p27Kip1 and Bim, which increase 
following epirubicin treatment, suggesting that epirubicin 
activates FOXO3a, which in turn promotes the transcription of 
the cell cycle inhibitor p27 and the pro-apoptotic factor Bim, 
resulting in cell cycle arrest and apoptosis. Another downstream 
target of FOXO3a, GADD45a, also showed an increase in protein 
levels following treatment with epirubicin.  GADD45 plays a key 
role at the G2/M checkpoint and the cell cycle arrest and DNA 
damage induced by epirubicin is likely to lead to its 
upregulation.  The effects of epirubicin are dose dependent, with 
increasing amounts leading to downregulation of phosphorylated 
FOXO3a, whilst upregulating p27Kip1 (Figure 3.5b).  
 
FOXO3a was also upregulated at the transcriptional level by 
epirubicin.  RTq-PCR analysis confirmed that FOXO3a mRNA 
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increased following drug treatment (Figure 3.7a), correlating 
with the changes seen at protein level.  This upregulation in 
protein and mRNA was accompanied by increased FOXO3a 
promoter activity.  When the human FOXO3a promoter was 
transfected into MCF-7 cells and the cells were then treated with 
1μM epirubicin results confirmed that the FOXO3a promoter is 
activated by epirubicin (Figure 3.7b).  The longer timepoint of 
48h was not analysed in the promoter assays as a large amount 
of cell death had occurred by this point, causing cells to detach 
and be unavoidably lost in the washing steps of the luciferase 
assays.  However, the results confirm that by 24h, epirubicin 
upregulates FOXO3a at the protein, mRNA and gene promoter 
levels.    
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Figure 3.6 The effects of epirubicin on FOXO3a and 
targets. MCF-7 cells were treated with 1µM epirubicin and 
protein lysates were obtained at the times indicated. Protein 
expression was analysed by Western blotting using the indicated 
antibodies.   
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Figure 3.7  Epirubicin activates FOXO3a at the 
transcriptional and gene promoter level. A)  MCF-7 cells 
were treated with 1µM epirubicin for the indicated time points.  
Cells were collected and total RNA was isolated.  FOXO3a mRNA 
levels were analysed by real-time quantitative PCR and the 
results normalised with L19 mRNA levels.  B)  MCF-7 cells were 
transfected with 10ng of the FOXO3a promoter and treated with 
1µM epirubicin for the indicated time points before cells were 
collected for luciferase reporter assays.  The relative luciferase 
activity values were corrected for cotransfected renilla activity.  
Results are the average +/- SD of three independent 
experiments.       
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3.2.6 Epirubicin induces FOXO3a nuclear 
sublocalisation in MCF-7 cells 
 
The transcriptional activity of FOXO proteins is regulated by 
their subcellular localisation. When phosphorylated, FOXO 
proteins are sequestered in the cytoplasm, where they are 
inactive. When activated, they are shuttled into the nucleus, 
where they are then able to activate their downstream effectors 
involved in cell cycle arrest and apoptosis.  To investigate the 
effects of epirubicin on subcellular localisation of FOXO3a, MCF-
7 cells were treated with 1μM epirubicin, harvested at 0, 8 and 
24h and then nuclear and cytoplasmic components were 
separated using a fractionation kit.  Western blot analysis 
confirmed that epirubicin treatment causes a nuclear 
accumulation of FOXO3a protein over 24h and this is 
accompanied by a reduction in cytoplasmic phosphorylated 
FOXO3a, consistent with shuttling of FOXO3a from the 
cytoplasm to the nucleus and a shift from the inactive to 
transcriptionally active form of FOXO3a (Figure 3.8a).  Phospho-
FOXO3a is found in the cytosolic fraction only, whereas FOXM1 
is found in both the cytosolic and nuclear fractions and FOXM1 
protein in both subcellular compartments decreases following 
epirubicin treatment.  Efficient fractionation was confirmed with 
the controls – tubulin for the cytoplasmic compartment and 
Sp1, a transcriptional regulator, for the nuclear compartment. 
 
The Western blot findings were confirmed by confocal 
microscopy, where MCF-7 cells were treated with epirubicin and 
then stained with a FOXO3a specific antibody.  In the untreated 
MCF-7 cells, endogenous FOXO3a was visualised predominantly 
in the cytoplasm, but following 24h treatment with epirubicin, 
FOXO3a had relocated to the nucleus (Figure 3.8b).  Together, 
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these results suggest that epirubicin is inducing 
dephosphorylation of FOXO3a and causing its nuclear 
translocation and accumulation and subsequent transcriptional 
activity.   
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Figure 3.8 Epirubicin induces FOXO3a nuclear 
sublocalisation in MCF-7 cells.  A) MCF-cells were treated 
with 1µM epirubicin at the indicated time points.  Nuclear and 
cytoplasmic fractions were separated and protein expression 
was analysed by Western blotting.  B) Cells were cultured on 
coverslips, treated with 1µM epirubicin and fixed in 4% 
formaldehyde.  FOXO3a was visualised with a rabbit polyclonal 
antibody followed by the addition of Alexa Fluor 488 labelled 
anti rabbit sera.  DAPI was also applied to visualise the nuclei.   
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3.2.7 FOXM1 expression in a panel of breast cancer cell 
lines 
 
 
As FOXO3a was identified as a target of epirubicin, another 
member of the Forkhead family, FOXM1, was also studied and 
the effects of epirubicin on its expression investigated. Firstly, 
the expression of FOXM1 in a panel of cell lines was established. 
FOXM1 was found to be expressed in all cancer cell lines, 
although again there was a degree of heterogeneity between 
different cell lines (Figure 3.9).  Interestingly, the  
untransformed cell line MCF-10A did not express FOXM1, 
consistent with higher FOXM1 expression being found in cancer 
cells as opposed to normal epithelial cells.  FOXO3a expression 
did not correlate with FOXM1 expression. In fact, cells with high 
FOXM1 expression tended to have lower levels of FOXO3a 
expression and vice versa.      
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Figure 3.9 FOXM1 expression in a panel of breast cancer 
cell lines. Whole cell lysates were prepared from the panel of 
breast cancer cell lines as indicated. The expression of total 
FOXM1 was analysed by Western blotting.  Tubulin was used as 
a loading control.    
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3.2.8 FOXM1 is repressed by epirubicin at the protein, 
mRNA level and gene promoter level 
 
Work in the laboratory has previously shown that FOXM1 can be 
repressed by FOXO3a following treatment with gefitinib in 
sensitive breast cancer cell lines (McGovern et al., 2009).  The 
effect of other chemotherapeutic agents on FOXM1 has not been 
characterised.   Therefore, it was next of interest to look at 
FOXM1 expression following treatment with 1μM epirubicin. 
 
Western blot analysis confirmed that treatment of MCF-7 cells 
with epirubicin led to a decrease in FOXM1 protein levels as well 
as a decrease in its downstream targets, cyclin B1 and PLK1 
(Figure 3.10a).  RTQ-PCR confirmed these findings at the 
transcriptional level with a marked reduction in FOXM1 mRNA 
transcript by 24 and 48h (Figure 3.10b), suggesting FOXM1 is 
also a downstream signalling target of epirubicin in MCF-7 cells. 
 
3.2.9 Dose dependent effects of epirubicin on FOXM1 
and targets 
 
Increasing doses of epirubicin downregulated proteins levels of 
phosphorylated FOXO3a and increased levels of the FOXO3a 
downstream target p27.  Similarly, the dose dependent effects 
of epirubicin on FOXM1 and its downstream targets were 
investigated.  FOXM1 protein was downregulated by epirubicin 
in a dose dependent manner, as were the downstream targets 
PLK1 and cyclin B1 (Figure 3.11).  
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3.2.10 Epirubicin represses FOXM1 promoter activity  
 
 
 As the previous data suggested that both FOXO3a and FOXM1 
are targets of epirubicin treatment, the mechanisms involved in 
the repression of FOXM1 by epirubicin were investigated further.  
A full-length FOXM1 promoter reporter construct was transiently 
transfected into MCF-7 cells and the cells were then treated with 
epirubicin. A significant decrease in promoter activity was 
observed (Figure 3.12a).  However, when a FOXM1 promoter 
construct was used where two FOXO3a binding sites were 
mutated, the repression of promoter activity by epirubicin was 
much less (Figure 3.12b).  This would suggest that the 
repression of FOXM1 by epirubicin is mediated, at least in part, 
by FOXO3a. Epirubicin can activate FOXO3a and can repress 
FOXM1, and this repression appears to be dependent on 
FOXO3a – if FOXO3a is prevented from binding to the FOXM1 
promoter, the repression of FOXM1 by epirubicin is abrogated.  
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Figure 3.10 Epirubicin represses FOXM1 protein and 
mRNA. A) MCF-7 cells were treated with 1µM epirubicin and 
protein lysates were obtained at the times indicated. Protein 
expression was analysed by Western blotting using the indicated 
antibodies.  B)  MCF-7 cells were treated with 1µM epirubicin for 
the indicated time points.  Cells were collected and total RNA 
was isolated.  FOXM1 mRNA levels were analysed by real-time 
quantitative PCR and the results normalised with L19 mRNA 
levels. Results are the average +/- SD of three independent 
experiments.   
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Figure 3.11 Dose dependent effects of epirubicin on 
FOXM1 and targets.  MCF-7 cells were treated with a dose 
titration of epirubicin and harvested after 24h of exposure to the 
drug. Whole cell lysates were prepared and analysed by 
Western blotting with the indicated antibodies.  
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Figure 3.12 Epirubicin represses FOXM1 promoter 
activity. A)  MCF-7 cells were transfected with 10ng of the 
FOXM1 promoter or B) a FOXM1 promoter with mutated 
FOXO3a binding sites and treated with 1µM epirubicin for the 
indicated time points before cells were collected for luciferase 
reporter assays. The relative luciferase activity values were 
corrected for cotransfected renilla activity. Results are the 
average +/- SD of three independent experiments.   
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3.2.11 Silencing of FOXO3a by siRNA confers protection 
to the cytotoxic effects of epirubicin 
 
To further examine the role of FOXO3a in epirubicin mediated 
cytotoxicity, the effects of treating cells with epirubicin following 
knockdown of FOXO3a was investigated.  MCF-7 cells were 
transfected with a FOXO3a specific siRNA or a non specific 
control siRNA.  Western blot analysis confirmed efficient 
knockdown of endogenous FOXO3a (Figure 3.13a) and 
subsequent SRB assay analysing the effects of this knockdown 
on MCF-7 survival following drug treatment confirmed that the 
cytotoxic effects of epirubicin were less in the FOXO3a siRNA 
cells than in the control cells (Figure 3.13b).  This suggests that 
loss of FOXO3a confers some protection against epirubicin and 
that FOXO3a is required in mediating cell death induced by 
epirubicin in MCF-7 cells. To characterise the relationship 
between FOXO3a and FOXM1, changes in FOXM1 following 
epirubicin treatment when FOXO3a was silenced by siRNA was 
looked at.  In the control transfected cells, epirubicin lead to 
down regulation of FOXM1 and its targets, but in the FOXO3a 
knockout cells, FOXM1 levels were essentially unchanged and 
the downregulation of the FOXM1 targets cyclin B1 and PLK1 
was also much less (Figure 3.13a).  This would suggest that 
FOXO3a is required for the repression of FOXM1 following 
epirubicin treatment and when FOXO3a is silenced, derepression 
of FOXM1 leads to MCF-7 cells being less sensitive to the effects 
of epirubicin, conferring some protection against drug 
treatment.   
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Figure 3.13 Silencing of FOXO3a protects cells against the 
cytotoxic effects of epirubicin.  A) Cells were transfected 
with siRNA specifically targeting FOXO3a or a NSC. 48h post 
transfection, Western blot analysis was performed to confirm 
efficient FOXO3a knockdown and FOXM1 expression levels. B) 
24h post siRNA transfection, cells were replated in 96 well 
plates, treated with 1μM epirubicin for the given time points and 
cell proliferation analysed by SRB assay.  Results are the mean 
±SD of six replicates. *p<0.05.  
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3.2.12 Expression of a constitutively active FOXM1 (ΔN-
FOXM1) abrogates the cytotoxic effects of 
epirubicin 
 
To confirm that FOXM1 is a downstream target of epirubicin, 
MCF-7 cells were transfected with an expression vector 
encoding for a constitutively active NH2 –terminal truncated 
form of FOXM1, ΔN-FOXM1.  The ΔN-FOXM1 cells were treated 
with 1µM epirubicin and their cell cycle profile following 
treatment was analysed by FACS.  Epirubicin causes G2M arrest 
in MCF-7 cells but in the ΔN cells, this effect was abrogated and 
minimal cell cycle arrest or cell death was seen (Figure 3.14a).  
Western blot analysis of cell lysates from epirubicin treated wild- 
type MCF-7 cells and the ΔN-FOXM1 transfected cells confirmed 
repression of endogenous FOXM1 levels by epirubicin in the wild 
type cells, corresponding with cell cycle arrest and cell death, 
but in the ΔN-FOXM1 transfected cells, the constitutively active 
ΔN-FOXM1 was not repressed by epirubicin and the downstream 
target of FOXM1, cyclin B1, was repressed to a much lesser 
extent than in the wild-type cells (Figure 3.14b).  This would 
suggest that overexpression of a constitutively active form of 
FOXM1 can overcome the antiproliferative and cytotoxic effects 
of epirubicin. 
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Figure 3.14 Expression of a constitutively active FOXM1 
(ΔN-FOXM1) abrogates the cytotoxic effects of epirubicin.  
A)  MCF-7 cells were transfected with a vector containing a 
constitutively active ΔN-FOXM1 and treated with epirubicin. 
Cells were fixed at the indicated timepoints and cell cycle phase 
distribution was analysed by flow cytometry after propidium 
iodide staining.  Pecentage of cells in each phase of the cell 
cycle are indicated (< 2N,G1, S and G2M.) B) Wild type MCF-7 
cells and the transfected ΔN-FOXM1 cells were treated with 1µM 
epirubicin at the indicated timepoints and the expression of 
FOXM1 and its targets was analysed by Western blotting.  
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3.3 DISCUSSION 
 
To continue to improve outcomes in breast cancer, a greater 
understanding of the mechanisms through which chemotherapy 
exerts its cytotoxic effects is required, allowing better selection 
of patients for individual treatments and identifying patients 
who may be resistant to particular drugs or treatment regimens. 
Epirubicin is used widely in the clinical setting for the treatment 
of breast cancer, but not all patients will show a response.  
Thus, identifying the cellular pathways involved in mediating the 
effects of epirubicin could be of clinical benefit in the future.  
 
The work in this chapter demonstrates that FOXO3a plays a key 
role in the response of MCF-7 cells to the chemotherapeutic 
agent epirubicin.  Epirubicin is highly toxic to most of the breast 
cell lines tested (Figure 3.3), with only MDA-MB-231 cells being 
resistant to the drug, an ER and HER2 negative cell line.  In the 
clinical setting, debate is ongoing about which particular 
subtypes of breast cancer are more sensitive to the 
anthracyclines.  ER negative cancers appear to derive the most 
benefit from chemotherapy and there is some evidence that 
HER2 positive cancers are more sensitive to anthracyclines, due 
to the close proximity of the HER2 gene to the TOP2A gene on 
chromosome 17 – coamplification of both may contribute to 
anthracycline sensitivity (Pritchard et al., 2008).  Both HER2 
positive cell lines tested (BT474 and SKBR3) were epirubicin 
sensitive.  
 
Doses of at least 1μM were required in vitro to achieve a 
significant amount of cell death in MCF-7 cells and this was the 
dose carried forward for subsequent experiments. 1μM is 
sufficient to induce G2/M cell cycle arrest, which starts to occur 
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at 16h post-treatment (Figure 3.4).  By 48h, a significant 
amount of cell death has occurred, suggesting that the damage 
induced by epirubicin is unrecoverable and cell cycle arrest is 
followed by cell death.  G2/M arrest is not unique to epirubicin - 
although chemotherapeutic agents may have different 
mechanisms of action, a common theme is that they all confer 
DNA damage, directly or indirectly, and induce cell cycle 
checkpoints.  Paclitaxel, a mitotic spindle poison, also induces 
G2/M arrest in MCF-7 cells (Sunters et al., 2003).  Both FOXO3a 
and FOXM1 have roles at the G2/M checkpoint.  In response to 
stress, FOXO3a can induce a delay in G2M by regulating cyclin 
G2 and GADD45a, in an attempt to repair damaged DNA.  
FOXM1 is critical for G1/S and G2M cell cycle progression and 
also for mitotic spindle integrity (Myatt and Lam, 2007). The 
activation of FOXO3a and repression of FOXM1 seen after 
epirubicin treatment is therefore likely to play a significant role 
in the G2/M cell cycle arrest observed.  
 
Consistent with its role in the cell cycle and anti-proliferative 
effects, FOXO3a expression can be induced by serum starvation 
and FOXO3a protein, mRNA and promoter activity are all 
highest in serum starved MCF-7 cells (Figure 3.2).  FOXO 
proteins can contribute to exit from the cell cycle, into 
quiescence (G0).  FOXO3a is known to control transcription of 
the retinoblastoma-like p130 protein, which is 
hypophosphorylated and bound to the transcription factor E2F-
4, maintaining cell in G0 (Kops et al., 2002b).   When conditions 
are favourable (i.e. when serum is reintroduced) FOXO3a levels 
fall as cell renter the cell cycle and begin to proliferate.  This 
demonstrates the different functions of FOXO3a – serum 
starvation and epirubicin can both upregulate FOXO3a and lead 
to cell cycle arrest.  However, the decision to reenter the cell 
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cycle or undergo apoptosis will depend on the damage inflicted 
on the cell.  Cells can tolerate serum starvation in the short 
term but clearly cannot recover from the DNA damage induced 
by epirubicin and hence undergo programmed cell death.   
 
Treatment with epirubicin leads to a reduction in levels of 
phosphorylated Akt, suggesting that the activity of the PI3K 
pathway is repressed by epirubicin.  Akt directly phosphorylates 
FOXO3a and repression of Akt activity may be an early event in 
the activation of FOXO3a – low Akt activity following epirubicin 
treatment renders FOXO3a dephosphorylated and located in the 
nucleus.  Indeed, levels of phosphorylated FOXO3a also fall 
following epirubicin treatment.  Further evidence for FOXO3a 
activation is the upregulation of p27Kip1 and Bim, two known 
FOXO3a targets, following epirubicin treatment. By 24 and 48h, 
as cells are arresting and undergoing apoptosis, protein levels of 
both p27Kip1 and Bim increase (Figure 3.6). Bim has been shown 
previously to be transcriptionally regulated by FOXO3a following 
treatment of MCF-7 cells with paclitaxel (Sunters et al., 2003).  
Bim is also unregulated following gefitinib treatment in sensitive 
cells (Krol et al., 2007).   Bim, as a BH3 protein, acts as a 
sensor of cellular damage and when activated by FOXO3a, can 
trigger mitochondrial permeabilisation and the release of other 
pro-apoptotic proteins from the mitochondrion, initiating cell 
death (Letai, 2008).   To some extent, the effects of epirubicin 
are dose dependent and increasing doses of the drug are 
associated with greater induction of p27Kip1 and decreasing 
amounts of phosphorylated FOXO3a (Figure 3.5).  However, at 
very high doses of epirubicin (10μM) there is no induction of 
p27Kip1, which may be just a reflection of a large amount of cell 
death and poor protein integrity.     
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The nuclear localization of FOXO3a is a prerequisite for 
transcriptional activation and when MCF-7 cells are treated with 
epirubicin, a clear rise in seen in nuclear FOXO3a with an 
accompanying fall in phosphorylated cytoplasmic FOXO3a 
(Figure 3.8).  This was confirmed with immunofluorescent 
studies, with little or no cytoplasmic FOXO3a identifiable after 
24h treatment with epirubicin.  This confirms the hypothesis 
that epirubicin is activating FOXO3a – treatment with the drug 
leads to shuttling of FOXO3a from the cytoplasm, where it is 
transcriptionally inactive and phosphorylated by Akt, into the 
nucleus where it can activate target genes.  FOXM1 is active 
when nuclear and phosphorylated – epirubicin reduced both the 
nuclear and cytoplasmic expression of FOXM1.     
 
Silencing of FOXO3a renders MCF-7 cells more resistant to the 
effects of epirubicin. Cells that would normally undergo 
apoptosis may instead survive in the absence of FOXO3a, 
resulting in increased drug resistance.  Loss of FOXO3a function 
leads to a decreased ability to induce cell cycle arrest. The DNA 
damage induced by epirubicin would normally be expected to 
trigger the activation of a number of cell cycle regulators, 
including FOXO3a, which would arrest the cells and prevent 
them passing through key cell cycle checkpoints with damaged 
DNA. If the damage cannot be repaired, cells will undergo 
apoptosis. Silencing of FOXO3a is likely to reduce the ability of 
cells to arrest in response to epirubicin, resulting in the 
replication of damaged DNA and increased cell survival. This 
would further support the role of FOXO3a as a tumour 
suppressor – the decreased ability to repair damaged DNA due 
to the absence of FOXO factors results in the survival of 
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damaged cells, promoting genomic instability, one of the 
hallmarks of cancer.  In other tissues, reduced FOXO3a 
expression has been associated with increased resistance to 
therapeutic agents.  In prostate cancer, FOXO3a function is 
compromised in androgen independent prostate cancer cells 
versus androgen dependent LnCaP cells (Lynch et al., 2005).  
Thus, as cells progress from androgen sensitive to androgen 
resistant, FOXO3a expression and function is lost.  Therefore, 
the expression of FOXO3a may be of use in predicting the 
likelihood of response to treatment and cancers expressing low 
levels of FOXO3a may be less likely to respond to particular 
treatments.   
 
This work also identifies FOXM1 as a downstream signalling 
target of epirubicin. Treatment of MCF-7 cells with epirubicin 
leads to a reduction in FOXM1 protein levels, which coincides 
with a decrease in FOXM1 activity, as seen by the concomitant 
decrease in expression of the FOXM1 targets cyclin B1 and PLK1 
(Figure 3.10).  This repression of FOXM1 by epirubicin occurs at 
the transcriptional and gene promoter level, as a reduction in 
FOXM1 mRNA accompanies the fall in protein levels and a 
decrease in FOXM1 promoter activity is seen following treatment 
(Figure 3.12).  The downregulation of FOXM1 expression by 
epirubicin may be another critical target for the cytotoxic effects 
of the drug – FOXM1 is a crucial regulator of cell proliferation 
and regulates the expression of a number of target genes 
involved in cell cycle progression and survival. An increase in 
FOXM1 expression is seen at the onset of S phase and continues 
throughout G2 and mitosis, activating the transcription of 
Cdc25B, survivin, PLK1 and the Cdk-cyclin B complex (Costa, 
2005).   That FOXM1 is a target of the antiproliferative effects of 
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epirubicin  is further confirmed by the observation that 
overexpression of a constitutively active FOXM1, ΔN-FOXM1, 
abrogates the proliferative arrest and apoptosis induced by 
epirubicin, suggesting FOXM1 has a functional role in mediating 
the effects of the drug (Figure 3.14).  
 
The repression of FOXM1 expression appears to be dependent in 
part on FOXO3a. FOXO3a is activated by epirubicin, whilst 
FOXM1 is repressed.  Transient transfection of a FOXM1 
promoter reporter construct showed a decrease in promoter 
activity following epirubicin treatment. However, with the 
FOXM1 mutant promoter, where two FOXO binding sites were 
mutated to make it refractive to FOXO transactivation, no 
significant decrease in promoter activity was seen.  This would 
suggest that FOXO3a is required for the repression of FOXM1 
promoter activity.  Similarly, when FOXO3a is silenced by siRNA 
and cells are then treated with epirubicin, FOXM1 protein levels 
are not downregulated, again supporting the hypothesis that 
FOXO3a is involved in the repression of FOXM1 (Figure 3.13).  It 
is also of interest to note the inverse correlation of FOXO3a and 
FOXM1 expression in the cell line panel – cells with high 
expression of FOXM1, such as ZR-75-1, MDA-MB-231 and MDA-
MB-453, express lower levels of FOXO3a than some of the other 
cell lines.  
 
3.4 FUTURE WORK 
 
There is scope to further explore the relationship between 
FOXO3a and FOXM1.  Chromatin immunoprecipitation (ChIP) 
could be used to see whether FOXO3a is associated with the 
FOXM1 promoter in vivo. FOXO3a may act as a transcriptional 
repressor of FOXM1 by binding directly to the FOXM1 promoter.   
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Further analysis of the FOXO3a promoter would be useful also 
to try and identify key regions involved in the promoter 
activation caused by epirubicin, which may identify other 
important co-activators or repressors involved in the response 
to epirubicin.  Deletion mapping of responsive elements on the 
FOXO3a promoter would also be useful to identify key 
regulatory areas involved.   
 
GST pulldown experiments would be useful to identify other 
binding partners of FOXO3a and the role of other stress 
signalling molecules such as JNK and NFκB and their interaction 
with FOXO3a in response to drug treatment will give more 
insight into cross talk between different signalling pathways in 
response to drug treatment.       
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CHAPTER 4                                            
CHARACTERISING THE ROLE OF ID1 IN         
BREAST CANCER CELLS 
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4.1 INTRODUCTION AND OBJECTIVES 
 
Inhibitor of DNA binding (Id) proteins are regulatory proteins 
that belong to the helix-loop-helix (HLH) family of transcription 
factors which  are involved in a wide range of developmental 
and cellular processes, including cell lineage determination, cell 
proliferation and differentiation.  Id proteins lack a basic DNA 
binding domain, but are capable of dimerizing with other basic 
HLH (bHLH) factors.  However,   the resulting heterodimers 
formed are unable to bind DNA and initiate transcription – thus 
Id proteins function as dominant negative regulators of bHLH 
transcription factors (Desprez et al., 2003).   
 
Id1 is the most well characterized Id protein.  In normal 
development, Id1 is highly expressed during mouse mammary 
gland development and in pregnancy, during epithelial ductal 
cell proliferation, but levels become undetectable post-partum 
and in the lactating period, corresponding to a highly 
differentiated state (Parrinello et al., 2001).  In haematopoeitic 
cell lineages, high expression of Id1 is seen in precursor cells 
but decreases as cells progress through differentiation and Id1 
is capable of blocking erythrocyte differentiation in cultured 
K562 cells  (Cammenga et al., 2003; Kreider et al., 1992).     
 
There is increasing evidence to suggest an oncogenic role of Id1 
in human cancer.  Id1 is overexpressed in a variety of cancers 
and may act as a marker of progression, metastases and 
outcome.  In this chapter, the expression and role of Id1 in 
breast cancer cells was characterised and the effects of 
treatment with epirubicin on Id1 was demonstrated.  The 
hypothesis that FOXO3a may regulate Id1 in breast cancer was 
also investigated.   
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4.2 RESULTS 
 
4.2.1 Id1 expression in breast cancer cell lines 
 
To establish the expression of Id1 in a variety of cell lines, a 
comparative protein expression analysis was performed by 
Western blotting to look at the expression of Id1 protein in a 
panel of 10 breast cancer cell lines, including the non-
transformed cell line MCF-10A (Figure 4.1). 
 
Id1 was expressed in all cell lines in the panel, but there was a 
degree of heterogeneity in Id1 expression amongst the different 
cell lines.  Id1 was expressed in both ER positive and ER 
negative cell lines, and also in both HER2 positive (BT474, 
SKBR3) and HER2 negative cell lines. MDA-MB-231 cells had the 
highest relative expression of Id1 in the panel, with ZR-751 cells 
expressing low amounts of Id1.  Id1 expression was also low in 
the non transformed breast epithelial cell line MCF-10A, 
consistent with the observation that Id1 expression is generally 
higher in malignant cells than in normal epithelial breast cells.            
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Figure 4.1 The expression of Id1 in a breast cancer cell 
line panel. Whole cell lysates were prepared from the panel of 
breast cancer cell lines as indicated. The expression of Id1 
protein was analysed by Western blotting.  Tubulin was used as 
a loading control.    
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4.2.2 Id1 expression is highest in proliferating cells 
 
Id proteins have a critical role in the cell cycle, and are known 
to be mitogen responsive in fibroblasts – quiescent cells express 
low or undetectable levels.  To establish the expression of Id1 in 
MCF-7 cells and to correlate expression with proliferation, MCF-7 
cells were serum starved for 24h. Full medium (with 10% FCS) 
was then reintroduced to the cells, and cells were harvested at 
different time points following readdition of serum.  
Synchronisation and re-entry to the cell cycle was confirmed by 
FACS analysis (Figure 4.2a). Following 24h of serum starvation, 
nearly 90% of cells were arrested in G1. After 16h, cells were 
seen to be progressing through S phase and into G2M i.e 
returning to a normal cell cycle profile. Both Id1 protein and 
mRNA levels were analysed in parallel with the FACS samples 
and results confirmed that in growth arrested cells, Id1 protein 
and mRNA levels are low, but increase significantly by 16h, as 
cells re-enter the cell cycle (Figure 4.2b anc 4.2c).  This 
confirms Id1 as a proliferation dependent protein and identifies 
Id1 as serum responsive in MCF-7 breast cancer cells.      
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Figure 4.2 Expression of Id1 in growth arrested cells.  A)  
MCF-7 cells were grown for 24 h in the absence of serum before 
restimulation with complete media containing 10% FCS for the 
indicated timepoints. Cells were harvested and analysed by 
FACS B)Whole cell lysates were prepared and the expression of 
Id1 was analysed by Western blotting. C)  Total RNA was 
isolated in parallel and the expression of Id1 mRNA was 
measured by RTq-PCR and normalised to the level of L19.  The 
results represent the average ±SD of three independent 
experiments.  *p<0.05.   
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4.2.3 Epirubicin rapidly downregulates Id1 expression 
 
In the previous chapter, results showed that both FOXO3a and 
FOXM1 are targets of the anthracycline epirubicin.  Epirubicin 
upregulates FOXO3a protein and mRNA and activates the 
FOXO3a promoter whilst repressing FOXM1 at the protein, 
mRNA and gene promoter level.  The most significant changes 
are seen after at least 16h of drug treatment. The effects of 
epirubicin on Id1 have not previously been characterized.   
 
To investigate whether Id1 is a cellular target of epirubicin, 
MCF-7 cells were treated with 1μM epirubicin and then 
harvested at the indicated timepoints post treatment to assess 
changes in Id1 protein and mRNA levels. Downregulation of Id1 
at both protein and mRNA level was observed (Figure 4.3a and 
4.3b).  The changes in protein and mRNA levels were relatively 
rapid, occurring within a few hours of drug treatment. Id1 would 
therefore seem to be an early cellular target of epirubicin and 
repression of Id1 at both protein and mRNA levels appears to 
precede the changes in FOXO3a and FOXM1 seen in Chapter 3, 
suggesting Id1 repression is an early upstream event of the 
cascade of cellular responses to epirubicin.          
 
 
4.2.4 Epirubicin represses Id1 promoter activity 
 
 
As epirubicin downregulates Id1 protein and mRNA, the effect of 
epirubicin on the Id1 promoter was next investigated.  Id1 has a 
short half-life and is known to be degraded by proteolysis 
through the ubiquitin-proteasome pathway (Bounpheng et al., 
1999). However, the downregulation of Id1 following epirubicin 
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treatment cannot simply be due to its degradation.   Gene 
promoter analysis confirmed that epirubicin represses the Id1 
promoter and therefore the downregulation of Id1 mRNA 
observed is due to direct repression of the transcriptional 
activity of the Id1 promoter (Figure 4.4).  The repression of 
promoter activity lags behind the changes seen in both Id1 
protein and mRNA, with maximal promoter repression being 
seen by 16h of drug treatment.  This could be due to 
comparative longer half life of luciferase in the reporter system 
or additional mechanisms not yet determined.    
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Figure 4.3 Epirubicin downregulates Id1 transcriptionally 
and translationally. A) Whole cell lysates were prepared from 
MCF-7 cells treated with 1μM epirubicin at the indicated 
timepoints and the expression of Id1 was analysed by Western 
blotting.  Tubulin was used as a loading control. B)  Total RNA 
was isolated in parallel and the expression of Id1 mRNA was 
measured by RTq-PCR and normalised to the level of L19.  The 
results represent the average ±SD of three independent 
experiments.  *p<0.05.    
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Figure 4.4. Epirubicin represses Id1 at the gene promoter 
level. MCF-7 cells were transfected with 10ng of the Id1 
promoter and treated with 1µM epirubicin for the indicated time 
points before cells were collected for luciferase reporter assays.  
The relative luciferase activity values were corrected for 
cotransfected renilla activity.  Results are the average +/- SD of 
three independent experiments.       
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4.2.5 Id1 expression is higher in aggressive and 
resistant cell lines 
 
 
The expression of Id1 varies in breast cancer cell lines, as does 
the sensitivity of cell lines to the cytotoxic effects of epirubicin.  
In the previous chapter, SRB assays confirmed the sensitivity of 
MCF-7 cells to epirubicin, whilst the ER negative cell line MDA-
MB-231 was epirubicin resistant and cells continued to 
proliferate in the presence of the drug.  It was therefore of 
interest to look at the expression of Id1 in sensitive and 
resistant cells lines and to assess whether there is any 
correlation between Id1 expression and chemosensitivity. MCF-
10a cells, non-tumorigenic immortalized breast epithelial cells, 
were used for comparison. 
 
Western blot analysis confirmed higher expression of Id1 in the 
rapidly proliferating and epirubicin resistant MDA-MB-231, when 
compared to both MCF-7 cells and the untransformed MCF-10a 
cells (Figure 4.5a).  Id1 mRNA expression correlated well with 
protein levels, again with MDA-MB-231 cells having the highest 
relative expression of Id1 mRNA (Figure 4.5b).  
 
Another good model for a drug resistant cell line is the 
doxorubicin resistant MCF-7 cell line (Dox-R), generated in the 
laboratory by long term culture of MCF-7 cells in the presence of 
0.01mg/ml of the anthracycline doxorubicin.   These cells grow 
normally and proliferate in doxorubicin and are therefore a good 
model for a more aggressive, drug resistant cell line.   The 
expression of Id1 is higher in the Dox-R cells lines than in the 
wild-type MCF-7 cells, implicating Id1 as a possible contributor 
to a more drug resistant phenotype (Figure 4.6a.)  
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To investigate the effects of epirubicin on these Dox-R MCF-7 
cells, and to characterize whether Id1 may contribute any part 
to their resistant profile, a dose titration of epirubicin treatment 
was performed in the cells, with treatment ranging from 0.1μM 
to 10μM epirubicin.  Across all doses, the effects of epirubicin 
were significantly less than compared to WT MCF-7 cells (Figure 
3.3a). Even at high doses of 5 and 10μM, Dox-R MCF-7 cells 
were still proliferating, suggesting this is undoubtedly a highly 
anthracycline resistant cell line (Figure 4.6b).  Western blot 
analysis confirmed that, unlike the epirubicin sensitive wildtype 
MCF-7 cells, over 48h of drug treatment, no changes in Id1 
protein or mRNA levels were observed, confirming that early 
downregulation of Id1 is specific only to sensitive cells (Figure 
4.6c and 4.6d).           
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Figure 4.5 Id1 expression is highest in aggressive cell 
lines.   A) Whole cell lysates were prepared from MCF-10a, 
MCF-7 and MDA-MB-231 cells and the expression of Id1 was 
analysed by Western blotting. B)  Total RNA was isolated in 
parallel and the expression of Id1 mRNA was measured by RTq-
PCR and normalised to the level of L19.  The results represent 
the average ±SD of three independent experiments.     
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Figure 4.6 Id1 expression following epirubicin treatment 
in Dox-R MCF-7 cells. A) Total cell lysates from MCF-7 cells 
and Dox-R MCF-7 cells were analysed by Western blotting for 
Id1 expression. B) Dox-R MCF-7 cells were treated with a dose 
titration of epirubicin and cell survival analysed by SRB assay. 
C) Dox-R MCF-7 cells were treated with 1μM epirubicin for the 
indicated times and protein lysates were analysed for Id1 
expression by Western blotting. D) RNA was extracted in 
parallel and Id1 mRNA was measured by RTq-PCR and 
normalised to the level of L19.  The results represent the 
average ±SD of three independent experiments.  
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4.2.6 Silencing of Id1 slows proliferation of breast 
cancer cells  
 
MCF-7 cells proliferate in vitro with a doubling time of 
approximately 48h (Figure 4.7d).  Id1 is a proliferation 
dependent protein and expression is highest in proliferating cells 
and lowest in growth arrested cells (Figure 4.2).   To investigate 
more specifically at the effects of Id1 on the cell cycle in MCF-7 
cells, cells were transfected with an Id1 specific siRNA, mock 
transfected and non specific control (NSC) siRNA.  Western blot 
analysis confirmed efficient knockdown of endogenous Id1 
protein and RTq-PCR showed similar efficient knockdown of Id1 
mRNA (Figure 4.7a and 4.7b).  
 
To study the effects of Id1 silencing on the cell cycle, an Id1 
specific siRNA pool was transfected into MCF-7 cells the cell 
cycle profile was then analysed by FACS analysis 48h post- 
transfection.  The cell cycle profile confirmed that silencing of 
Id1 leads to a greater accumulation of cells in the G1 phase of 
the cell cycle – 75% compared to 63% for the mock and NSC 
(Figure 4.7c).  This is consistent with a role for Id1 in cell cycle 
progression - in fibroblasts Id proteins have a critical role in 
promoting G1-S cell cycle transition.  These results suggest that 
in breast cancer cells, a similar cell cycle role is likely, with more 
cells accumulating in G1 and thus less progression through to S 
phase for DNA synthesis and subsequent mitosis during G2/M.  
 
This change in cell cycle profile is confirmed by SRB assay 
(Figure 4.7d).  The mock and control siRNA transfected cells 
continue to proliferate, but the cells transfected with an Id1 
specific siRNA show much slower proliferation, confirming Id1 is 
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required for normal MCF-7 proliferation and cell cycle 
progression.   
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Figure 4.7 Silencing of Id1 slows proliferation of MCF-7 
cells. A)  MCF-7 cells were transfected with an Id1 specific 
siRNA, mock and NSC. Western blot analysis confirmed 
knockdown of endogenous Id1. B) RNA from cells transfected in 
parallel was used to monitor siRNA Id1efficiency at mRNA level. 
C)  Cells were transfected with an Id1 specific siRNA, mock and 
NSC for 48h, fixed in ethanol and stained with propidium iodide 
then analysed by FACS. The % of cells in each phase of the cell 
cycle is indicated. D) Following siRNA Id1 transfection, cells 
were replated in 96 well plates for 48h and cell survival 
measured by SRB assay. Results are the average +/-SD of three 
independent experiments with 6 replicates. *p<0.05. 
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4.2.7 Id1 silencing can reduce the growth of resistant 
and aggressive cell lines and increase sensitivity 
to epirubicin 
 
MDA-MB-231 cells therefore express high levels of Id1 and are 
resistant to epirubicin.  To see if Id1 contributed to this resistant 
phenotype, knockdown of Id1 was performed using siRNA 
(Figure 4.8a) and then MDA-MB-231 cells were treated with 
epirubicin for 48h.  SRB assay confirmed that knockdown of Id1 
can significantly slow the proliferation of MDA-MB-231 cells and 
increases the cytotoxic effects of epirubicin (Figure 4.8b).  
However, in these particular cells, silencing of Id1 is unable to 
reverse a resistant phenotype. 
 
The other cell line shown to express high levels of Id1 and to be 
resistant to epirubicin is the Dox-R MCF-7 cell line.  An Id1 
specific siRNA was transfected into these cells and they were 
then treated with 1μM epirubicin for 48h. Their cell cycle profile 
was then analysed by FACS.  Western blot analysis confirmed 
good knockdown of endogenous Id1 protein (figure 4.9a).  
When the cell cycle profile of the siId1 transfected cells was 
compared to the mock or control transfected cells, the number 
of sub G1 cells had doubled (Figure 4.9b).  Although the order of 
change was relatively small, from approximately 5% sub G1 to 
10%, this did suggest that Id1 may contribute to drug 
resistance in these cells.   
 
 
 
 
 
 
 178 
 
 
A                                     B 
 
 
 
 
 
 
 
 
Figure 4.8 Silencing of Id1 slows the proliferation of 
MDA-MB-231 cells treated with epirubicin. A) MDA-MB-231 
cells were transfected with an Id1 specific siRNA pool, and NSC. 
RNA from cells transfected in parallel was used to monitor siRNA 
Id1efficiency at mRNA level. B) Following siRNA Id1 
transfection, cells were replated in 96 well plates for 48h, 
treated with 1μM epirubicin and cell survival measured by SRB 
assay. Results are the average +/-SD of three independent 
experiments with 6 replicates. *p<0.05. 
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Figure 4.9 Silencing of Id1 in Dox-R MCF-7 cells 
introduces some sensitivity to epirubicin.A) Dox-R MCF-7 
cells were transfected with an Id1 specific siRNA pool, mock and 
NSC. Western blot anaylsis confirmed knockdown of 
endogenous Id1. B)  Cells were transfected with an Id1 specific 
siRNA, mock and NSC and treated with 1μM epirubicin for 48h, 
fixed in ethanol and stained with propidium iodide then analysed 
by FACS. The % of cells in each phase of the cell cycle is 
indicated.  
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4.2.8 Id1 knockdown increases epirubicin cytotoxicity 
in MCF7 cells   
 
 
Earlier results have shown that Id1 is an early target of 
epirubicin in breast cancer cells.  Treatment with epirubicin 
leads to downregulation of Id1 protein and mRNA and Id1 
promoter activity is repressed following addition of the drug.  
Silencing of Id1 by siRNA slows the proliferation of MCF7 cells 
and leads to a greater accumulation of cells in G1.  It was 
therefore of interest to look at whether Id1 silencing has an 
effect on the sensitivity of MCF7 cells to epirubicin and whether 
targeting Id1 can increase the cytotoxic effect of epirubicin. 
 
MCF7 cells were transfected with an Id1 specific siRNA or 
control siRNA then grown for 48h either with or without the 
addition of epirubicin.  In the control, untreated cells, 
proliferation was as expected, with a growth doubling time of 
approximately 48h.  In the untreated cells, transfected with an 
Id1 siRNA, proliferation was slower, as previously shown.  
However, when cells were treated with epirubicin, silencing of 
Id1 increased the cytotoxic effects of epirubicin and Id1 
knockout cells were more sensitive to epirubicin than their 
control transfected counterparts (Figure 4.10b). 
 
Thus, not only does silencing of Id1 simply slow proliferation of 
MCF-7 cells, but it also increases their sensitivity to 
chemotherapy and targeting Id1 prior to treatment with 
epirubicin increases the cytotoxic effect of the drug.  This effect 
was not unique to epirubicin. Two other cytotoxic drugs – 
cisplatin and docetaxel – were also investigated in similar 
experiments.   The same results were observed, in that Id1 
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knockout cells were more sensitive to both cisplatin and 
docetaxel than the control transfected cells.  Interestingly, the 
doses used of both drugs on their own (10μM cisplatin and 
10nM docetaxel) were not particularly toxic to MCF-7 cells and 
although cell proliferation slowed, a decrease in cell survival was 
not observed until after 24h or drug treatment (Figure 4.11a 
and 4.11b). However, in the siRNA Id1 transfected cells, after 
24h, a decrease in cell survival was observed, suggesting 
knockout of Id1 can contribute to making MCF-7 cells more 
sensitive to sub-lethal doses of chemotherapeutic drugs.      
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Figure 4.10 Silencing of Id1 increases the cytotoxicity of 
epirubicin.  A) MCF-7 cells were transfected with an Id1 
specific siRNA or NSC.  Western blot analysis confirmed efficient 
knockdown of endogenous Id1. B) Cells were untreated or 
epirubicin was added for 48h.  Cell survival was measured by 
SRB assay. Results are the average +/-SD of three independent 
experiments with 6 replicates. * p<0.05 
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                                    10nM docetaxel 
 
Figure 4.11 Silencing of Id1 increases the sensitivity of 
MCF-7 cells to cisplatin and docetaxel. MCF-7 cells were 
transfected with an Id1 specific siRNA or NSC.  Cells were 
untreated or A) 1μM cisplatin or B) 10nM docetaxel was added 
for 48h.  Cell survival was measured by SRB assay. Results are 
the average +/-SD of three independent experiments with 6 
replicates.  * p<0.05 
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4.2.9 Cyclin D1 is downregulated following Id1 
silencing  
 
These results have shown that Id1 is expressed in a variety of 
breast cancer cell lines and expression is highest in proliferating 
cells.  Id1 is rapidly downregulated by epirubicin at the protein, 
mRNA and gene promoter level.  Silencing of Id1 slows 
proliferation of cells and leads to a greater accumulation of cells 
in the G1 phase of the cell cycle.  This effect on the cell cycle 
appears to increase the sensitivity of MCF-7 cells to 
chemotherapy, with a greater cytotoxic effect observed 
following knockdown of Id1.   
 
Another key regulator of the G1 phase of the cell cycle is cyclin 
D1. Cyclin D1 expression is seen early following cell cycle entry 
and its assembly with Cdk4 is key to allowing cells to progress 
through the restriction point following mitogenic stimulation 
(Alberts et al., 2008). To see whether any changes were 
observed in cyclin D1 as a result of Id1 silencing, MCF-7 cells 
were transfected with an Id1 specific siRNA and mock and non-
specific control.  Interestingly, Id1 protein knockdown was 
accompanied by reduced expression of cyclin D1 at both the 
protein and mRNA level (Figure 4.12a and 4.12b). No changes 
were seen in the protein levels of p21 or p27, two other key G1 
regulators. This suggests that Id1 may have an effect on the 
regulation of cyclin D1 expression and the loss of Id1 may in 
turn reduce the expression of cyclin D1 which would contribute 
to the inhibition of proliferation observed in these cells.      
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Figure 4.12 Cyclin D1 is downregulated following 
silencing of Id1.  A) MCF-7 cells were transfected with an Id1 
specific siRNA, mock and NSC siRNA for 48h.  Whole cell lysates 
were prepared and  protein expression was analysed by Western 
blotting using the indicated antibodies.  B)  Total RNA was 
isolated in parallel and the expression of cyclin D1 mRNA was 
measured by RTq-PCR and normalised to the level of L19.  The 
results represent the average ±SD of three independent 
experiments.   
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4.2.10 Overexpression of Id1 confers protection to 
epirubicin 
 
In many epithelial cancers, correlation has been seen between 
levels of Id1 and malignant potential.  Higher levels of Id1 
expression have been seen in invasive cancers, compared to 
ductal carcinoma in situ and introduction of a constitutively 
expressed Id1 cDNA into the non aggressive T47D cell line 
confers a more aggressive phenotype (Lin et al., 2000). 
 
An Id1 expression vector was transiently transfected into MCF-7 
cells and the effects of epirubicin on cell survival was measured 
by SRB assay.  Western blot analysis confirmed overexpression 
of Id1 (Figure 4.13a).  Interestingly, cyclin D1 levels were 
unchanged in the Id1 overexpressed cells, even though the 
earlier reciprocal experiment, where Id1 was silenced, had 
shown reduced expression of cyclin D1 following Id1 
knockdown. This could be because cyclin d1 is already at 
maximal levels as these are normal cycling cells. No changes 
were observed in p21Cip1, p27Kip1 or phosphorylated Akt. 
However, the SRB assay showed that overexpression of Id1 
confers some protection against the effects of epirubicin and 
overexpression of Id1 provided MCF-7 cells with some 
resistance to epirubicin (Figure 4.13b).    
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Figure 4.13 Overexpression of Id1 confers resistance to 
epirubicin. A)  MCF-7 cells were transfected with a vector 
expressing Id1 (pLZRS-Id1) or an empty vector and analysed 
for the expression of Id1 by western blotting. B) MCF-7 cells 
transfected in parallel were plated in 96 well plates, treated for 
48h with epirubicin and cell survival analysed by SRB assay.  
Results are the average +/-SD of three independent 
experiments with 6 replicates. *p<0.05. 
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4.2.11 FOXO3a does not regulate Id1 in breast cancer 
cells 
 
Id1 has previously been shown to be highly expressed in the 
Bcr-Abl transformed K562 cell line.  Inhibition of Bcr-Abl activity 
by imatinib resulted in activation of FOXO3a and downregulation 
of Id1 expression.  FOXO3a was shown to be a transcriptional 
repressor of Id1, by directly binding to the Id1 promoter 
(Birkenkamp et al., 2007).  Myeloid leukaemic cells are 
characterized by both uncontrolled proliferation but also failure 
to differentiate and as an inhibitor of differentiation, it is clear to 
see that Id1 may play a role in the leukaemic process. 
 
Little is known about the regulation of Id1 in solid, epithelial 
tumours.  This work has shown that FOXO3a is activated by 
epirubicin and Id1 is repressed by epirubicin – it was therefore 
of interest to investigate whether FOXO3a activation is 
responsible for Id1 repression in response to chemotherapy, as 
has previously been shown to be the case in leukeamic cell 
lines. 
 
MCF-7 cells were transfected with a FOXO3a specific siRNA or 
control siRNA and relative mRNA levels were measured by RTq-
PCR. If FOXO3a is functioning as a repressor of Id1 and if Id1 is 
a downstream target of FOXO3a, silencing of FOXO3a may be 
expected to increase Id1 expression as this repression is 
relieved.  However, FOXO3a knockdown did not have any effect 
on Id1 levels (Figure 4.14a).  The reciprocal experiment, where 
Id1 was silenced, also had no effect on FOXO3a expression 
(Figure 4.14b). 
 
To further investigate whether Id1 may be a downstream target 
of FOXO3a, gene promoter studies were performed. In 
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leukaemic cells, treatment with imatinib has been shown to 
repress Id1 promoter activity.  However, when a key FOXO3a 
binding site in the Id1 promoter (-134 to -128bp upstream of 
the ATG start codon) is mutated from a TTT core sequence to 
CGT, no repression was observed.  This lead to the conclusion 
that binding of FOXO3a to this critical site is required for 
downregulation of Id1 promoter activity in K562 cells 
(Birkenkamp et al., 2007). 
 
To test if a similar effect was observed in MCF-7 cells, the cells 
were transfected with either the wild type or the mutated 
promoter and then treated with epirubicin.  As expected, 
epirubicin repressed the activity of the wild type promoter 
(Figure 4.15a).  However, a similar pattern of repression was 
also seen in the mutated promoter (Figure 4.15b).  This would 
suggest that epirubicin is repressing Id1 promoter activity 
independent of FOXO3a and that mutating a putative FOXO3a 
binding site has little effect on Id1 promoter repression.  Thus, 
the regulation of Id1 promoter activity differs between 
haematopoeitic and epithelial cancer cells.   
 
To confirm that Id1 repression by epirubicin is not dependent on 
FOXO3a, a further knockdown experiment was performed.  
MCF-7 cells were transfected with a FOXO3a specific siRNA or 
non-specific control and then treated over 48h with epirubicin.  
Western blot analysis confirmed good knockdown of endogenous 
FOXO3a protein. However, in both the knockdown and control 
cells, Id1 protein levels were downregulated by epirubicin and 
were undetectable from 8h post treatment (Figure 4.16).  This 
again suggests that Id1 is a target of epirubicin but is not 
downstream of FOXO3a.  
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Figure 4.14 FOXO3a silencing does not affect Id1 mRNA 
levels.MCF-7 cells were transfected with A) a FOXO3a specific 
siRNA, mock and NSC siRNA and B) an Id1 specific siRNA, mock 
and NSC siRNA for 48h. Total RNA was isolated and the 
expression of FOXO3a and Id1 mRNA was measured by RTq-
PCR and normalised to the level of L19. The results represent 
the average ±SD of three independent experiments.   
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A                          Id1 WT PROMOTER 
 
 
 
 
 
 
 
B                         Id1 MUT PROMOTER 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 Epirubicin represses both the wildtype and 
mutated Id1 promoter. MCF-7 cells were transfected with A) 
10ng of the Id1 promoter or B) an Id1 promoter with mutated 
FOXO3a binding sites and treated with 1µM epirubicin for the 
indicated time points before cells were collected for luciferase 
reporter assays. The relative luciferase activity values were 
corrected for cotransfected renilla activity. Results are the 
average +/- SD of three independent experiments.   
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Figure 4.16 Id1 repression by epirubicin is independent 
of FOXO3a.  MCF-7 cells were transfected with a FOXO3a 
specific siRNA or NSC then treated for 48h with 1μM epirubicin.                      
Whole cell lysates were prepared and FOXO3a and Id1 protein 
expression was analysed by Western blotting. Tubulin was used 
as a loading control.  
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4.3 DISCUSSION 
 
Over the last decade, there has been increasing evidence for an 
oncogenic role for Id1 in human cancers.  Correlation has been 
seen between expression of Id1, malignant potential and clinical 
outcome.  However, the molecular mechanisms responsible for 
the function of Id1, particularly in breast cancer, are not known. 
Therefore further characterization of the function of Id1 and the 
effects of chemotherapy on its expression would provide 
interesting data in determining whether Id1 may be a useful 
therapeutic target in cancer.  
 
Id1 protein is expressed is all breast cancer cell lines 
investigated in this work, and expression correlates with a more 
aggressive and drug resistant phenotype - both MDA-MB-231 
cells and a  doxorubicin resistant MCF-7 derivative have 
relatively higher expression levels of Id1 (Figure 4.5).  This 
confirms results seen in other epithelial cancers – in 
oesophageal squamous cell carcinoma for example, Id1 
expression is higher in cancerous cell lines than the 
immortalized, non-transformed NE1 cell line (Yuen et al., 2007). 
It is also evident that Id1 expression is highest in proliferating 
cells and that serum starvation leads to downregulation of Id1 
in MCF-7 cells, confirming Id1 is induced by mitogens (Figure 
4.2). MCF-7 cells are ER positive and are therefore sensitive to 
the effects of oestradiol. Withdrawal of serum and the 
downregulation of Id1 may be a direct result of steroid hormone 
deprivation.  Studies have shown previously that in the non-
aggressive T47D breast cancer cell line, treatment with 
oestradiol downregulates Id1. However, MDA-MB-231 cells 
constitutively express high levels of Id1 regardless of the 
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presence of serum (Lin et al., 2000) and thus one mechanism 
for linking high expression of Id1 and an aggressive phenotype 
is the loss of serum dependent regulation of Id1 gene 
expression.  This could also provide one hypothesis for the high 
expression of Id1 found in ovarian, endometrial and prostate 
tumours - cancers which initially arise in hormone dependent 
tissues. 
 
Id1 protein is downregulated by epirubicin and RTq-PCR analysis 
showed Id1 transcript levels also decreasing with time, as an 
early event following epirubicin treatment – correlating well with 
changes in Id1 protein levels (Figure 4.3). Thus, Id1 appears to 
be an early target of epirubicin treatment and suggests that 
epirubicin is directly suppressing gene transcription as Id1 
promoter activity is also suppressed. This is an interesting 
observation indicating that epirubicin inhibits Id1 expression at 
the promoter level and not through mechanisms modulating 
protein and mRNA stability.  For example, in prostate cancer, 
treatment of DU145 and PC-3 cells with TNFα downregulates 
Id1 protein levels also, but this is not accompanied by changes 
in Id1 mRNA or promoter activity and TNFα was shown to 
downregulate Id1 through the activation of the 
ubiquitin/proteasome degradation pathway (Ling et al., 2006)   
Therefore, although Id1 may be a target of a number of drugs 
and cytokines, the mechanisms by which it is repressed can 
differ and Id1 appears to be a transcriptional target of epirubicin 
in MCF-7 cells.   
 
To further characterize the role of Id1, a number of experiments 
were performed to look at the effects of silencing Id1 by siRNA.  
In particular, the effects of Id1 knockdown on the cell cycle 
profile and proliferative ability of MCF-7 cells was investigated.  
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FACS analysis of cells transfected with an Id1 specific siRNA 
showed that loss of Id1 causes a greater accumulation of cells in 
G1 (Figure 4.7).  G1 is the key cell cycle phase required for 
growth and protein synthesis and is the point at which cells 
respond to extracellular stimuli and commit to DNA replication.  
The cell cycle profile was confirmed by SRB assay which showed 
a slowing in the proliferation rate of MCF-7 cells following Id1 
knockdown, suggesting that Id1 must have an important role in 
cell cycle progression through G1 and without it, fewer cells are 
able to commit to progression through G1 and on into S phase 
and G2/M.  There is relatively little information known about 
how Id1 may regulate the cell cycle so to investigate further the 
mechanisms underlying Id1 mediated cell proliferation, other 
cell cycle proteins were analysed following Id1 silencing.  p21Cip1 
and p27Kip1 are both key cell cycle regulators and both can lead 
to G1 cell cycle arrest. In fibroblasts, the regulation of p21Cip1 by 
the HLH transcription factor E2A has been shown to be 
antagonized by Id1.   (Prabhu et al., 1997).   However, although 
silencing of Id1 leads to cells accumulating in G1, proteins levels 
of p21Cip1 and p27Kip1 are unchanged.  However, downregulation 
of cyclin D1 is observed following knockdown of Id1, at both the 
protein and mRNA level (Figure 4.12).  Cyclin D1 expression is 
usually an early event in cell cycle entry and this allows 
progression of cells through the restriction point and the 
phosphorylation and inactivation of Rb. Id1 may require cyclin 
D1 for its proliferative effects – knockdown of Id1 also results in 
reduced cyclin D1 protein and mRNA, implicating regulation of 
cyclin D1 in Id1 mediated inhibition of proliferation.    The 
promoter of the cyclin D1 gene is known to contain a number of 
consensus motifs for several transcription factors that can 
interact with Id proteins (Yates et al., 1999). However, 
conversely, cyclin D1 levels did not increase following 
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overexpression of Id1 suggesting that Id1, rather than 
increasing expression of cyclin D1, may simply potentiate its 
effect.    
 
Having established the antiproliferative effect of silencing Id1, it 
was also of interest to see whether this had any implications on 
the sensitivity of MCF-7 cells to chemotherapy, in particular to 
epirubicin.  Results in chapter 3 confirmed that MCF-7 cells were 
sensitive to 1µM epirubicin, causing G2/M cell cycle arrest and 
apoptosis.  Earlier work in this chapter identified Id1 as a direct 
target of epirubicin and the role that Id1 plays in 
chemosenstivity was characterized further.  SRB assays 
confirmed that silencing of Id1 not only slows proliferation of 
MCF-7 cells but also increases the sensitivity of MCF-7 cells to 
chemotherapy (Figure 4.10).  Control transfected cells begin to 
die following treatment with epirubicin but this effect is 
enhanced in cells where Id1 has been silenced.  This effect was 
not unique to epirubicin but was also seen in cells treated with 
cisplatin and docetaxel, drugs which have a different mechanism 
of action to the anthracyclines.  Inactivation of Id1 seems to 
increase a cells susceptibility to chemotherapy.  Studies have 
shown similar findings in prostate cancer cells, where 
inactivation of Id1 leads to decreased cell viability following 
treatment with paclitaxel (Zhang et al., 2006).How loss of Id1 
increases sensitivity to chemotherapy is unclear.  
Chemotherapeutic agents are likely to target a number of cell 
signaling pathways, including the PI3K pathway and MAPK. 
Similarly, Id protein function is likely to be regulated thorough 
multiple molecular pathways as they have a diverse range of 
cellular roles. Id proteins function as dominant negative 
regulators, binding to other proteins and transcription factors, 
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rendering them transcriptionally inactive.  Perhaps loss of Id1 
allows these binding partners to become activated and respond 
to the cellular stress induced by chemotherapy, triggering 
activation of the apoptotic pathway and increasing cell death.  
Interestingly, the reciprocal experiment of overexpressing Id1 
confers some protection against the cytotoxic effects of 
epirubicin.  When cells are transfected with an Id1 containing 
retroviral vector, less cell death was observed following 
epirubicin treatment (Figure 4.13).  Resistant and aggressive 
cell lines express high levels of Id1 and the transient 
overexpression of Id1 may similarly introduce some drug 
resistance.   
 
The protective role of Id1 in drug or cytokine induced apoptosis 
has previously been reported in LNCaP prostate cells – stable 
expression of Id1 renders resistance to TNF-α induced apoptosis 
and this is through activation of the NFκB signaling pathway 
(Ling et al., 2004).  Similarly, in oesophageal cancer cells, 
overexpression of Id1 protects cells from TNF-α induced 
apoptosis and is accompanied by an increased expression of 
phosphorylated Akt, suggesting Id1 may be activating the PI3K 
(Carpten et al., 2007). However, there was no evidence of this 
in the transfected MCF-7 cells and overexpression of Id1 did not 
upregulate levels of phosphorylated Akt.    
 
One of the principle reasons for studying Id1 in this thesis was 
because it has been identified as a downstream target of 
FOXO3a in Bcr-Abl transformed K562 cells.  The expression of 
Id1 is abrogated by FOXO3a activation and FOXO3a was 
identified as a transcriptional repressor of Id1 and binds to the 
Id1 promoter in leukaemic cell lines.  This does not appear to be 
the case in breast cancer cell lines, and FOXO3a does not 
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regulate Id1 in MCF-7 cells.  This was confirmed by a number of 
different experiments.  Silencing of FOXO3a did not affect Id1 
protein or mRNA levels (Figure 4.14) and epirubicin repressed 
the activity of both the wild-type Id1 promoter and a promoter 
where a key FOXO3a binding site is mutated.  If FOXO3a was 
truly a transcriptional repressor of Id1, mutating its binding site 
should relieve the repression on Id1 promoter activity, but this 
was not observed (Figure 4.15).  Also, the downregulation of 
Id1 protein following epirubicin treatment is independent of 
FOXO3a activity, as Id1 levels in control and FOXO3a knockout 
cells follow a similar trend i.e epirubicin targets Id1 with or 
without endogenous FOXO3a activity (Figure 4.16).  
 
It would therefore appear that Id1 as a target of FOXO3a may 
be dependent on cell type and malignancy.  Solid, epithelial 
tumours are very different in characteristics and behaviour to 
the haematological malignancies. One of the characteristics of 
diseases such as CML is the eventual progression into blast 
phase, where haematopoeitic differentiation arrests and 
immature blasts accumulate in the bone marrow.  Thus, as 
Inhibitors of differentiation, Id1 proteins are likely to have a key 
role in the pathogenesis of the disease.  Solid tumours behave 
differently, and can often be well differentiated and Id1 may 
have more of a role in proliferation.  A differing role for Id1, 
depending on tumour type, may account for different 
mechanisms of regulation.  Much of the published literature 
regarding Id1 is based on cells of non-epithelial origin. For 
example, in cardiac myocytes, ectopic expression of Id1 induces 
apoptosis and Id3 induces apoptosis in fibroblasts – directly 
contrasting with the function of Id1 seen in epithelial cells (Ling 
et al., 2003).  FOXO activation also can be cell type specific, 
with programmed cell death induced in haematopoietic cells but 
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a block in proliferation seen in other cells.  MnSOD in not 
induced by FOXO activation in haematopoietic cells, but can 
elicit a cell survival signal in other cells (Birkenkamp and Coffer, 
2003).  Thus, FOXO3a regulation of Id1 may be cell type 
specific, occurring in leukaemic cells but not in breast cancer 
cells.  
 
4.4 FUTURE WORK 
 
To further characterize the role and regulation of Id1 it would be 
useful to try and identify exactly how Id1 interacts with the 
apoptotic pathway in response to chemotherapy.  The binding 
partners of Id1 in breast cancer cells remain largely unknown 
and pulldown experiments may be useful to identify other 
cellular proteins that Id1 binds to.   
 
Generation of stable Id1 knockout or Id1 expressing cell lines 
may provide useful models for analyzing the role of Id1 in cell 
cycle progression and the response to chemotherapy. Much of 
the work in this chapter involved transient transfections and 
stable cell lines may allow greater insight into the phenotypic 
changes associated with loss or overexpression of Id1. 
 
The relationship between cyclin D1 and Id1 should be explored 
further and luciferase assays may confirm whether silencing of 
Id1 can represses cyclin D1 promoter activity.  Similarly, 
mapping of responsive sites on the Id1 promoter may give more 
insight into the epirubicin mediated promoter repression 
observed. 
 
Also, silencing of FOXO1, FOXO3a and FOXO4 together would be 
of interest – there may be compensatory mechanisms involved 
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so that silencing of FOXO3a alone is insufficient to repress Id1, 
but when all FOXO proteins are silenced, there may yet be a 
role for FOXO negatively regulating Id1.   
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CHAPTER 5                                            
THE EXPRESSION OF FOXO3a AND 
TARGETS IN CLINICAL SAMPLES 
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5.1 INTRODUCTION 
 
Although MCF-7 cells are widely used as a good laboratory 
model of ER positive breast cancer, changes seen within cells in 
culture may not necessarily be a true surrogate for the 
physiological behaviour of breast cancer in patients.  Therefore, 
translating in vitro findings is an integral component of 
validating and confirming results obtained in cell line work.   
 
In the clinical management of breast cancer, patients who have 
large tumours or locally advanced disease at presentation are 
often treated up front with neo-adjuvant chemotherapy, in an 
attempt to downstage their disease and avoid the need for 
mastectomy.  All patients have a diagnostic pre- treatment core 
biopsy and then have their definitive surgery after completion of 
chemotherapy. Thus, a direct comparison can be made between 
pre-treatment and post-treatment tissue. To this end, it was 
possible to obtain clinical samples from breast cancer patients 
treated in Charing Cross Hospital, London.  The first cohort of 
patient samples was from patients who had received neo-
adjuvant FEC chemotherapy and had a good clinical response to 
treatment.  Single agent chemotherapy is not indicated in this 
setting, so unfortunately patients did not receive epirubicin 
alone, but had also received 5-FU and cyclophosphamide.  
Nevertheless, in this chapter, the expression of FOXO3a, FOXM1 
and Id1 pre and post chemotherapy was investigated.  Tissue 
was also available from a second cohort of patients who had 
received neo-adjuvant gefitinib, an epidermal growth factor 
receptor (EGFR) inhibitor.  Work in the laboratory had already 
established FOXO3a as a target of gefitinib in breast cancer 
cells. FOXO3a dephosphorylation and nuclear localization was 
shown to have a direct role in mediating gefitinib induced 
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proliferative arrest (Krol et al., 2007). In this chapter, the effect 
of gefitinib on FOXO3a was further investigated and, in 
particular, the role and regulation of FOXM1 in the response to 
gefitinib treatment was explored.   
 
(N.B Figure 5.7 was the result of a collaboration of work with Dr 
Janna Krol and Dr Andreas Polychronis).       
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5.2 RESULTS 
 
5.2.1 The expression of FOXO3a, FOXM1 and Id1 in 
normal breast tissue and invasive carcinoma. 
 
In chapters 3 and 4, the role of FOXO3a and Id1, and the 
FOXO3a target FOXM1, was investigated in response to 
epirubicin in MCF-7 cells.  To translate these in vitro findings, 
normal and malignant breast tissue was immunohistochemically 
stained to compare the expression of each between normal 
tissue and invasive ductal carcinoma (Figure 5.1).  FOXO3a was 
expressed in both types of breast tissue, but FOXM1 and Id1 
expression was higher in invasive carcinoma when compared to 
normal breast tissue.  This was consistent with the findings from 
the breast cancer cell lines, where FOXM1 and Id1 expression 
was much higher in the cancer cell lines when compared to the 
untransformed MCF-10A cell line, and confirmed expression of 
FOXM1 and Id1 as markers or malignancy.   
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Figure 5.1 The expression of FOXO3a, FOXM1 and Id1 in 
normal and malignant breast tissue.  Normal breast tissue 
and tumour samples were obtained which had been formalin 
fixed and paraffin embedded. Tissue was 
immunohistochemically stained with FOXO3a, FOXM1 and Id1 
antibodies using the streptavidin-biotin-peroxidase technique.  
Examples shown are representative of staining patterns 
observed (Magnification x200). 
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5.2.2 The expression of FOXO3a, FOXM1 and Id1 in 
different histological subtypes of breast cancer.  
 
Invasive ductal carcinoma is the most common histological 
subtype of breast cancer, followed by invasive lobular carcinoma 
(Cancer Research UK, 2006).  Cancers can be further divided 
into subclasses depending on the expression of ER and HER2. 
Cancers belonging to different subgroups behave differently 
clinically. The expression of ER in breast cancer is an 
independent prognostic factor (Burcombe et al., 2004).  Studies 
have shown that the likelihood of achieving a pathological 
complete response (pCR) with neo-adjuvant chemotherapy is 
significantly higher in ER negative tumours (Tewari et al., 
2008).  There is emerging evidence that HER2 expression can 
also be used as a predictor of response to chemotherapy and 
that HER2 positive tumours will benefit particularly from an 
anthracycline containing regimen (Pritchard et al., 2008).  The 
expression of HER2 is an adverse prognostic factor, with HER2 
positive breast cancers behaving more aggressively, with a 
higher rate of recurrence and shorter disease-free interval than 
HER2 negative tumours (Gonzalez-Angulo et al., 2006).   
 
Therefore, it was of interest to look at the expression of 
FOXO3a, FOXM1 and Id1 in clinical samples and compare the 
expression of each between the different histological sub-types.  
Staining was positive in all subtypes and there was no 
discernable difference in expression between ductal and loubular 
cancers (Figure 5.2), ER positive and ER negative cancers 
(Figure 5.3) and HER2 positive and HER2 negative cancers 
(Figure 5.4).  Thus, FOXM1 and Id1 are only weakly expressed 
in normal breast tissue, but are highly expressed in invasive 
cancers, irrespective of histological subtype.  FOXO3a is 
expressed in both normal and malignant breast tissue.  
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Figure 5.2 The expression of FOXO3a, FOXM1 and Id1 in 
invasive ductal and lobular carcinomas. Samples from 
patients with ductal and lobular carcinomas were obtained which 
had been formalin fixed and paraffin embedded. Tissue was 
immunohistochemically stained with FOXO3a, FOXM1 and Id1 
antibodies using the streptavidin-biotin-peroxidase technique.  
Examples shown are representative of staining patterns 
observed (Magnification x200). 
 
 
 
 
 
 
 
 
 
 
 
Invasive ductal
carcinoma 
Invasive lobular 
carcinoma
FOXO3a
FOXM1
Id1
 208 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3 the expression of FOXO3a, FOXM1 and Id1 in 
ER positive and ER negative invasive ductal carcinoma. 
Samples from patients with ER positive and ER negative ductal 
carcinomas were obtained which had been formalin fixed and 
paraffin embedded. Tissue was immunohistochemically stained 
with FOXO3a, FOXM1 and Id1 antibodies using the streptavidin-
biotin-peroxidase technique. Examples shown are representative 
of staining patterns observed (Magnification x200). 
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Figure 5.4 The expression of FOXO3a, FOXM1 and Id1 in 
HER2 positive and HER2 negative breast cancers. Samples 
from patients with HER2 positive and HER2 negative ductal 
carcinomas were obtained which had been formalin fixed and 
paraffin embedded. Tissue was immunohistochemically stained 
with FOXO3a, FOXM1 and Id1 antibodies using the streptavidin-
biotin-peroxidase technique. Examples shown are representative 
of staining patterns observed (Magnification x200). 
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5.2.3 The effects of FEC chemotherapy in clinical 
samples. 
 
To visualize the changes in expression of FOXO3a, FOXM1 and 
Id1 induced by chemotherapy, samples were analysed before 
and after neo-adjuvant chemotherapy with FEC (Figure 5.5). 
Patients received 6 cycles of treatment over a period of 18 
weeks. Core biopsies pre-treatment and the corresponding post 
chemotherapy residual tumour were stained and expression 
levels compared.  FOXO3a expression was found in both pre and 
post treatment specimens. Interestingly, both Id1 and FOXM1 
expression was visibly reduced following chemotherapy, with 
very little Id1 expression in particular observed following 
treatment.  These findings were consistent with the results 
obtained in chapters 3 and 4, confirming that chemotherapy 
downregulates the expression of FOXM1 and Id1 in vitro and in 
vivo. FOXO3a was expressed in both the pre and post FEC 
treatment samples.  Post FEC treatment, there was an observed 
increase in nuclear staining of FOXO3a, and although this was 
not formally quantified due to small patient numbers, this would 
be consistent with activation of FOXO3a and its nuclear 
localization following drug treatment.   
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Figure 5.5 A) Pre and post FEC chemotherapy staining. 
Pre treatment core biopsies and post FEC chemotherapy tissue 
samples were obtained which had been formalin fixed and 
paraffin embedded. Patients had received 6 cycles of FEC 
chemotherapy. Tissue was immunohistochemically stained with 
FOXO3a, FOXM1 and Id1 antibodies using the streptavidin-
biotin-peroxidase technique, pre and post treatment.   Examples 
shown are representative of staining patterns observed 
(Magnification x200). B) Higher magnification FOXO3a to 
highlight increased nuclear staining post FEC.  
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5.2.4   A dose titration of gefitinib induces FOXO3a 
activity and represses FOXM1. 
 
The work in chapter 3 of this thesis has shown FOXO3a to be a 
target of epirubicin.  Previous work in this laboratory had also 
shown that FOXO3a was a critical signaling effector of the EGFR 
inhibitor, gefitinib (Krol et al., 2007).  Thus, signaling via 
FOXO3a is a key mechanism by which both epirubicin and 
gefitinib bring about their cellular effects.  Analysis of clinical 
samples in this chapter has so far only been from patients who 
received neo-adjuvant FEC chemotherapy. However, samples 
were also available from patients who had received neo-
adjuvant gefitinib treatment.  Again, this allows a direct 
comparison between expression of FOXO3a and FOXM1 pre and 
post treatment.  Thus, the following work was performed to 
contribute to an ongoing project in the laboratory.    
 
To firstly confirm that gefitinib functions via FOXO3a and 
FOXM1, a dose titration of gefitinib was performed in SKBR3 
cells.  The effects of gefitinib on FOXO3a, FOXM1 and their 
downstream targets were comparable to those observed with 
epirubicin (Figure 5.6).  Cells were treated with 0, 0.1, 0.5, 1, 5 
and 10µM of gefitinib and the results showed a dose dependent 
induction of FOXO3a activity as shown by a reduction in FOXO3a 
phosphorylation but not protein level and confirmed by the 
induction of the FOXO3a targets Bim and p27kip1.  This was 
associated with a dose-dependent decrease in FOXM1 
expression and its downstream targets PLK and cyclin B.   
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Figure 5.6 Dose titration of gefitinib in SKBR3 cells. 
SKBR3 cells were treated with 0, 0.1, 0.5, 1, 5 and 10μM 
gefitinib and protein lysates prepared after 24 h of drug 
treatment. Protein expression levels were analysed by western 
blotting using specific antibodies.   
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5.2.5   Gefitinib induces FOXO3a nuclear accumulation 
and FOXM1 downregulation in breast cancer patient 
samples 
 
Having demonstrated that the use of neo-adjuvant FEC 
chemotherapy can down-regulate FOXM1 expression in breast 
cancer samples, immunohistochemical staining was also used to 
analyse the expression of FOXO3a and FOXM1 in breast cancer 
patient samples obtained before and after 4 weeks of gefitinib 
treatment, from a neoadjuvant study in patients with early 
breast cancer (Polychronis et al., 2005).  Samples were also 
stained for Ki67, a marker for cell proliferation. Staining was 
performed on 11 cases in patients whose tumour size reduced 
more than 1 cm after gefitinib treatment as measured by 
ultrasonography. Tumour tissue sections from 11 patients that 
had no treatment between biopsy and surgical tumour excision 
were used as controls. After estimating staining intensity using 
H-scores for nuclear FOXO3a, FOXM1 and Ki67 expression 
(Table 5.1, as described in materials and methods)  FOXM1 
expression was significantly downregulated in response to 
gefitinib, concomitant with a reduction in Ki67 staining and an 
increase in the level of nuclear FOXO3a (Figure 5.7).  T-test 
analysis also indicated that a significant difference in FOXM1 
staining between the treated group before and after gefitinib 
(p<0.05) and between treated and control groups after 
treatment. The relationship between fold changes in FOXM1 and 
Ki67 or nuclear FOXO3a was statistically analysed using 
Pearson’s correlation test based upon their H-scores, and was 
considered significant at p<0.05 (t-test). The results indicated a 
significant and strong positive correlation between FOXM1 and 
Ki67 expression (n=22; Pearson coefficient=0.697; p<0.05) 
and a significant inverse correlation between FOXM1 and 
nuclear FOXO3a expression (n=20; Pearson coefficient=-0.669; 
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p<0.05) in response to treatment (i.e. gefitinib or control) 
(Figure 5.8). These results confirm that FOXM1 and cell 
proliferation are repressed by gefitinib, and this is accompanied 
by activation of FOXO3a, a mechanism of action similar to that 
previously demonstrated in response to epirubicin.    
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Figure 5.7 Gefitinib treatment correlates with 
upregulation of nuclear FOXO3a and downregulation of 
Ki67 and FOXM1 expression in breast cancer patient 
samples. A. Tumour tissue samples obtained from breast 
cancer patients, formalin fixed and paraffin-embedded were 
immunohistochemically stained with Ki67, FOXO3a and FOXM1 
antibodies using the streptavidin-biotin-peroxidase technique. 
Control patients received no treatment between primary biopsy 
and subsequent tumour resection. Examples of staining of 
samples from a gefitinib treated patient are shown (X200 
magnification). B. The relationships between Ki67, nuclear 
FOXO3a or FOXM1 expression before and after gefitinib 
treatment were analysed using Box-and-Whisker plots 
illustrating the median values, first and third quartile, and 
smallest and largest values of Ki67, nuclear FOXO3a and FOXM1 
before and after gefitinib treatment. 
FOXO3a FOXM1 Ki67
Pre-
treatment
Gefitinib:
A
Post-
treatment
Ki67
Nuclear FOXO3a
FOXM1
Pre-treatment Post-treatment
0
200
300
100
H
-S
co
re
**
**
** ** p<0.01
 217 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.1 Immunohistochemical staining results with H-
scores on Ki67, nuclear FOXO3a and FOXM1. Intensity of 
Ki67, FOXM1 and FOXO3a was evaluated using 0 to 3 scoring 
system.  Results were quantified by calculating H-scores that 
consider both the staining intensity and the percentage cells 
stained at a specific range of intensities.   
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Figure 5.8 Analysis of the relationship between Ki67, 
nuclear FOXO3a, and FOXM1 expression in breast cancer 
patient samples.  A. To test for differences between FOXM1 
expression before and after treatment in gefitinib treated and 
control groups, Dunnett’s t-test was performed, and the mean 
difference considered significant at the p<0.05 level. B. The 
relationship between the fold of change in FOXM1 status and 
Ki67 or nuclear FOXO3a expression was statistically analysed 
using Pearson’s correlation test based upon the H-scores, and 
was considered significant at p<0.05.  
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5.3 DISCUSSION 
 
The use of neo-adjuvant chemotherapy in breast cancer has a 
number of advantages, allowing down-staging of tumours and 
reducing the need for mastectomy. This also enables the 
monitoring of treatment efficacy and allows the possibility of 
identifying markers of response. In this chapter, the expression 
of FOXO3a, FOXM1 and Id1 was characterised in invasive 
cancers and the changes induced by neo-adjuvant treatment 
with FEC chemotherapy and gefitinib treatment was 
investigated.  
 
Immunohistochemical staining confirmed that FOXO3a, FOXM1 
and Id1 are all expressed in invasive ductal carcinomas of the 
breast.  FOXO3a is also expressed in normal breast tissue, 
however, FOXM1 and Id1 expression is much higher in invasive 
tumour than in normal breast tissue (Figure 5.1).  This is 
consistent with the known role of both FOXM1 and Id1 in 
proliferation and the development and progression of cancer.  
FOXM1 is highly expressed in proliferating cells and although 
found in all embryonic tissues, it is not normally expressed at 
high levels in adult tissue.  However, overamplification of the 
FOXM1 gene locus on chromosome 12 does occur in breast 
cancer, which could promote overexpression of FOXM1 leading 
to tumourigenesis by driving the cell cycle and proliferation, and 
promoting undifferentiated cells towards malignant 
transformation (Costa, 2005; Spirin et al., 1996).  Similarly, Id1 
expression has been shown to be high in invasive, high grade 
tumours, correlating with more aggressive behaviour and worse 
outcome in patients (Schindl et al., 2001; Schindl et al., 2003).  
In colorectal cancers for example, Id1 expression is elevated in 
tumours when compared to normal bowel mucosa (Wilson et al., 
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2001).  These results suggest a similar expression pattern for 
both FOXM1 and Id1, with expression being elevated in tumours 
when compared to normal breast tissue.  Neither histological 
sub-type, ER of HER2 appears to influence expression of 
FOXO3a, FOXM1 or Id1 – levels are high in invasive cancers, 
whether ductal or lobular and regardless of ER or HER2 status, 
suggesting that FOXO3a, FOXM1 and Id1 expression are not 
specific to any particular subtype of breast cancer but are 
expressed as a marker of malignancy (Figures 5.2, 5.3 and 
5.4).   
 
Some care does need to be taken when interpreting these 
results.  Despite optimising staining techniques, the Id1 
antibody in particular did show a high degree of non-specific 
staining and could be considered a “dirty” antibody in terms of 
giving high background staining. The use of positive and 
negative controls, for example tissue containing high levels of 
Id1 such as cerebral cortex, could be used to corroborate 
immunohistochemical findings.  
 
In response to FEC chemotherapy, FOXM1 and Id1 expression is 
downregulated (Figure 5.5). The changes in FOXO3a expression 
following chemotherapy are not so easy to characterise as 
changes in subcellular localisation as opposed to expression 
levels per se are more important in determining FOXO3a activity 
and function. However, neo-adjuvant chemotherapy inflicts 
significant changes on the histological appearances of tumour 
cells, disrupting the normal architecture of the epithelial cells 
including distortion of glandular structure, enlarged cells due to 
an increased cytoplasm, pleomorphic and bizarre nuclei and 
decreased mitotic activity (Sahoo and Lester, 2003).  Thus, a 
direct comparison between pre and post chemotherapy FOXO3a 
 221 
expression is difficult to interpret.  However, in the gefitinib 
treated patients, the cellular architectural changes following 
treatment are much less dramatic - patients received only 4 
weeks of drug as opposed to 18 weeks of chemotherapy.  This 
allowed a formal staining score to be applied and it was possible 
to estimate staining intensity using H-scores, enabling 
quantification of the changes in expression of FOXO3a and 
FOXM1.  FOXM1 was significantly downregulated following 
gefitinib treatment, concomitant with an increase in the level of 
nuclear FOXO3a.  The downregulation of FOXM1 expression was 
associated with a decrease in cell proliferation as revealed by a 
reduction in the level of Ki-67, a marker for cell proliferation 
(Figure 5.7).  
 
EGFR inhibitors are a relatively new class of drug and gefitinib is 
a selective EGFR tyrosine kinase inhibitor, which acts through 
competitive inhibition of ATP binding to the catalytic domain of 
EGFR tyrosine kinase (Campos, 2008).  Recent phase II trials 
have shown that gefitinib has antitumour activity in breast 
cancer when used as a monotherapy or in combination with 
other drugs, such as docetaxel and anastrazole (Polychronis et 
al., 2005).  Identifying the downstream targets of gefitinib, such 
as FOXM1 and FOXO3a, may allow the selection of patients 
more likely to benefit from anti-EGFR inhibitors.  If tumours 
expressing high levels of FOXO3a or FOXM1 respond well to 
EGFR inhibition, drugs such as gefitinib could be used 
concurrently with standard chemotherapy regimens to increase 
efficacy or used on their own to avoid chemotherapy related 
toxicity.  
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5.4 FUTURE WORK 
 
There is much scope for a more in depth analysis of patient 
samples, to try and identify prognostic and predictive factors in 
patients treated with neo-adjuvant chemotherapy.  For the work 
in this chapter, it was particularly difficult to obtain matched 
patient samples (i.e pre and post FEC chemotherapy) which 
limited the amount of quantitative analysis that could be 
undertaken. With a larger number of complete patient samples, 
there would be scope for a much more detailed analysis.  
Formal H-score assessment and pathological evaluation would 
give a more quantitative assessment of response to 
chemotherapy.  Furthermore, retrospective and prospective 
analysis of clinical data may provide some predictive data, for 
example, correlation between changes in FOXO3a, FOXM1 and 
Id1 expression and time to disease progression.  Significant 
changes in FOXM1 and Id1 after treatment may equate to 
longer disease free survival and overall survival, and provide a 
useful prognostic tool for the future.     
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CHAPTER 6                                            
FINAL DISCUSSION 
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6.1 Overview 
 
Early stage breast cancer is increasingly accepted as a systemic 
disease and as such, the use of adjuvant treatment, including 
endocrine treatment and chemotherapy, has increased 
significantly over the last twenty years.  Epirubicin remains one 
of the most widely used chemotherapeutic agents in the 
management of breast cancer. Epirubicin, administered usually 
in combination with 5-Fluorouracil and methotrexate (FEC), has 
a well established and proven role in improving outcome and 
survival in breast cancer.  Though known to inhibit 
topoisomerase II and introducing irreversible DNA damage, the 
exact cellular mechanisms via which epirubicin exerts its 
cytotoxic effects are not yet fully understood.   
 
One of the main aims of this thesis was to identify cellular 
targets of epirubicin and to characterize how these targets are 
regulated and play a role in cell death. The work explored the 
hypothesis that FOXO3a was a potential target of epirubicin and 
that FOXM1 and Id1 may also be targets of epirubicin and could 
be regulated by FOXO3a. 
 
In chapter 3, epirubicin was shown to induce a dose dependent 
G2/M arrest in MCF-7 cells and this was accompanied by a 
decrease in levels of phosphorylated FOXO3a protein.  Together 
with the upregulation of the FOXO3a target p27Kip1, this 
suggested that FOXO3a was indeed a target of epirubicin.  This 
was confirmed by time course experiments, where 48h of 
treatment with epirubicin in MCF-7 cells suppressed the activity 
of the PI3K pathway, downregulated phospho-FOXO3a and 
upregulated the FOXO3a targets p27Kip1, Bim and GADD45a.  
FOXO3a mRNA levels also increased following epirubicin 
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treatment and promoter assays confirmed epirubicin was 
activating FOXO3a promoter activity and identified FOXO3a as a 
cellular target of epirubicin.  
 
Experiments investigating the subcellular localization of FOXO3a 
gave further insight into the mechanism via which epirubicin 
targets FOXO3a. After 24h of drug treatment, nuclear levels of 
FOXO3a rise, whereas cytoplasmic FOXO3a and phospho-
FOXO3a levels fall.  Fluorescent microscopy confirmed this, with 
cytoplasmic and nuclear FOXO3a visualised before treatment, 
but only nuclear FOXO3a visualized after 24h of treatment.  This 
suggests that epirubicin induces shuttling of FOXO3a from the 
cytoplasm to the nucleus, where it can be transcriptionally 
active.   
 
Having established FOXO3a as a target of epirubicin, FOXM1 
was next investigated as an epirubicin target and also the 
hypothesis that FOXO3a may regulate FOXM1 was tested. 
Epirubicin downregulated FOXM1 at the protein, mRNA and gene 
promoter level, inversely correlating with the changes seen in 
FOXO3a.  The FOXM1 promoter repression induced by epirubicin 
appeared to be dependent on FOXO, as mutation of the FOXO3a 
binding sites within the FOXM1 promoter relieved the repression 
induced by epirubicin.  Further evidence for the regulation of 
FOXM1 by FOXO3a was shown when FOXO3a was silenced – 
epirubicin treatment downregulated FOXO3a in control cells, but 
in the FOXO3a knockdown cells, no such repression of FOXM1 
was seen.  This suggests that FOXO3a is required for the 
repression of FOXM1 following epirubicin treatment. Failure of 
FOXO3a to repress FOXM1 also provides cells with a survival 
advantage and knockdown of FOXO3a renders cells more 
resistant to epirubicin.   
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Overexpression of FOXM1 also contributes to a drug resistant 
phenotype – when MCF-7 cells were transfected with a 
constitutively active truncated form of FOXM1, ΔN-FOXM1, the 
cytotoxic effects of epirubicin were abrogated,  implicating 
FOXM1 as an important mediator of drug resistance.  
Interestingly, the two cell lines with the highest relative 
expression of FOXM1 – ZR751 and MDA-MB-231 cells – were 
the least sensitive to epirubicin, providing further evidence for a 
role of FOXM1 in chemotherapy resistance.   
 
In chapter 4, epirubicin was shown to rapidly down-regulate Id1 
protein, mRNA and promoter activity.  Id1 expression was found 
to be high in chemotherapy resistant cell lines and silencing of 
Id1 by siRNA slowed proliferation of cells and increased the 
sensitivity of MCF-7 cells to epirubicin, docetaxel and cisplatin.  
Unlike haematopoetic cells, FOXO3a does not appear to regulate 
Id1 in breast cancer and when FOXO3a is silenced, Id1 is still 
downregulated as an early event in response to epirubicin.  This 
would suggest that the role of Id1 pertains more to proliferation 
of cells and cell cycle progression as opposed to a direct role in 
the apoptotic pathway.  Loss of Id1 leads to downregulation of 
cyclin D1, a key mediator of cell cycle entry, and may “prime” 
cells into being more susceptible to the effects of chemotherapy.  
It is likely that other, as yet unidentified, proteins may also 
interact with or bind to Id1 and there may be cross-talk with 
other signaling pathways, so that once Id1 is silenced, the 
effects of chemotherapy are potentiated.     
 
The tissue staining performed in Chapter 5 corroborated the 
findings in the cancer cell lines.  FOXO3a, FOXM1 and Id1 were 
all highly expressed in breast cancer samples.  No obvious 
difference was seen in expression when comparing ER positive 
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and ER negative tumours, HER2 positive and HER2 negative 
tumours and between invasive lobular and ductal carcinomas.  
However, with regards to Id1 and FOXM1 expression, normal 
breast tissue had much lower expression of both when 
compared to invasive ductal carcinomas.  There was also a 
marked reduction in Id1 and FOXM1 expression following neo-
adjuvant treatment with FEC chemotherapy, confirming the 
downregulation observed in MCF-7 cells following drug 
treatment.  It is not possible to study the effects of epirubicin 
alone in clinical samples as single agent epirubicin is not a 
standard treatment in the neo-adjuvant setting.  However, 
assessing the effects of gefitinib as a single agent treatment in 
the neo-adjuvant setting was possible.  As had been shown with 
epirubicin, gefitinib also targeted FOXO3a and a titrating dose of 
gefitinib in the sensitive SKBR3 cell line downregulated 
phospho-FOXO3a, whilst upregulating the FOXO3a targets Bim 
and p27kip1 as well as downregulating FOXM1 and its 
downstream targets cyclin B and PLK1, suggesting epirubicin 
and gefitinib share a similar FOXO3a dependent mechanism of 
inducing cell death.  FOXM1 expression is downregulated 
following gefitinib treatment in patient samples and this is 
accompanied by nuclear accumulation of FOXO3a.  Similarly, in 
cell lines, silencing of FOXO3a upregulates FOXM1 and its 
targets and rescued cells from gefitinib induced cell proliferative 
arrest.   
 
6.2 Clinical relevance 
 
Identifying the cellular mechanisms via which 
chemotherapeutics achieve their toxic effects may allow better 
selection of both patients and drug combinations in the 
treatment of cancer.  One of the most significant problems with 
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chemotherapy encountered in the clinical setting is 
chemoresistance.  Some patients fail to respond up-front to 
chemotherapy – inherent or de novo drug resistance, whilst 
many others eventually develop resistance after multiple lines of 
treatment.  To be able to identify patients who are more likely 
to respond to specific drugs and to be able to predict outcome 
would be of huge benefit in the clinical setting.  Just as the 
expression of ER and HER2 are used to guide treatment choices 
in breast cancer, the expression of FOXO3a, FOXM1 and Id1 
may be useful in the future as predictors of response to 
particular drugs. If the anthracyclines function via FOXO3a, 
perhaps patients with tumours which express little or no 
FOXO3a may benefit from alternative non-anthracycline 
containing regimens such as CMF or the taxanes. Similarly, if 
high expression of FOXM1 confers resistance to treatment, 
targeting FOXM1 specifically may be useful in improving the 
chances of response.  As mentioned previously thiostrepton, a 
thiopepetide antibiotic, has been shown to selectively target 
FOXM1 in breast cancer cells, and this could be given in 
combination with standard chemotherapy to improve outcome 
(Kwok et al., 2008). This approach has been adopted 
successfully with other tumour types, where targeted 
treatments are given in combination with well established 
chemotherapy regimens and good outcomes have been 
observed.  The anti-EGFR monoclonal antibody cetuximab and 
bevacizumab, an anti-VEGF monoclonal antibody, have both 
been used to improve outcome in colorectal cancer when given 
in combination with oxaliplatin, irinotecan and 5-FU containing 
chemotherapy regimens (Cassidy et al., 2008; Saltz et al., 
2007). The use of poly ADP ribose polymerase (PARP) inhibitors, 
currently in clinical trials, exploits a similar therapeutic strategy, 
where inhibition of the base excision repair pathway by PARP 
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inhibitors leads to increased drug sensitivity in patients with 
BRCA mutations (Tuma, 2009). In the future this may be a 
further mechanism for sensitizing patients to the effects of 
chemotherapy.       
 
Also of clinical relevance is the potential role of FOXO3a, FOXM1 
and Id1 as markers of response to chemotherapy.  FOXM1 and 
Id1 expression was downregulated by FEC chemotherapy, in 
samples from patients who had a good clinical response to neo-
adjuvant treatment. Similarly, cellular FOXO3a localization 
differed pre and post gefitinib treatment, with post treatment 
nuclear accumulation of FOXO3a occuring. It is currently difficult 
to predict how a patient will respond to chemotherapy.  Studies 
looking at expression of Bcl-2, ER, p53, HER2 and Ki67 pre and 
post neo-adjuvant chemotherapy have failed to identify any 
good predictors or response – all markers, except Ki67, were 
similar before and after chemotherapy (Faneyte et al., 2003). 
Thus, FOXO3a, FOXM1 and Id1 expression could provide new 
biomarkers in assessing outcome and predicting response to 
chemotherapy.   
 
6.3 Id1 as a therapeutic target 
 
The work in Chapter 4 identified Id1 also as a target of 
epirubicin, something never previously characterized in the 
literature.  Treatment of MCF-7 cells lead to a rapid down-
regulation of Id1 protein and mRNA and there was a direct 
effect at the gene promoter level, with epirubicin repressing Id1 
promoter activity.  The expression of Id1 was highest in more 
aggressive cell lines, including MDA-MB-231 cells and the 
anthracycline resistant Dox-R MCF-7 cells.  Interestingly, 
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silencing of Id1 had a negative effect on proliferation but also, 
perhaps more importantly, could increase the sensitivity of MCF-
7 cells to a variety of cytotoxic agents.   
 
From a clinical viewpoint, the increased sensitivity of cells to 
chemotherapy following silencing of Id1 could be very 
interesting.  Over the last two decades, a number of new drugs 
have been developed which have specific molecular targets, 
such as PI3K and mTOR (Markman et al., 2009).  By particularly 
targeting key events in signaling pathways, these drugs may 
prove to have significant anti-cancer properties, whilst avoiding 
much of the toxicity associated with standard chemotherapy. 
Targeted agents may also improve the efficacy of 
chemotherapy, for example, phase I clinical trials are now 
ongoing to study the effects of PI3K inhibitors, which have 
shown activity in breast, lung and cancer models and enhanced 
anti-tumour activity when combined with chemotherapy with 
paclitaxel and carboplatin (Papadopoulos et al., 2008).  If Id1 
expression can be inhibited by siRNA to reduce proliferation and 
increase the sensitivity of cells to cytotoxics, this presents a 
novel therapeutic strategy for cancer treatment.  Drugs 
specifically targeting Id1 may have multiple effects on tumour 
progression as Id1 plays a key role in growth, invasion, 
metastases and angiogenesis (Carpten et al., 2007).  One study 
has shown this to be a potential viable therapeutic strategy, 
where targeting Id1 expression with antisense Id1 cDNA 
reduced the metastatic spread of 4T1 breast cancer cells in mice 
(Fong et al., 2003).  Also, as shown in this work, Id1 expression 
is highest in aggressive cell lines and high grade breast cancer 
tumours, when compared to non-transformed cells or normal 
breast tissue. This could therefore be an advantage for systemic 
therapy, as non-tumour tissue, expressing only low levels of 
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Id1, may show little effect to inhibition of Id1, thus sparing the 
normal tissue from any drug related toxicity.   
 
6.4 Future perspectives 
 
The work presented in this thesis has demonstrated the 
important function of FOXO transcription factors and Id1 in 
response to chemotherapy in breast cancer (Figure 7.1).  
FOXO3a has a role in mediating the effects of epirubicin in 
breast cancer cells and transcriptional activation of FOXO3a 
following drug treatment is a key event in the cell cycle arrest 
and cell death induced by epirubicin.  The regulation of FOXM1, 
another cellular mediator of epirubicin, by FOXO3a is a key step 
in defining drug sensitivity and loss of FOXO3a or 
overexpression of FOXM1 contributes to a more drug resistant 
phenotype in breast cancer cells.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1 Schematic representing the role of FOXO3a 
and Id1 as targets of chemotherapy. 
 
 
epirubicin
Id1FOXO3a
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+
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This is likely to be a mechanism shared with other therapeutic 
drugs as treatment of gefitinib sensitive breast cancer cells also 
activates FOXO3a, whilst repressing FOXM1,  leading to 
proliferative arrest and cell death. Although Id1 does not appear 
to be regulated by FOXO3a in breast cancer, this work has 
shown it also to be an important target of epirubicin and Id1 
plays a role in sensitivity to chemotherapy, as silencing of Id1 
increases the cytotoxic effects of epirubicin (figure 7.1).   
 
Expression of FOXO3a, FOXM1 and Id1 in clinical samples 
suggests that in the future, there could be a role for their use as 
biomarkers of response to chemotherapy.  Both FOXM1 and Id1 
are expressed at low levels in normal breast tissue and at much 
higher levels in high grade breast cancers.  Treatment of 
patients with FEC chemotherapy or gefitinib down-regulates 
FOXM1 expression and FEC chemotherapy also down regulates 
Id1 expression.  Therefore, there may be a role for developing 
specific targeted treatments against FOXM1 and Id1 to increase 
drug efficacy, avoid resistance and improve sensitivity to 
chemotherapy. Furthermore, the expression of FOXO3a, FOXM1 
and Id1 in clinical samples could be used to refine patient 
selection, assess responders from non responders and increase 
sensitivity to chemotherapy to ultimately improve the outcome 
of patients with breast cancer.  Future research into the 
FOXO3a-FOXM1 axis may ultimately give more insight into the 
mechanisms underlying sensitivity and resistance to 
chemotherapy in breast cancer.       
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